<SEC-DOCUMENT>0001193125-25-103868.txt : 20250429
<SEC-HEADER>0001193125-25-103868.hdr.sgml : 20250429
<ACCEPTANCE-DATETIME>20250429162544
ACCESSION NUMBER:		0001193125-25-103868
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		24
CONFORMED PERIOD OF REPORT:	20250624
FILED AS OF DATE:		20250429
DATE AS OF CHANGE:		20250429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Erasca, Inc.
		CENTRAL INDEX KEY:			0001761918
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831217027
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40602
		FILM NUMBER:		25888101

	BUSINESS ADDRESS:	
		STREET 1:		10835 ROAD TO THE CURE, SUITE 140
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 465-6511

	MAIL ADDRESS:	
		STREET 1:		10835 ROAD TO THE CURE, SUITE 140
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d897507ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:eras="http://erasca.com/20241231" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>DEF 14A</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;">
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden140094653" contextRef="P01_01_2024To12_31_2024">DEF 14A</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2024To12_31_2024" id="ixv-4809">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2024To12_31_2024" id="ixv-4810">0001761918</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eras-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="P01_01_2024To12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001761918</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001761918</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:IndividualAxis">eras:JonathanELimMDMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001761918</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:IndividualAxis">eras:DavidMChackoMDMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001761918</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:IndividualAxis">eras:ShannonRMorrisMDPhDMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><div><div style="line-height:normal;display: inline;"><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="-sec-ix-hidden:hidden140094653;display:inline;">SCHEDULE 14A</div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Proxy Statement Pursuant to Section&#160;14(a) of the </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities Exchange Act of 1934 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Amendment No. &#8195;) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&#8194;&#9744; </div><div style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#9744;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Preliminary Proxy Statement </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#9744;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Confidential, for Use of the Commission Only (as permitted by Rule <div style="white-space:nowrap;display:inline;">14a-6(e)(2))</div> </div></div> </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#9746;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Definitive Proxy Statement </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#9744;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Definitive Additional Materials </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#9744;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Soliciting Material under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#167;240.14a-12</div> </div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2024To12_31_2024" id="ixv-4853">Erasca, Inc.</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name of Registrant as Specified In Its Charter) </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#9746;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">No fee required </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#9744;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Fee paid previously with preliminary materials </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#9744;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">14a-6(i)(1)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">0-11</div> </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g897507g02g02.jpg" alt="LOGO" style="width:2.30833in;height:0.378239in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">2025 ANNUAL MEETING OF STOCKHOLDERS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">June&#160;24, 2025 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ERASCA, INC. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">3115 Merryfield Row, Suite 300 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">San Diego, CA 92121 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&#160;29, 2025 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholder: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the Annual Meeting of Stockholders (the Annual Meeting) of Erasca, Inc., a Delaware corporation (the Company), at 11:30 a.m. Pacific Time on Tuesday, June&#160;24, 2025. The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of Securities and Exchange Commission rules that allow companies to furnish proxy materials to their stockholders by providing access to these documents on the Internet instead of mailing printed copies. Those rules allow a company to provide its stockholders with the information they need, while lowering the costs of delivery and reducing the environmental impact of the Annual Meeting. Most of our stockholders will not receive printed copies of our proxy materials unless requested, but instead will receive a notice with instructions on how they may access and review our proxy materials on the Internet and how they may cast their vote via the Internet. If you would like to receive a printed or <span style="white-space:nowrap">e-mail</span> copy of our proxy materials, please follow the instructions for requesting the materials in the Notice of Internet Availability that is being sent to you. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notice of Annual Meeting of Stockholders and Proxy Statement on the following pages describe the matters to be presented at the Annual Meeting. Please see the section entitled &#8220;How can I attend the Annual Meeting?&#8221; of the proxy statement for more information about how to attend the virtual-only meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not you attend the Annual Meeting online, it is important that your shares be represented and voted at the Annual Meeting. Therefore, I urge you to promptly vote and submit your proxy by phone, via the Internet, or, if you received paper copies of these materials, by signing, dating and returning the enclosed proxy card in the enclosed envelope, which requires no postage if mailed in the United States. If you have received our Notice of Internet Availability of Proxy Materials, the instructions regarding how you can access your proxy materials and vote are contained in that notice. If you have received written proxy materials, the instructions regarding how you can access your proxy materials and vote are contained on the proxy card. If you decide to attend the Annual Meeting, you will be able to vote online, even if you have previously submitted your proxy. If you hold your shares through a bank or broker, you will need a proxy from your bank or broker to vote your shares online at the Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for your support. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:100%"/></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan E. Lim</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Jonathan E. Lim, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><span style="white-space:nowrap">Chairman,&#160;Chief&#160;Executive&#160;Officer,&#160;and&#160;Co-Founder</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">San Diego, California</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g897507g02g02.jpg" alt="LOGO" style="width:2.30833in;height:0.378239in"/>
 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notice of Annual Meeting of Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">To be Held Tuesday, June&#160;24, 2025 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ERASCA, INC. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3115 Merryfield Row, Suite 300, San Diego, California 92121 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Annual Meeting of Stockholders (the Annual Meeting) of Erasca, Inc., a Delaware corporation (the Company), will be held at 11:30 a.m. Pacific Time on Tuesday, June 24, 2025. The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. This means that you can attend the Annual Meeting online, vote your shares during the online meeting, and submit questions for consideration at the online meeting. To be admitted to the Annual Meeting&#8217;s live webcast, you must register at www.proxydocs.com/ERAS as described in the proxy materials or your proxy card. As part of the registration process, you must enter the Control Number included in your Notice of Internet Availability of Proxy Materials, your proxy card or on the instructions that accompanied your proxy materials. After completion of your registration, further instructions, including a unique link to access the Annual Meeting, will be emailed to you. The Annual Meeting will be held for the following purposes: <span style="font-weight:bold"> </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left"><span style="font-weight:bold">1.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To elect three directors to serve as Class I directors for a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified; <span style="font-weight:bold"> </span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left"><span style="font-weight:bold">2.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and <span style="font-weight:bold"> </span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left"><span style="font-weight:bold">3.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of Securities and Exchange Commission rules that allow companies to furnish proxy materials to their stockholders by providing access to these documents on the Internet instead of mailing printed copies. Those rules allow a company to provide its stockholders with the information they need, while lowering the costs of delivery and reducing the environmental impact of the Annual Meeting. Most of our stockholders will not receive printed copies of our proxy materials unless requested, but instead will receive a Notice of Internet Availability of Proxy Materials with instructions on how they may access and review our proxy materials on the Internet and how they may cast their vote via the Internet. If you would like to receive a printed or e-mail copy of our proxy materials, please follow the instructions for requesting the materials in the Notice of Internet Availability of Proxy Materials that is being sent to you. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing items of business are more fully described in the attached proxy statement, which forms a part of this notice and is incorporated herein by reference. Holders of record of our common stock as of the close of business on April 28, 2025 are entitled to notice of and to vote at the Annual Meeting, or any continuation, postponement or adjournment of the Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">It is important that your shares be represented regardless of the number of shares you may hold. Whether or not you plan to attend the Annual Meeting online, we urge you to vote your shares as soon as possible via the toll-free telephone number or over the Internet, as described in the enclosed proxy materials. If you received a copy of the proxy card by mail, you may sign, date and mail the proxy card in the enclosed return envelope. Promptly voting your shares will ensure the presence of a quorum at the Annual Meeting and will save us the expense of further solicitation. Submitting your proxy now will not prevent you from voting your shares at the Annual Meeting if you desire to do so, as your proxy is revocable at your option. For specific voting instructions, please refer to the information provided in the accompanying Proxy Statement and in the Notice of Internet Availability of Proxy Materials. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors, </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:99%"/></tr>


<tr style="font-size:1pt">
<td style="height:12pt" colspan="3"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Ebun S. Garner</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebun S. Garner</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Counsel and Corporate Secretary</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">San Diego, California</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&#160;29, 2025</p></td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:95%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_1">GENERAL</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_2">PROPOSAL 1: ELECTION OF DIRECTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_3">PROPOSAL 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_3a">EXECUTIVE OFFICERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_3b">CORPORATE GOVERNANCE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_4">EXECUTIVE AND DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_5">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_6">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_7">2026 STOCKHOLDER PROPOSALS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc897507_8">ERASCA&#8217;S ANNUAL REPORT ON FORM <span style="white-space:nowrap">10-K</span></a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PROXY STATEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ERASCA, INC. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">3115 Merryfield Row, Suite 300, San Diego, California 92121 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_1">General </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement is furnished in connection with the solicitation by the board of directors (the Board) of Erasca, Inc. of proxies to be voted at our Annual Meeting of Stockholders to be held virtually on Tuesday, June&#160;24, 2025 (the Annual Meeting), at 11:30 a.m., Pacific Time, and at any continuation, postponement or adjournment thereof. Holders of record of shares of our common stock, $0.0001 par value per share, as of the close of business on April&#160;28, 2025 (the Record Date), will be entitled to notice of and to vote at the Annual Meeting and any continuation, postponement or adjournment thereof. As of the Record Date, there were 283,287,382 shares of our common stock outstanding and entitled to vote at the Annual Meeting. Each share of common stock is entitled to one vote on any matter presented to stockholders at the Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement and the Company&#8217;s Annual Report to Stockholders for the year ended December&#160;31, 2024 (the 2024 Annual Report), or Notice of Internet Availability of Proxy Materials, as applicable, will be sent on or about May&#160;13, 2025 to our stockholders on the Record Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this proxy statement, Erasca, the Company, we, us and our refer to Erasca, Inc. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FOR THE STOCKHOLDER MEETING TO BE HELD ON TUESDAY, JUNE&#160;24, 2025: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">This Proxy Statement and our 2024 Annual Report to Stockholders are available at: </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">www.proxydocs.com/ERAS. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposals </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, our stockholders will be asked: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">1.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To elect Jonathan E. Lim, M.D., James A. Bristol, Ph.D., and Valerie Harding-Start, Ph.D. as Class&#160;I directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">2.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To ratify the appointment of KPMG LLP as our independent public accounting firm for the fiscal year ending December&#160;31, 2025; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">3.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently know of no other business that will be presented at the Annual Meeting. If any other matter properly comes before the stockholders for a vote at the Annual Meeting, however, the proxy holders named on the Company&#8217;s proxy card will vote your shares in accordance with their best judgment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recommendations of the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board recommends that you vote your shares as indicated below. If you return a properly completed proxy card, or vote your shares by telephone or Internet, your shares of common stock will be voted on your behalf as you direct. If not otherwise specified, the shares of common stock represented by the proxies will be voted, and the Board recommends that you vote, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">1.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">FOR each of the nominees for election as a Class&#160;I director as set forth in this proxy statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">2.</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">FOR the ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2025. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any other matter properly comes before the stockholders for a vote at the Annual Meeting, the proxy holders named on the Company&#8217;s proxy card will vote your shares in accordance with their best judgment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information about this Proxy Statement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Why you received this proxy statement. </span>You are viewing or have received these proxy materials because the Board is soliciting your proxy to vote your shares at the Annual Meeting. This proxy statement includes information that we are required to provide to you under the rules of the Securities and Exchange Commission (the SEC) and that is designed to assist you in voting your shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Notice of Internet Availability of Proxy Materials. </span>As permitted by SEC rules, we are making this proxy statement and our 2024 Annual Report available to our stockholders electronically via the Internet. On or about May&#160;13, 2025, we will mail to our stockholders a Notice of Internet Availability of Proxy Materials (the Internet Notice) containing instructions on how to access this proxy statement and our 2024 Annual Report and vote online. If you received an Internet Notice by mail, you will not receive a printed copy of the proxy materials in the mail unless you specifically request them. Instead, the Internet Notice instructs you on how to access and review all of the important information contained in the proxy statement and 2024 Annual Report. The Internet Notice also instructs you on how you may submit your proxy over the Internet. If you received an Internet Notice by mail and would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting such materials contained on the Internet Notice. We encourage our stockholders to take advantage of the availability of the proxy materials on the Internet to help reduce the environmental impact of its annual meetings and reduce the cost to us associated with the printing and mailing of materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Printed copies of our proxy materials. </span>If you received printed copies of our proxy materials, then instructions regarding how you can vote are contained on the proxy card included in the materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Householding. </span>The SEC&#8217;s rules permit us to deliver a single Internet Notice or set of proxy materials to one address shared by two or more of our stockholders. This delivery method is referred to as &#8220;householding&#8221; and can result in significant cost savings. To take advantage of this opportunity, we have delivered only one Internet Notice or one set of proxy materials to multiple stockholders who share an address, unless we received contrary instructions from the impacted stockholders prior to the mailing date. We agree to deliver promptly, upon written or oral request, a separate copy of the Internet Notice or proxy materials, as requested, to any stockholder at the shared address to which a single copy of those documents was delivered. If you prefer to receive separate copies of the Internet Notice or proxy materials, we will provide copies of these documents, free of charge, upon written request to Erasca, Inc., 3115 Merryfield Row, Suite 300, San Diego, California 92121, Attention: Corporate Secretary or by calling (858) <span style="white-space:nowrap">465-6511.</span> Such requests by street name holders should be made through their bank, broker or other holder of record. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders sharing an address that are receiving multiple copies of the Internet Notice can request delivery of a single copy of the proxy statement or annual report or Internet Notice by contacting their broker, bank or other intermediary or sending a written request to Erasca, Inc. at the above address or by calling (858) <span style="white-space:nowrap">465-6511.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Questions and Answers about the Annual Meeting </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Who is entitled to vote on matters presented at the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Record Date for the Annual Meeting is April&#160;28, 2025. You are entitled to vote on the matters presented at the Annual Meeting if you were a record holder at the close of business on the Record Date. Each outstanding share of common stock is entitled to one vote for all matters before the Annual Meeting. At the close of business on the Record Date, there were 283,287,382 shares of common stock outstanding and entitled to vote at the Annual Meeting. Common stock is our only class of stock entitled to vote. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What is the difference between being a &#8220;record holder&#8221; and holding shares in &#8220;street name&#8221;? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, on the Record date, your shares were registered directly in your name then you are a stockholder of record. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, on the Record Date, your shares were held in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in &#8220;street name&#8221; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Am I entitled to vote if my shares are held in &#8220;street name&#8221;? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. If your shares are held in street name, these proxy materials, along with instructions on how to vote your shares, are being provided to you by your brokerage firm, bank, dealer or other similar organization. As the beneficial owner, you have the right to direct your brokerage firm, bank, dealer or other similar organization how to vote your shares, and the brokerage firm, bank, dealer or other similar organizations is required to vote your shares in accordance with your instructions. If your shares are held in street name, you may not vote your shares in person at the Annual Meeting, unless you obtain, and present at the Annual Meeting, a legal proxy from your brokerage firm, bank, dealer or other similar organization. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">How many shares must be present to hold the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum must be present at the Annual Meeting for any business to be conducted. Under Delaware law and our Amended and Restated Bylaws (the Bylaws), the presence at the Annual Meeting online, or by proxy, of the holders of a majority in voting power of the common stock issued and outstanding and entitled to vote, on the Record Date will constitute a quorum for the transaction of business at the Annual Meeting. The inspector of election will determine whether a quorum is present and will tabulate the votes cast at the Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">How can I attend the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, we have decided to hold the Annual Meeting entirely online this year. You may attend the Annual Meeting only if you are a record holder or beneficial owner of our common stock as of the Record Date. If you are a record holder you are entitled to vote at the Annual Meeting. If you hold your shares in street name you must obtain a valid proxy from your brokerage firm, bank, dealer or other similar organization to vote at the Annual Meeting. To attend and participate in the Annual Meeting, you will need the Control Number included in your Internet Notice, your proxy card or on the instructions that accompanied your proxy materials. If your shares are held in &#8220;street name,&#8221; you should contact your bank or broker to obtain your Control Number or otherwise vote through the bank or broker. To be admitted to the Annual Meeting and vote your shares, you must register to attend the Annual Meeting at www.proxydocs.com/ERAS and provide the Control Number by 2:00&#160;p.m. Pacific Time on June&#160;20, 2025. After completion of your registration, further instructions, including a unique link to access the Annual Meeting, will be emailed to you. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This year&#8217;s stockholder question and answer session will include questions submitted in advance of the Annual Meeting. You may submit a question in advance of the meeting as a part of the registration process. Questions pertinent to meeting matters and that are submitted in accordance with our Rules of Conduct for the Annual Meeting will be answered during the Annual Meeting, subject to applicable time constraints. Questions and answers may be grouped by topic and substantially similar questions may be grouped and answered once. In order to promote fairness, efficient use of time and in order to ensure all stockholders are responded to, we will respond to up to two questions from a single stockholder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What if a quorum is not present at the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a quorum is not present at the scheduled time of the Annual Meeting, (i)&#160;the Chairperson of the Annual Meeting or (ii)&#160;the holders of a majority of the shares entitled to vote, present at the virtual meeting, or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
represented by proxy, at the virtual meeting are authorized by our Amended and Restated Bylaws to adjourn the Annual Meeting until a quorum is present or represented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What does it mean if I receive more than one Internet Notice or more than one set of proxy materials? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It means that your shares are held in more than one account at the transfer agent and/or with banks or brokers. Please vote all of your shares. To ensure that all of your shares are voted, for each Internet Notice or set of proxy materials, please submit your proxy by phone, via the Internet or, if you received printed copies of the proxy materials, by signing, dating and returning the enclosed proxy card in the enclosed envelope. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">How do I vote? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the election of directors, you may either vote &#8220;For&#8221; all the nominees to the Board or you may &#8220;Withhold&#8221; your vote for any nominee you specify. With respect to the ratification of the appointment of KPMG&#160;LLP as our independent registered public accounting firm, you may vote &#8220;For,&#8221; &#8220;Against&#8221; or &#8220;Abstain&#8221; from voting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholders of Record: Shares Registered in Your Name </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, there are several ways for you to vote your shares. Whether or not you plan to attend the virtual Annual Meeting, we urge you to vote by proxy prior to the Annual Meeting to ensure that your vote is counted. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Via the internet</span>: You may vote at www.proxypush.com/ERAS, 24 hours a day, seven days a week, by following the instructions provided in the Internet Notice. You will need to use the Control Number included in your Internet Notice, your proxy card or on the instructions that accompanied your proxy materials to vote via the internet. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">By telephone</span>: You may vote using a touch-tone telephone by calling (866) <span style="white-space:nowrap">648-8133,</span> 24 hours a day, seven days a week. You will need to use the Control Number included in your Internet Notice, your proxy card or on the instructions that accompanied your proxy materials to vote by telephone. Votes submitted by telephone must be received by 11:29 a.m., Pacific Time, on June&#160;24, 2025. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">By mail</span>: If you request printed copies of the proxy materials by mail, you may vote using your proxy card by completing, signing, dating and returning the proxy card in the self-addressed, postage-paid envelope provided. If you properly complete your proxy card and send it to us in time to vote, your proxy (one of the individuals named on your proxy card) will vote your shares as you have directed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">At the virtual Annual Meeting</span>: You may vote during the virtual annual meeting through www.proxydocs.com/ERAS. To be admitted to the annual meeting and vote your shares, you must register to attend the annual meeting at www.proxydocs.com/ERAS by 2:00 p.m. Pacific Time on June&#160;20, 2025 and provide the Control Number included in your Internet Notice, your proxy card or on the instructions that accompanied your proxy materials. After completion of your registration, further instructions, including a unique link to access the Annual Meeting, will be emailed to you. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Beneficial owners: shares registered in the name of a broker, bank or other agent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received voting instructions from that organization rather than directly from us. Please check with your bank, broker, or other agent and follow the voting instructions they provide to vote your shares. Generally, you have three options for returning your proxy. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">By method listed on voting instruction card</span>: Please refer to your voting instruction card or other information provided by your bank, broker or other agent to determine whether you may vote by telephone or electronically on the Internet, and follow the instructions on the voting instruction card or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
other information provided by your broker, bank or other agent. A large number of banks and brokerage firms offer Internet and telephone voting. If your bank, broker or other agent does not offer Internet or telephone voting information, please follow the other voting instructions they provide to vote your shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">By mail</span>: You may vote by signing, dating and returning your voting instruction card in the <span style="white-space:nowrap">pre-addressed</span> envelope provided by your broker, bank or other agent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">At the virtual Annual Meeting</span>: To vote online during the virtual Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker or bank to request the proxy form authorizing you to vote the shares. You must also register to attend the Annual Meeting at www.proxydocs.com/ERAS and provide the Control Number included in your Internet Notice, your proxy card or on the instructions that accompanied your proxy materials. After completion of your registration, further instructions, including a unique link to access the Annual Meeting, will be emailed to you. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Can I change my vote after I submit my proxy? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. If you are a record holder, you may revoke your proxy and change your vote any time before the proxy is voted at the Annual Meeting: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by submitting a duly executed proxy bearing a later date than your prior proxy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by granting a subsequent proxy through the Internet or telephone; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by giving written notice of revocation to the Corporate Secretary of Erasca prior to or at the Annual Meeting; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by voting online at the Annual Meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your most recent proxy card or telephone or Internet proxy is the one that is counted. Your attendance at the Annual Meeting by itself will not revoke your proxy. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in street name, you may change or revoke your voting instructions by following the specific directions provided to you by your bank or broker, or you may vote virtually at the Annual Meeting by obtaining a legal proxy from your bank or broker and submitting the legal proxy along with your ballot at the Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Who will count the votes? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A representative from Mediant Communications, Inc. is expected to tabulate the votes and an employee of the Company is expected to be our inspector of election and will certify the votes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What if I do not specify how my shares are to be voted? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a record holder and you indicate when voting on the Internet or by telephone that you wish to vote as recommended by the Board, then your shares will be voted at the Annual Meeting in accordance with the Board&#8217;s recommendation on all matters presented for a vote at the Annual Meeting. Similarly, if you are a record holder and submit a proxy but do not indicate any voting instructions, the persons named as proxies will vote in accordance with the recommendations of the Board. The Board&#8217;s recommendations are indicated on page 1 of this proxy statement, along with the description of each proposal in this proxy statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares held in street name and do not provide the organization that holds your shares with specific voting instructions, then, the organization that holds your shares may generally vote your </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares in their discretion on &#8220;routine&#8221; matters but cannot vote on <span style="white-space:nowrap">&#8220;non-routine&#8221;</span> matters. If the organization that holds your shares does not receive instructions from you on how to vote your shares on a <span style="white-space:nowrap">non-routine</span> matter, that organization will inform the inspector of election that it does not have the authority to vote on that matter with respect to your shares. This is generally referred to as a &#8220;broker <span style="white-space:nowrap">non-vote.&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What are broker <span style="white-space:nowrap">non-votes</span> and do they count for determining a quorum? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares represented by proxies that reflect a broker <span style="white-space:nowrap">non-vote</span> will be counted as present for purposes of determining the presence of a quorum. As discussed above, broker <span style="white-space:nowrap">non-votes</span> occur when shares held by a broker in &#8220;street name&#8221; for a beneficial owner are not voted with respect to a particular proposal because (1)&#160;the broker has not received voting instructions from the beneficial owner and (2)&#160;the broker lacks discretionary voting power to vote those shares on a particular matter. A broker has discretionary power to vote shares without instruction from the beneficial owner on routine matters, such as the ratification of the appointment of KPMG&#160;LLP as our independent registered public accounting firm. Thus, broker <span style="white-space:nowrap">non-votes</span> are not expected on that proposal. On the other hand, absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on <span style="white-space:nowrap">non-routine</span> matters. Broker <span style="white-space:nowrap">non-votes</span> on the election of directors, which is considered a <span style="white-space:nowrap">non-routine</span> matter, will have no effect because they are not considered votes cast, and the three directors that receive the highest number of votes will be elected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What is an abstention and how will votes withheld and abstentions be treated? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of common stock held by persons attending the Annual Meeting but not voting, and shares represented by proxies that reflect withheld votes or abstentions as to a particular proposal, will be counted as present for purposes of determining the presence of a quorum. A &#8220;vote withheld,&#8221; in the case of the proposal regarding the election of directors, or an &#8220;abstention,&#8221; in the case of the ratification of the appointment of KPMG LLP, represents a stockholder&#8217;s affirmative choice to decline to vote on a proposal. Votes withheld have no effect on the election of directors, as the three directors that receive the highest number of votes will be elected, and abstentions are not considered to be a vote cast and will have no effect on the ratification of the appointment of KPMG LLP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">How many votes are required for the approval of the proposals to be voted upon and how will abstentions and broker <span style="white-space:nowrap">non-votes</span> be treated? </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Proposal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Votes Required</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Effect of Votes Withheld /<br/></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Abstentions and Broker<br/></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal 1 &#8211; Election of directors</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The plurality of the votes cast. This means that the three nominees receiving the highest number of affirmative &#8220;FOR&#8221; votes will be elected as Class&#160;I directors.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Votes withheld and broker <span style="white-space:nowrap">non-votes</span> will have no effect.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal 2 &#8211; Ratification of appointment of independent registered public accounting firm</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of a majority of the votes cast for or against the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Abstentions will have no effect. We do not expect any broker <span style="white-space:nowrap">non-votes</span> on this proposal.</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Will any other business be conducted at the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently know of no other business that will be presented at the Annual Meeting. If any other matter properly comes before the stockholders for a vote at the Annual Meeting, however, the proxy holders named on the Company&#8217;s proxy card will vote your shares in accordance with their best judgment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Where can I find the voting results of the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to announce preliminary voting results at the Annual Meeting and we will report the final results in a Current Report on Form <span style="white-space:nowrap">8-K,</span> which we intend to file with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form <span style="white-space:nowrap">8-K</span> within four business days after the Annual Meeting, we intend to file a Form <span style="white-space:nowrap">8-K</span> to publish preliminary results and, within four business days after the final results are known to us, file an additional Form <span style="white-space:nowrap">8-K</span> to publish the final results. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Proposals To Be Voted On &#8195; </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_2">Proposal 1 &#8211; Election of directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, three Class&#160;I directors are to be elected to hold office for a three-year term expiring at the Annual Meeting of Stockholders to be held in 2028 and until such director&#8217;s successor is elected and qualified or until such director&#8217;s earlier death, resignation or removal. Based on the recommendation of the Nominating and Corporate Governance Committee, the Board has nominated Jonathan E. Lim, M.D., James A. Bristol, Ph.D., and Valerie Harding-Start, Ph.D. for <span style="white-space:nowrap">re-election</span> as Class&#160;I directors at the Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proposal regarding the election of directors requires the approval of a plurality of the votes cast. This means that the three nominees receiving the highest number of affirmative &#8220;FOR&#8221; votes will be elected as Class&#160;I directors. Votes withheld and broker <span style="white-space:nowrap">non-votes</span> are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Certificate of Incorporation (the Charter) and Bylaws provide that the authorized number of directors shall be fixed from time to time exclusively by resolution adopted by a majority of the Board. We currently have eight authorized directors on our Board. As set forth in our Charter, the Board is currently divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. The following table summarizes the age, position at the Company, independence, and director class of our directors: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:38%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:36%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Independent</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Director&#160;Class<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan E. Lim, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">53</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chairman of the Board,&#160;Chief Executive Officer, and <span style="white-space:nowrap">Co-Founder</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">I</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Bristol, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">78</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Lead Independent Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">I</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Harding-Start, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">65</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">I</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander W. Casdin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">57</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">II</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julie Hambleton, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">67</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">II</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael D. Varney, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">66</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chair of Research and Development and Scientific Advisory Board member</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">II</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean I. Liu, J.D..</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">56</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">III</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pratik S. Multani, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">58</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">X</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">III</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Class&#160;I directors are nominated for <span style="white-space:nowrap">re-election</span> at the Annual Meeting with a term to expire at the 2028 annual meeting. The terms of Class&#160;II directors expire at the 2026 annual meeting. The terms of Class&#160;III directors expire at the 2027 annual meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The division of our Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our Company. Our directors may be removed only for cause and only by the affirmative vote of the holders of at least <span style="white-space:nowrap">two-thirds</span> of the voting power of the then-outstanding shares of capital stock entitled to vote in the election of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event any of the nominees should become unable to serve, or for good cause will not serve, as a director, it is intended that votes will be cast for a substitute nominee designated by the Board or the Board may elect to reduce its size. The Board has no reason to believe that the nominees named below will be unable to serve if elected. Each of the nominees has consented to being named in this proxy statement and to serve if elected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the persons whose names and biographies appear below are currently serving as our directors. Each of our directors brings to the Board significant leadership experience derived from their professional experience and service as executives or board members of other corporations and/or private equity and venture capital firms. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process undertaken by the Nominating and Corporate Governance Committee in recommending qualified director candidates is described below under &#8220;Board experience and director nomination process.&#8221; Certain individual qualifications and skills of our directors that contribute to the Board&#8217;s effectiveness as a whole are described in the following paragraphs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote required </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proposal regarding the election of directors requires the approval of a plurality of the votes cast. This means that the nominees receiving the highest number of affirmative &#8220;FOR&#8221; votes will be elected as Class&#160;I Directors. Votes withheld and broker <span style="white-space:nowrap">non-votes</span> are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Board unanimously recommends a vote FOR the election of the three nominees for Class&#160;I directors. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information regarding directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees for director: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nominees for election to the Board: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Class&#160;I directors (terms to expire at the Annual Meeting) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jonathan E. Lim, M.D. </span><span style="white-space:nowrap">co-founded</span> Erasca in July 2018, joined us as Executive Chairman in October 2018, and has served as our Chairman and Chief Executive Officer since March 2019. Dr.&#160;Lim has also served as a Venture Partner at ARCH Venture Partners since December 2018 and as Managing Partner at City Hill since founding it in 2010. Prior to founding Erasca, in 2011 Dr.&#160;Lim <span style="white-space:nowrap">co-founded</span> and served as Chairman of Ignyta, Inc., a public precision oncology company, and led it from 2012 as Chairman, Chief Executive Officer and President through its acquisition by Roche in February 2018 and subsequent integration into Roche and Genentech in July 2018. During his tenure at Ignyta, in 2015 Dr.&#160;Lim <span style="white-space:nowrap">co-founded</span> Bonti, Inc., a private pain management and anesthetics company, and served as its Chairman from February 2016 until its acquisition by Allergan plc in October 2018. Prior to joining Ignyta, Dr.&#160;Lim served as Chairman and Chief Executive Officer of Eclipse Therapeutics, Inc., a private oncology company targeting cancer stem cells that he <span style="white-space:nowrap">co-founded</span> in March 2011 as a spinout from Biogen Idec and that was sold to Bionomics Ltd. in 2012. Prior to Eclipse, Dr.&#160;Lim served as the President, Chief Executive Officer and a Director (including as Chairman from 2004 to 2005) of Halozyme Therapeutics, Inc., a public biotechnology company, from May 2003 to December 2010. Prior to Halozyme, Dr.&#160;Lim&#8217;s experience included management consulting at McKinsey&#160;&amp; Company, a National Institutes of Health Postdoctoral<span style="font-style:italic"> </span>Fellowship at Harvard Medical School and the Dana-Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. Dr.&#160;Lim has also served as a member of the board of directors of Maze Therapeutics, Inc., a publicly traded company advancing precision medicines for both rare and common diseases, since October 2019, and as Chairman and <span style="white-space:nowrap">co-founder</span> of Boundless Bio, Inc., a publicly traded precision oncology company, since December 2018. Dr.&#160;Lim has been a member of the Board of Overseers at Scripps Research since October 2018, a member of the Board of Visitors of the Moores Cancer Center at the University of California, San Diego since 2015, and a member of the Stanford Interdisciplinary Biosciences Council since 2014. Dr.&#160;Lim has B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard University. Dr.&#160;Lim&#8217;s intimate knowledge of our business as a <span style="white-space:nowrap">co-founder</span> of our Company and his extensive experience as an executive officer and director of multiple public and private biotechnology companies contributed to our Board&#8217;s conclusion that he should serve as a director of our Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">James A. Bristol, Ph.D.</span> has served on our Board since July 2018. Dr.&#160;Bristol worked for more than three decades in drug discovery, research and preclinical development at Schering-Plough Corporation, Parke-Davis and Pfizer Inc., serving in various senior research and development roles. From 2003 until his retirement in 2007, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&#160;Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research&#160;&amp; Development. In 2009, Dr.&#160;Bristol joined Frazier Healthcare Ventures as a Senior Advisor, and since 2007, Dr.&#160;Bristol has been working as a consultant with James Bristol LLC. He has served as Chairperson of Deciphera Pharmaceuticals, Inc. since 2015 and as a director since 2007, as well as a director of Ignyta, Inc. from 2014 to February 2018 and Cadent Therapeutics, Inc. from 2011 to January 2021. Dr.&#160;Bristol has been involved with the discovery and development of both drugs that have been approved by the FDA, including Lipitor, Lyrica, and Ibrance, and drug candidates currently in clinical development. Dr.&#160;Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan (NIH Postdoctoral Fellow) and at The Squibb Institute for Medical Research. Dr.&#160;Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College. Dr.&#160;Bristol&#8217;s extensive research and development and board-level experience in the biopharmaceutical industry contributed to our Board&#8217;s conclusion that he should serve as a director of our Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Valerie Harding-Start, Ph.D. </span>has served on our Board since June 2019. Since February 2019, Dr.&#160;Harding-Start has been a principal and advisor at Start Pharma Consulting LLC. From 2015 to January 2019, Dr.&#160;Harding-Start served as Ignyta, Inc.&#8217;s Senior Vice President of Chemistry, Manufacturing and Controls (CMC), as well as Site Head during Ignyta&#8217;s acquisition by Roche. Prior to Ignyta, Dr.&#160;Harding-Start served as Vice President of Product Differentiation, Pharmaceutical Sciences for Worldwide Research and Development at Pfizer, Inc. Dr.&#160;Harding-Start is also a member of the community of practice and thought partner for Smallify LLC, an innovation capacity-building firm. Dr.&#160;Harding-Start holds a B. Pharm. from the University of London and a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham. Dr.&#160;Harding-Start&#8217;s extensive experience in the biopharmaceutical industry and her expertise in CMC contributed to our Board&#8217;s conclusion that she should serve as a director of our Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Continuing members of the Board: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Class&#160;II directors (terms to expire at the 2026 annual meeting) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Alexander W. Casdin </span>has served on our Board since July 2018. Mr.&#160;Casdin has served as the Chief Executive Officer and President of Epirium Bio Inc., a biotechnology company, since December 2024. Mr.&#160;Casdin has held roles of increasing responsibility at Epirium since October 2020, having served as the Chief Financial Officer and Chief Operating Officer. Previously, Mr.&#160;Casdin was the founder and served as the Chief Executive Officer and portfolio manager of Reneo Capital Management LP from January 2015 to October 2020. From September 2012 through December 2014, Mr.&#160;Casdin was a private investor focused on the healthcare sector. From October 2011 through September 2012, Mr.&#160;Casdin was the Chief Financial Officer of Sophiris Bio, Inc., a Canadian public urology company. Prior to Sophiris Bio, Mr.&#160;Casdin served as the Vice President, Finance of Amylin Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Bristol-Myers Squibb in 2012, a position he held from October 2009 to October 2011. Prior to his position at Amylin Pharmaceuticals, Mr.&#160;Casdin founded and operated Casdin Advisors LLC, where he served as a strategic advisor to companies in the life sciences industry. Before founding Casdin Advisors, Mr.&#160;Casdin was the Chief Executive Officer and Portfolio Manager of Cooper Hill Partners, LLC, a healthcare investment fund. Mr.&#160;Casdin has also held previous positions at Pequot Capital Management and Dreyfus Corporation. Mr.&#160;Casdin has served on the board of directors for multiple life sciences companies, including Ignyta, Inc. from 2013 to 2018 and DUSA Pharmaceuticals Inc. from 2009 to 2012. Mr.&#160;Casdin holds a B.A. in political science from Brown University and an M.B.A. from Columbia Business School, where he graduated Beta Gamma Sigma. Mr.&#160;Casdin&#8217;s extensive financial experience in the biopharmaceutical industry contributed to our Board&#8217;s conclusion that he should serve as a director of our Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Julie Hambleton, M.D. </span>has served on our Board since March 2021. From August 2020 to March 2021, Dr.&#160;Hambleton served as interim President and Chief Executive Officer of Arch Therapeutics, Inc., a private biotechnology company. From June 2018 to April 2020, when she retired, Dr.&#160;Hambleton was Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, Inc., an oncology medicine </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company. From September 2017 to May 2018 and from March 2016 to May 2016, Dr.&#160;Hambleton served as an independent strategic consultant for various life sciences companies. From May 2016 to September 2017, she served as Vice President, Head US Medical at Bristol-Myers Squibb, a global biopharmaceutical company. From August 2015 to February 2016, Dr.&#160;Hambleton served as Executive Vice President, Chief Medical Officer at Five Prime Therapeutics, a biotechnology company, and as Senior Vice President, Chief Medical Officer from December 2012 to August 2015. From April 2010 to November 2012, Dr.&#160;Hambleton served as Vice President, Clinical Development at Clovis Oncology, and from 2003 to 2010, Dr.&#160;Hambleton held roles of increasing responsibility in BioOncology at Genentech. Dr.&#160;Hambleton serves on the boards of two publicly traded biotechnology companies: IGM Biosciences, Inc., since August 2018, and SpringWorks Therapeutics, Inc., since May 2020. Dr.&#160;Hambleton completed her hematology-oncology training at the University of California, San Francisco, where she then served on the faculty from 1993 to 2003. Dr.&#160;Hambleton holds a B.S. in nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine, and was board-certified in hematology and internal medicine. Dr.&#160;Hambleton&#8217;s extensive executive leadership experience in the biopharmaceutical industry and her medical expertise in oncology, hematology-oncology and internal medicine contributed to our Board&#8217;s conclusion that she should serve as a director of our Company.<span style="font-style:italic"> </span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Michael D. Varney, Ph.D. </span>has served as our Chair of Research and Development and Scientific Advisory Board member since August 2020 and on our Board since December 2020. From 2005 until his retirement in July 2020, Dr.&#160;Varney served in progressing roles at Genentech, Inc., most recently as Executive Vice President and Head of Research and Early Development, as well as a member of the Corporate Executive Committee of Roche, Genentech&#8217;s parent company. Prior to Genentech, from 1987 to 2005 Dr.&#160;Varney served as Head of Research at Agouron Pharmaceuticals, Inc., a biotechnology company later acquired by Pfizer, Inc. From January 2021 until July 2023, Dr.&#160;Varney served on the board of directors of Pardes Biosciences, Inc., a publicly traded biopharmaceutical company focused on the treatment and prevention of viral diseases. Dr.&#160;Varney served on the board of directors of Foundation Medicine, Inc. (acquired by Roche Holdings AG) from 2015 until March 2018. Dr.&#160;Varney was an American Cancer Society postdoctoral fellow at Columbia University, and holds a B.S. in chemistry from the University of California, Los Angeles and a Ph.D. in synthetic organic chemistry from the California Institute of Technology. Dr.&#160;Varney&#8217;s extensive executive leadership experience in the biopharmaceutical industry and his extensive drug discovery and development expertise contributed to our Board&#8217;s conclusion that he should serve as a director of our Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Class&#160;III directors (terms to expire at the 2027 annual meeting) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Jean I. Liu, J.D.</span> has served on our Board since April 2022. Ms.&#160;Liu was the Chief Legal Officer and Corporate Secretary of Seagen Inc., a publicly traded, global, multi product biotechnology company, from 2014 until Seagen&#8217;s acquisition by Pfizer in December 2023. Prior to that, she served as Vice President and General Counsel of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from November 2011 to November 2014. From 1998 to 2011, she was with Durect Corporation, a publicly traded biotechnology company, where she served in positions of increasing responsibility, including most recently Chief Legal Officer and Corporate Secretary. Prior to Durect, Ms.&#160;Liu was in private practice at the law firms of Pillsbury, Madison&#160;&amp; Sutro (now Pillsbury Winthrop) and Venture Law Group in the areas of intellectual property litigation and corporate transactions. Ms.&#160;Liu has served on the board of directors of Connect Biopharma Holdings Limited, a publicly traded biotechnology company developing treatments for T cell-driven inflammatory diseases, since August 2021. Ms.&#160;Liu received her B.S. in Cellular and Molecular Biology with highest distinction from the University of Michigan, her M.S. in Biology from Stanford University and her J.D. from Columbia University where she was a Harlan Fiske Stone Scholar. Ms.&#160;Liu&#8217;s executive and legal experience in the biopharmaceutical industry and experience with respect to corporate governance matters contributed to our Board&#8217;s conclusion that she should serve as a director of our Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pratik S. Multani, M.D. </span>has served on our Board since July 2018. Dr.&#160;Multani has served as Chief Medical Officer of ORIC Pharmaceuticals, Inc., a publicly traded oncology therapeutic company, since September 2018. From 2015 to February 2018, Dr.&#160;Multani served as the Chief Medical Officer of Ignyta, Inc. From 2009 to 2015, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&#160;Multani was Chief Medical Officer at Fate Therapeutics, Inc., a biopharmaceutical company. Prior to that, Dr.&#160;Multani was Vice President of Clinical Development at Kalypsys, Inc. and Senior Vice President of Clinical Development and Chief Medical Officer at Kanisa Pharmaceuticals, Inc. Dr.&#160;Multani also held academic and clinical positions at Harvard Medical School and Massachusetts General Hospital, where he was a member of the bone marrow transplant unit. He completed his internship and residency training in internal medicine at Massachusetts General Hospital and his oncology fellowship at the Dana-Farber/Partners combined program. Dr.&#160;Multani has served on the board of directors of Chimerix, Inc., a publicly traded biopharmaceutical company, since February 2020. Dr.&#160;Multani holds an M.D. from Harvard Medical School, an M.S. in epidemiology from the Harvard School of Public Health and a B.S. in chemistry and biology from Yale University. Dr.&#160;Multani&#8216;s executive and academic experience in the biopharmaceutical industry and his medical expertise in oncology and hematology-oncology contributed to our Board&#8217;s conclusion that he should serve as a director of our Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_3">Proposal 2 &#8211; Ratification of appointment of independent registered public accounting firm </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee has appointed KPMG LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2025. The Board has directed that this appointment be submitted to our stockholders for ratification. Although ratification of our appointment of KPMG LLP is not required, we value the opinions of our stockholders and believe that stockholder ratification of our appointment is a good corporate governance practice. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KPMG LLP also served as our independent registered public accounting firm for the fiscal years ended December&#160;31, 2024 and 2023. Neither the accounting firm nor any of its members has any direct or indirect financial interest in or any connection with us in any capacity other than as our auditors, providing audit and <span style="white-space:nowrap">non-audit</span> services. A representative of KPMG LLP is expected to attend the Annual Meeting, and to have an opportunity to make a statement and will be available to respond to appropriate questions from stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the appointment of KPMG LLP is not ratified by the stockholders, the Audit Committee will consider this fact when it appoints the independent registered public accounting firm for the fiscal year ending December&#160;31, 2026. Even if the appointment of KPMG LLP is ratified, the Audit Committee retains the discretion to appoint a different independent registered public accounting firm at any time if it determines that such a change is in the interest of the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote required </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively. Abstentions are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal. Because brokers have discretionary authority to vote on the ratification of the appointment of KPMG LLP, we do not expect any broker <span style="white-space:nowrap">non-votes</span> in connection with this proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Board unanimously recommends a vote FOR the ratification of the appointment of KPMG LLP as our independent registered public accounting firm. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independent registered public accounting firm fees and other matters </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the fees of KPMG LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years for audit services and billed to us in each of the last two fiscal years for other services: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Fiscal&#160;Years&#160;Ended</span><br/><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Fee Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees(1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">894,389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">506,220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">896,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">508,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Audit Fees consist of fees for the audit of our consolidated financial statements, the review of the unaudited interim consolidated financial statements included in our quarterly reports on Form <span style="white-space:nowrap">10-Q</span> and the issuance of consents and comfort letters in connection with registration statements. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All Other Fees consist of fees billed for a subscription to an online accounting research service. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Audit Committee <span style="white-space:nowrap">pre-approval</span> of audit and <span style="white-space:nowrap">non-audit</span> services </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has established a policy that all audit and permissible <span style="white-space:nowrap">non-audit</span> services provided by our independent registered public accounting firm will be <span style="white-space:nowrap">pre-approved</span> by the Audit Committee, and all such services were <span style="white-space:nowrap">pre-approved</span> in accordance with this policy during the fiscal year ended December&#160;31, 2024. These services may include audit services, audit-related services, tax services and other services. The Audit Committee considers whether the provision of each <span style="white-space:nowrap">non-audit</span> service is compatible with maintaining the independence of our auditors. <span style="white-space:nowrap">Pre-approval</span> is detailed as to the particular service or category of services and is generally subject to a specific budget. Our independent registered public accounting firm and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this <span style="white-space:nowrap">pre-approval,</span> and the fees for the services performed to date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Report of the Audit Committee of the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has reviewed the Company&#8217;s audited consolidated financial statements for the fiscal year ended December&#160;31, 2024 and has discussed these financial statements with management and the Company&#8217;s independent registered public accounting firm. The Audit Committee has also received from, and discussed with, the Company&#8217;s independent registered public accounting firm various communications that such independent registered public accounting firm is required to provide to the Audit Committee, including the matters required to be discussed by statement on Auditing Standards No.&#160;1301 (Communications with Audit Committees), as adopted by the Public Company Accounting Oversight Board (the PCAOB). The Audit Committee is not employed by the Company, nor does it provide any expert assurance or professional certification regarding the Company&#8217;s consolidated financial statements. The Audit Committee relies, without independent verification, on the accuracy and integrity of the information provided, and representations made, by management and the Company&#8217;s independent registered public accounting firm. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s independent registered public accounting firm also provided the Audit Committee with a formal written statement required by PCAOB Rule 3526 (Communications with Audit Committees Concerning Independence) describing all relationships between the independent registered public accounting firm and the Company, including the disclosures required by the applicable requirements of the PCAOB regarding the independent registered public accounting firm&#8217;s communications with the Audit Committee concerning </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
independence. In addition, the Audit Committee discussed with the independent registered public accounting firm its independence from Erasca, Inc. The Audit Committee also considered whether the independent registered public accounting firm&#8217;s provision of certain other <span style="white-space:nowrap">non-audit</span> related services to the Company is compatible with maintaining such firm&#8217;s independence. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the reviews and discussions referred to above, the Audit Committee recommended to the Board that the audited consolidated financial statements be included in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2024. The Audit Committee and the Board also have recommended, subject to stockholder approval, the ratification of the appointment of KPMG LLP as the Company&#8217;s independent registered public accounting firm for 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report of the Audit Committee is not &#8220;soliciting material,&#8221; shall not be deemed &#8220;filed&#8221; with the SEC and shall not be incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing report has been furnished by the Audit Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Respectfully submitted, </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:right">Audit Committee </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Alexander W. Casdin, <span style="font-style:italic">Chair</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Julie Hambleton, M.D. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Jean I. Liu, J.D. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_3a">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table identifies our executive officers as of April&#160;28, 2025: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:31%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:62%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan E. Lim, M.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">53</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chairman of the Board, Chief Executive Officer, and <span style="white-space:nowrap">Co-Founder</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David M. Chacko, M.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer and Chief Business Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shannon R. Morris, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebun S. Garner, J.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">General Counsel and Corporate Secretary</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is biographical information for our executive officers other than Dr.&#160;Lim, whose biographical information is included under &#8220;Information regarding directors &#8211; Nominees for election to the Board&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">David M. Chacko, M.D. </span>has served as our Chief Financial Officer and Chief Business Officer since April 2023, having previously served as Chief Financial Officer since December 2020. Dr.&#160;Chacko joined Erasca in August 2019 as our Chief Business Officer. In April 2023 he reassumed his role as Chief Business Officer as well as remaining as our Chief Financial Officer. Prior to Erasca, he was a Principal at Versant Ventures from September 2017 to August 2019, where he held a dual investing/operating role, helping lead investment opportunities across multiple therapeutic areas. Operationally, he was intimately involved in advancing several Versant portfolio companies through company formation, fundraising, business development, and clinical and regulatory activities. Dr.&#160;Chacko joined Versant from Alcon, where he was as Chief of Staff to the CEO from 2014 to September 2017. At Alcon he worked alongside the executive leadership team to develop and implement high priority corporate initiatives to accelerate growth and innovation. Prior to Alcon, Dr.&#160;Chacko was an Engagement Manager at McKinsey&#160;&amp; Company from 2011 to 2014. While at McKinsey Dr.&#160;Chacko led multiple teams serving pharmaceutical and medical companies across sales, marketing, R&amp;D, finance and other functions. Previously, Dr.&#160;Chacko worked at SR One, the venture capital arm of GSK. He also worked at Amgen in commercial operations and at Morgan Stanley in investment banking. Dr.&#160;Chacko holds an M.D. from the University of Pennsylvania, where he was a Gamble Scholar and President of the medical student body, and an M.B.A. from the Wharton School. He earned an M. Phil. from Oxford University, where he was a Marshall Scholar, and B.A. and B.S. degrees in biology and business from the University of Southern California, where he graduated as the University Valedictorian. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Shannon R. Morris, M.D., Ph.D. </span>has served as our Chief Medical Officer since April 2023. Dr.&#160;Morris joined Erasca in May 2022 as Senior Vice President, Clinical Development. Dr.&#160;Morris brings over 20 years of experience in the life sciences industry with a focus in oncology. Prior to joining Erasca, from September 2020 to March 2022, Dr.&#160;Morris was Vice President, Head of Clinical Development, and a member of the Executive Committee at Istari Oncology, Inc. Prior to Istari Oncology, from April 2017 to September 2020, Dr.&#160;Morris was Vice President of Clinical Development at G1 Therapeutics, Inc., where she led the development of Cosela, achieving breakthrough therapy designation as well as a successful new drug application submission. Prior to G1 Therapeutics, from October 2014 to March 2017, Dr.&#160;Morris was a Senior Director at MedImmune, the global biologics research and development arm of AstraZeneca PLC, where she supported the successful biologics license application for Imfinzi<sup style="font-size:75%; vertical-align:top">&#174;</sup> and led the development of multiple early phase immuno-oncology assets. Prior to MedImmune, Dr.&#160;Morris held roles of increasing responsibility at GSK plc (formerly known as GlaxoSmithKline plc), where her efforts focused on the early phase development of small molecule inhibitors of AKT, PI3K, and MEK, including the approved MEK inhibitor Mekinist. During her time at GSK and MedImmune, Dr.&#160;Morris maintained an adjunct appointment at the University of North Carolina where her practice focused on the clinical care of patients with breast and gastrointestinal cancers. Dr.&#160;Morris completed her internal medicine residency and oncology fellowship at the University of North Carolina, earned an M.D. and Ph.D. in molecular virology from Case Western Reserve University, and received a B.S. in biological sciences from Stanford University. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Ebun S. Garner, J.D. </span>has served as our General Counsel and Corporate Secretary since April 2021. Prior to joining us, Mr.&#160;Garner served as Assistant General Counsel of Acadia Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he was the primary legal support for business development and public company reporting, from August 2020 until April 2021. Prior to Acadia, Mr.&#160;Garner served as the Chief Legal Officer and Corporate Secretary of Imbria Pharmaceuticals, Inc., a private therapeutics company, where he oversaw all legal and intellectual property matters from April 2019 to July 2020. Prior to Imbria, Mr.&#160;Garner served as Associate General Counsel at Neurocrine Biosciences, Inc., a publicly traded biopharmaceutical company, where he was the primary legal support for all <span style="white-space:nowrap">non-commercial</span> legal matters and public company reporting from March 2017 to April 2019 . Prior to that, Mr.&#160;Garner served as the Senior Vice President, General Counsel and Corporate Secretary of Alphatec Spine, Inc., a publicly traded medical device company, where he worked from 2005 until February 2017. Mr.&#160;Garner was a corporate associate in the New York office of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. from 2000 to 2005. He received a B.A. in Economics from the University of Pennsylvania and a J.D. from New York University School of Law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_3b">Corporate Governance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has adopted Corporate Governance Guidelines, a Code of Business Conduct and Ethics and charters for our Nominating and Corporate Governance Committee, Audit Committee and Compensation Committee to assist the Board in the exercise of its responsibilities and to serve as a framework for the effective governance of the Company. You can access our current committee charters, our Corporate Governance Guidelines and our Code of Business Conduct and Ethics in the &#8220;Corporate Governance&#8221; section of the &#8220;Investors&#8221; page of our website located at www.erasca.com, or by writing to our Secretary at our offices at 3115 Merryfield Row, Suite&#160;300, San Diego, California 92121. Please note, however, that the information contained on the website is not incorporated by reference in, or considered part of, this proxy statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director independence </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board currently consists of eight members. The Board has determined that all of our directors, other than Drs.&#160;Lim and Varney, are independent directors in accordance with the listing requirements of the Nasdaq Global Select Market (Nasdaq). The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, the Board has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, the Board reviewed and discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board experience and director nomination process </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee is responsible for reviewing with the Board, on an annual basis, the appropriate characteristics, skills and experience required for the Board as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for election or appointment, the Nominating and Corporate Governance Committee, in recommending candidates for election, and the Board will take into account many factors, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">personal and professional integrity, strong ethics and values and the ability to make mature business judgments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience in corporate management, such as serving as an officer or former officer of a publicly traded company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience as a board member or executive officer of another publicly traded company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience in finance and accounting and/or executive compensation practices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">strong leadership skills; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">contribution to the range of backgrounds, perspectives, and experiences on the board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">relevant academic expertise or other proficiency in an area of our business operations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether the candidate has the time required for preparation, participation and attendance at Board meetings and committee meetings, as applicable. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, the Board evaluates each individual in the context of the Board as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than the foregoing, there are no stated minimum criteria for director nominees, although the Nominating and Corporate Governance Committee may also consider such other factors as it may deem to be in the best interests of our Company and our stockholders. The Nominating and Corporate Governance Committee does, however, believe </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
it appropriate for at least one member of our Board to meet the criteria for an &#8220;audit committee financial expert&#8221; as defined by SEC rules, and that a majority of the members of our Board meet the definition of &#8220;independent director&#8221; under Nasdaq qualification standards. The Nominating and Corporate Governance Committee also believes it is appropriate for our Chief Executive Officer to serve as a member of our Board and as our Chairman. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Identification and evaluation of nominees for directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee identifies nominees for director by first evaluating the current members of our Board willing to continue in service. Current members with qualifications and skills that are consistent with the Nominating and Corporate Governance Committee&#8217;s criteria for Board service and who are willing to continue in service are considered for <span style="white-space:nowrap">re-nomination,</span> balancing the value of continuity of service by existing members of our Board with that of obtaining a new perspective or expertise. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any member of our Board does not wish to continue in service or if our Board decides not to <span style="white-space:nowrap">re-nominate</span> a member for <span style="white-space:nowrap">re-election</span> or if the Board decides to expand the size of the board, the Nominating and Corporate Governance Committee identifies the desired skills and experience of a new nominee in light of the criteria above. The Nominating and Corporate Governance Committee generally polls our Board and members of management for their recommendations. The Nominating and Corporate Governance Committee may also review the composition and qualification of the boards of directors of our competitors and may seek input from industry experts or analysts. The Nominating and Corporate Governance Committee reviews the qualifications, experience and background of the candidates. Final candidates are interviewed by the members of the Nominating and Corporate Governance Committee and by certain of our other independent directors and executive management. In making its determinations, the Nominating and Corporate Governance Committee evaluates each individual in the context of our Board as a whole, with the objective of assembling a group that can best contribute to the success of our Company and represent stockholder interests through the exercise of sound business judgment. After review and deliberation of all feedback and data, the Nominating and Corporate Governance Committee makes its recommendation to our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee evaluates nominees recommended by stockholders in the same manner as it evaluates other nominees. We have not received director candidate recommendations from our stockholders, and we do not have a formal policy regarding consideration of such recommendations. However, any recommendations received from stockholders will be evaluated in the same manner that potential nominees suggested by members of our Board, management or other parties are evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our Bylaws, a stockholder wishing to suggest a candidate for director should write to our Secretary and provide such information about the stockholder and the proposed candidate as is set forth in our Bylaws and as would be required by SEC rules to be included in a proxy statement. In addition, the stockholder must include the consent of the candidate and describe any arrangements or undertakings between the stockholder and the candidate regarding the nomination. In order to give the Nominating and Corporate Governance Committee sufficient time to evaluate a recommended candidate and include the candidate in our proxy statement for the annual meeting, the recommendation should be received by our Corporate Secretary at our principal executive offices in accordance with our procedures detailed in the section below entitled &#8220;Stockholder Proposals.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board skills and experience </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board comprises a diverse group of individuals with various complementary skills and business experience. We believe that our Board collectively has an appropriate mix of skills to guide and assist Erasca as we seek to achieve our long-term goals. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:52%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Expertise</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Lim</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Bristol</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Casdin</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Hambleton</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Harding-</span><br/><span style="font-weight:bold">Start</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Liu</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Multani</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Varney</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biopharma Industry</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operational Leadership</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drug Discovery, Development and Regulatory</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate Governance</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center">&#8718;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Communication from stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board will give appropriate attention to written communications that are submitted by stockholders, and will respond if and as appropriate. Our Secretary is primarily responsible for monitoring communications from stockholders and for providing copies or summaries to the directors as he considers appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Communications are forwarded to all directors if they relate to important substantive matters and include suggestions or comments that our Secretary and Chairman of the Board consider to be important for the directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances and matters&#160;as to which we tend to receive repetitive or duplicative communications. Stockholders who wish to send communications on any topic to the Board should address such communications to the Board in writing: c/o&#160;Secretary, Erasca, Inc., 3115 Merryfield Row, Suite 300, San Diego, California 92121. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director attendance at annual meetings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not have a formal policy regarding attendance by members of our Board at our Annual Meeting, we encourage all of our directors to attend. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board leadership structure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board is currently led by our Chairman, Jonathan E. Lim, M.D. The Board recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as we continue to grow. We do not currently separate the roles of Chief Executive Officer and Chairman of the Board. The Board has determined that having an employee director serve as Chairman is in the best interest of our stockholders at this time because combining the roles allows one person to drive strategy and agenda-setting at the board level, as well as maintaining responsibility for executing on that strategy. The Board has concluded that our current leadership structure is appropriate at this time. In 2023, in recognition of the importance of independent oversight over management, the Board created the position of Lead Independent Director. The Lead Independent Director is elected by the independent members of the Board. The Board will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Lead Independent Director </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The responsibilities of the Lead Independent Director, as set forth in our Corporate Governance Guidelines, include, but are not limited to: presiding over all meetings of the Board at which the Chairman of the Board is not present, including any executive sessions of the independent directors; calling separate meetings of the independent directors, if needed; providing feedback on Board meeting schedules and agendas; acting as the liaison between the independent directors and the Chief Executive Officer and Chairman of the Board; providing the Chairman of the Board with feedback and counsel regarding the Chairman&#8217;s interactions with the Board; providing the Chairman of the Board and management with feedback on the quality, quantity, and timeliness of information provided to the Board; responding to stockholder questions that are directed to the Lead Independent Director or the independent directors as a group; and such other functions and responsibilities as requested by the Board from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by the Board, the Lead Independent Director shall serve for an initial three-year term or, if earlier than the expiration of such three-year term, until such director&#8217;s successor has been duly elected and qualified or until such director&#8217;s earlier death, resignation or removal. James Bristol, Ph.D., was elected as the Lead Independent Director in July 2023, with a term that runs until the 2025 Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of Board in risk oversight process </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has responsibility for the oversight of our risk management processes and, either as a whole or through its committees, regularly discusses with management our major risk exposures, their potential impact on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>
<div style="display: none"><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="eras-20241231.xsd"/></ix:references></ix:header></div><div><div><div style="line-height:normal;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from Board committees and members of senior management to enable the Board to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the Audit Committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance, including with respect to cybersecurity. Oversight by the Audit Committee includes direct communication with our external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The Compensation Committee is responsible for assessing whether any of our compensation policies or programs has the potential to encourage excessive risk-taking. The Nominating and Corporate Governance Committee manages risks associated with the independence of the Board, corporate disclosure practices, and potential conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly informed through committee reports about such risks. Matters of significant strategic risk are considered by the Board as a whole. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Board evaluation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Corporate Governance Guidelines require the Nominating and Corporate Governance Committee to oversee a periodic assessment by the Board of the Board&#8217;s performance. As provided in our Corporate Governance Guidelines, the Nominating and Corporate Governance Committee, acting in consultation with the Board, is responsible for establishing the evaluation criteria and implementing the process for such evaluation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Code of ethics </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a written Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of the code in the &#8220;Corporate Governance&#8221; section of the &#8220;Investors&#8221; page of our website located at www.erasca.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Prohibition against pledging and hedging </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain an insider trading compliance policy that prohibits our officers, directors and employees from pledging our stock as collateral to secure loans and from engaging in hedging transactions, including prepaid variable forward contract, equity swaps, collars and exchange funds. It further prohibits margin purchases of our stock or placing our stock in a margin account, short sales of our stock, and any transactions in puts, calls or other derivative securities involving our stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Insider trading compliance policy </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has <ix:nonNumeric name="ecd:InsiderTrdPoliciesProcAdoptedFlag" contextRef="P01_01_2024To12_31_2024" format="ixt:fixed-true" id="ixv-4857">adopted</ix:nonNumeric> an Insider Trading Compliance Policy and Procedures applicable to our directors, officers, employees, and other covered persons that we believe are reasonably designed to promote compliance with insider trading laws, rules and regulations, and Nasdaq listing standards. It is also the Company&#8217;s policy to comply with U.S. insider trading laws and regulations, including with respect to transactions in our own securities. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Attendance by members of the Board at meetings </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were six meetings of the Board during the fiscal year ended December&#160;31, 2024. During the fiscal year ended December&#160;31, 2024, each director attended at least 75% of the aggregate of all meetings of the Board and meetings of the committees on which such director served during the period in which he or she served as a director. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Committees of the Board </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has established three standing committees &#8211; the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee; each of which operates under a charter that has been approved by the Board. All of the members of each of the Board&#8217;s three standing committees are independent as defined under the Nasdaq rules. In addition, all members of the Audit Committee meet the independence requirements for Audit Committee members under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10A-3</div> under the Securities Exchange Act of 1934 (the Exchange Act). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current members of each of the Board committees and committee Chairs are set forth in the following chart. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:53%"/>
<td style="vertical-align:bottom;width:14%"/>
<td/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td style="vertical-align:bottom;width:14%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Name of Director</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Audit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nominating&#160;and</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Corporate&#160;Governance</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">James A. Bristol, Ph.D.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">C</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">X</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Alexander W. Casdin</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">C&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Julie Hambleton, M.D.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pratik S. Multani, M.D.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">X</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valerie Harding-Start, Ph.D.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">C</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Jean I. Liu, J.D.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">C</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Committee Chair </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#8224;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Financial Expert </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Audit Committee </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee&#8217;s main function is to oversee our accounting and financial reporting processes and the audits of our consolidated financial statements. This committee&#8217;s responsibilities include, among other things: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">appointing our independent registered public accounting firm; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">evaluating the qualifications, independence and performance of our independent registered public accounting firm; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">approving the audit and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-audit</div> services to be performed by our independent registered public accounting firm; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical accounting policies; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">discussing with management and the independent registered public accounting firm the results of our annual audit and the review of our quarterly unaudited consolidated financial statements; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">reviewing, overseeing and monitoring the integrity of our consolidated financial statements and our compliance with legal and regulatory requirements as they relate to financial statements or accounting matters; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to the Board any changes to such investment policy; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">reviewing with management and our auditors any earnings announcements and other public announcements regarding our results of operations; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">preparing the report that the SEC requires in our annual proxy statement; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">discussing the Company&#8217;s policies with respect to risk assessment and risk management, including with respect to cybersecurity; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of conduct and ethics; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">reviewing and evaluating, at least annually, the performance of the Audit Committee and its members including compliance of the Audit Committee with its charter. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of our Audit Committee are Mr.&#160;Casdin, Dr.&#160;Hambleton, and Ms.&#160;Liu. Mr.&#160;Casdin serves as the Chair of the Audit Committee. All members of our Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. The Board has determined that Mr.&#160;Casdin is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations. The Board has determined each of Mr.&#160;Casdin, Dr.&#160;Hambleton, and Ms.&#160;Liu are independent under the applicable rules of the SEC and Nasdaq. All members of our Audit Committee are independent under Nasdaq rules and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10A-3.</div> The Audit Committee operates under a written charter that satisfies the applicable standards of the SEC and Nasdaq, which the Audit Committee will evaluate and review at least annually. The Audit Committee met four times during 2024. Both our external auditor and internal financial personnel meet privately with the Audit Committee and have unrestricted access to this committee. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Compensation Committee </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee reviews, approves and recommends to the Board policies relating to compensation and benefits of our officers, employees and directors. The Compensation Committee approves corporate goals and objectives relevant to the compensation of our chief executive officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these officers based on such evaluations. The Compensation Committee also reviews and approves or makes recommendations to the Board regarding the issuance of stock options and other awards under our equity plan. In addition, the Compensation Committee periodically reviews and recommends to the Board compensation for service on the Board and any committees of the Board. The Compensation Committee may delegate its authority under its charter to one or more subcommittees as it deems appropriate from time to time as further described in its charter. The Compensation Committee will review and evaluate, at least annually, its charter, as well as review and evaluate, at least annually, the performance of the Compensation Committee and its members, including compliance by the Compensation Committee with its charter. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee has retained Alpine Rewards, LLC (Alpine), as its independent compensation consultant to advise the Compensation Committee on matters pertaining to director and executive compensation, including advising as to market levels and practices, plan design and implementation, comparable company data, consulting best practices and governance principles, as well as on matters related to employee equity compensation. Alpine does not provide any other services to the Company. The Compensation Committee has determined, and Alpine has affirmed, that Alpine&#8217;s work does not present any conflicts of interest and that Alpine is independent. In reaching these conclusions, the Compensation Committee considered the factors set forth in Exchange Act <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;10C-1</div> and Nasdaq listing standards. The members of our compensation committee are Drs. Bristol, Hambleton and Harding-Start. Dr.&#160;Bristol serves as the Chair of the committee. Our Board has determined that each member of this committee is independent under the applicable rules and regulations of Nasdaq and is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;non-employee</div> director&#8221; as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">16b-3</div> promulgated under the Exchange Act. The Compensation Committee met five times during 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Compensation Committee interlocks and insider participation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the members of our Compensation Committee is currently, or has at any time been, one of our officers or employees. None of our executive officers currently serves, or has served during the past fiscal year, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions or, in the absence of any such committee, the entire board of directors) of any entity that has one or more executive officers serving as a member of our Board or Compensation Committee. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Nominating and Corporate Governance Committee </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee is responsible for assisting the Board in discharging the Board&#8217;s responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which directors are to be elected), and the selection of candidates to fill any vacancies on the Board and any committees thereof. In addition, the Nominating and Corporate Governance Committee is </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">responsible for overseeing our corporate governance policies, reporting and making recommendations to the Board concerning governance matters, oversight of the evaluation of the Board and reviewing and assisting the Board with oversight of matters relating to environmental, social and governance matters affecting the Company. The members of our Nominating and Corporate Governance Committee are Drs. Harding-Start, Bristol and Multani. Dr.&#160;Harding-Start serves as the Chair of the committee. The Board has determined that each member of this committee is independent under the applicable rules and regulations of Nasdaq relating to Nominating and Corporate Governance Committee independence. The Nominating and Corporate Governance Committee operates under a written charter, which the Nominating and Corporate Governance Committee will review and evaluate at least annually. The Nominating and Corporate Governance Committee met two times during 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Environmental, social and governance initiatives </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Erasca, while our mission to erase cancer inspires us, we know we can do more to make an even broader contribution to society. To that end, we are pursuing environmental, social, and governance (ESG) initiatives that are aligned with our core mission. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Erasca Foundation: </div></div>In May 2021, we established the Erasca Foundation, a nonprofit California public benefit corporation, which was funded by the donation of 1,093,557 shares of our common stock (which at the time represented 1% of our capital stock),&#160;in conjunction with our IPO. In addition, in April 2024 we made a $125,000 donation to the Erasca Foundation. In 2024 the Erasca Foundation provided funding for initiatives to positively impact society, including providing funding to the following organizations: </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Best Buddies International</div></div> (provides support to individuals with intellectual and developmental disabilities); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">The Clarity Foundation</div></div> (strives to improve the survival and quality of life of women with ovarian cancer); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cancer Angels of San Diego</div></div> (provides support to stage IV cancer patients in the greater San Diego area); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lazerex Cancer Foundation</div></div> (strives to improve cancer clinical trial diversity and enrollment, and patient access to care); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Life Science Cares</div></div> (seeks to disrupt the cycle of poverty and inequality in the communities in which it serves); and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Curebound</div></div> (funds cancer research). </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Environmental initiatives:</div></div> We strive to minimize our carbon footprint with respect to both our physical buildings and our manufacturing process. Both of our physical buildings limit their carbon footprint. Our San Diego office is Gold Level Leadership in Energy and Environmental Design (LEED) certified, and our San Francisco office is Platinum Level LEED certified. Each building is accessible by public transportation, and has electric vehicle charging stations and indoor bike racks. We also encourage our employees to recycle, including recycling programs for certain of our lab supplies. While we rely on third-party vendors to conduct our drug manufacturing, our chemists that are engaged in the manufacturing process are committed to increasing efficiencies, reducing materials, and minimizing waste. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Code of Conduct and Ethics: </div></div>Our Code of Business Conduct and Ethics applies to all of our employees, officers and directors, and requires the highest standards of business ethics. The Code of Business Conduct and Ethics and other corporate governance documents are located in the &#8220;Corporate Governance&#8221; section of the &#8220;Investors&#8221; page of our website located at www.erasca.com. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Inclusive clinical trial participation: </div></div>We intend to make clinical trials of our product candidates more accessible to all patient&#160;populations and plan to partner with others who are like-minded in this regard. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Drug access program: </div></div>If our products become commercially available<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">, </div></div>we intend to pursue initiatives to provide patients with access to such drugs, including through&#160;patient assistance programs and<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>compassionate use programs. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="toc897507_4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Executive and Director Compensation </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section&#160;discusses the material components of the executive compensation program for our executive officers who are named in the &#8220;Summary compensation table&#8221; below, whom we refer to as our named executive officers or NEOs. For 2024, our NEOs and their positions were as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Jonathan E. Lim, M.D., Chairman, Chief Executive Officer, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-Founder;</div> </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">David M. Chacko, M.D., Chief Financial Officer and Chief Business Officer; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Shannon R. Morris, M.D., Ph.D., Chief Medical Officer. </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Summary compensation table </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents summary information regarding the total compensation that was awarded to, earned by or paid to our NEOs for services rendered during the years ended December&#160;31, 2024 and 2023. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:44%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Name and</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">principal Position</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Salary</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Bonus</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stock</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">awards</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Option</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">awards</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">($)<div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space:nowrap;display:inline;">Non-equity</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">incentive&#160;plan</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">compensation</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">($)<div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px">(2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">All&#160;other</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">compensation</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">($)<div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px">(3) </div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Jonathan E. Lim, M.D.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">644,600</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2,794,308</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">444,774</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">10,350</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">3,894,032</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chairman, Chief Executive Officer, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Co-Founder</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">622,800</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">4,419,750</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">354,996</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">9,900</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">5,407,446</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">David M. Chacko, M.D.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">492,100</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">1,155,690</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">226,366</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">10,350</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">1,884,506</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chief Financial Officer and Chief Business Officer</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">475,500</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">1,767,900</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">180,690</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">9,900</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2,433,990</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shannon R. Morris, M.D., Ph.D.</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">486,500</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">866,870</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">223,790</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">10,350</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">1,587,510</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chief Medical Officer</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents the grant date fair value of stock options to purchase shares of our common stock computed in accordance with FASB ASC 718. See Note 10 to our consolidated financial statements included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K</div> for the year ended December&#160;31, 2024 filed with the SEC on March&#160;20, 2025, for a description of the assumptions used in valuing our stock options. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents annual performance bonuses earned with respect to the applicable year. For Dr.&#160;Lim, amount includes $125,000 of the 2023 annual performance bonus that was earned by him but which Dr.&#160;Lim voluntarily elected to forgo and did not receive. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Represents matching contributions under our 401(k) plan earned by the NEOs in 2024 and, for Drs. Lim and Chacko, in 2023, which are expected to be made by us on behalf of the NEOs in 2025 and 2024, respectively. </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Narrative disclosure to compensation tables </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary elements of compensation for our NEOs are base salary, annual performance bonuses and equity awards. The NEOs also participate in employee benefit plans and programs that we offer to our other employees, as described below. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Annual base salary </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We pay our NEOs a base salary to compensate them for the satisfactory performance of services rendered to us. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. Base salaries for our NEOs have generally been set at levels deemed necessary to attract and retain individuals with superior talent. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2024, Dr.&#160;Lim&#8217;s annual base salary was increased from $622,800 to $644,600, Dr.&#160;Chacko&#8217;s annual base salary was increased from $475,500 to $492,100, and Dr.&#160;Morris&#8217; annual base salary was increased from $470,000 to $486,500. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2025, each of Drs.&#160;Lim, Chacko, and Morris received a base salary increase to $670,400, $516,700, and $515,000, respectively, effective January&#160;1, 2025. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that base salaries for our NEOs will be reviewed periodically by our Compensation Committee, with adjustments expected to be made generally in accordance with the considerations described above and to maintain base salaries at competitive levels. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Bonus compensation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, our Board or Compensation Committee may approve bonuses for our NEOs based on individual performance, company performance, or as otherwise determined appropriate. Pursuant to their respective employment letter agreements, each NEO has an established target annual bonus amount. For 2024, our NEOs&#8217; target bonuses, expressed as a percentage of annual base salary, were 60% for Dr.&#160;Lim and 40% for Drs.&#160;Chacko and Morris. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For 2024, annual bonuses were based on corporate performance relative to key corporate objectives tied to clinical and regulatory priorities as well as operational and financial objectives. Following a comprehensive review of our corporate performance relative to these corporate objectives, our compensation committee approved the payment of annual bonuses to our NEOs at 115% of target levels. The annual bonuses paid to our NEOs for 2024 are reflected in the Summary Compensation Table above. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Equity-based incentive awards </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our equity-based incentive awards are designed to align our interests and the interests of our stockholders with those of our employees and consultants, including our NEOs. The Board and compensation committee is responsible for approving equity grants. We typically grant equity awards to new hires upon their commencing employment with us. Generally, our equity awards vest over four years, subject to the employee&#8217;s continued employment with us on each vesting date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2024, we granted Drs.&#160;Lim, Chacko, and Morris options to purchase 1,500,000, 600,000, and 535,800 shares of our common stock, respectively, under our 2021 Incentive Award Plan (the 2021 Plan). The options are eligible to vest over a period of four years, with 1/48th of the options vesting on a monthly basis following the vesting commencement date, or February&#160;1, 2024, subject to continuous service through each vesting date. These options are eligible for accelerated vesting on the terms provided in the Severance Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2024, we granted Drs.&#160;Lim, Chacko, and Morris options to purchase 632,759, 278,812, and 137,142 shares of our common stock, respectively, under our 2021 Plan. The options are eligible to vest over a period of four years, with 1/48th of the options vesting on a monthly basis following the vesting commencement date, or June&#160;20, 2024, subject to continuous service through each vesting date. These options are eligible for accelerated vesting on the terms provided in the Severance Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2025, we granted Drs.&#160;Lim, Chacko, and Morris options to purchase 2,500,000, 800,000, and 780,000 shares of our common stock, respectively, under our 2021 Plan. The options are eligible to vest over a period of four years, with 1/48th of the options vesting on a monthly basis following the vesting commencement date, or February&#160;1, 2025, subject to continuous service through each vesting date. These options are eligible for accelerated vesting on the terms provided in the Severance Plan. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Other elements of compensation </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Perquisites, health, welfare and retirement benefits </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our NEOs are eligible to participate in our employee benefit plans, including our medical, dental, vision, group life, disability and accidental death and dismemberment insurance plans, in each case, on generally the same basis as all of our other employees. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances.<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"> </div>Our Board may elect to adopt qualified or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified</div> benefit plans in the future if it determines that doing so is in our best interests. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">401(k) plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution employee retirement plan (401(k)) plan, for our employees. Our NEOs are eligible to participate in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">tax-qualified</div> plan under Section&#160;401(a) of the Internal Revenue Code. The 401(k) plan provides that each participant may make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-tax</div> deferrals from his or her compensation up to the statutory limit, which is $23,500 for calendar year 2025, and other testing limits. Participants that are 50 years or older can also make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;catch-up&#8221;</div> contributions, which in calendar year 2025 may be up to an additional $7,500 above the statutory limit. The 401(k) plan provides for discretionary matching and profit-sharing contributions. Commencing in 2021, we make safe harbor company contributions of 100% of employee contributions up to 3%&#160;of their eligible compensation. Participant contributions are held and invested, pursuant to the participant&#8217;s instructions, by the plan&#8217;s trustee. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Nonqualified deferred compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. Our Board may elect to provide our officers and other employees with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified</div> defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Termination or change in control benefits </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our NEOs may become entitled to certain benefits or enhanced benefits in connection with a change in control of our company. Our Severance Plan entitles each of our NEOs to certain benefits upon a qualifying termination and in connection with a change in control of our company. For additional discussion, please see &#8220;Severance plan&#8221; below. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Clawback policy </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a compensation recovery policy that requires the recovery of certain erroneously paid incentive compensation received by our Section&#160;16 officers on or after October&#160;2, 2023, as required by new SEC rules and Nasdaq Stock Market Listing Standards implemented pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act. </div><ix:nonNumeric name="ecd:AwardTmgMnpiDiscTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_140094662" id="ixv-2315"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Equity Award Grant Practices </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="ecd:AwardTmgMethodTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-2320"><ix:nonNumeric name="ecd:AwardTmgMnpiCnsdrdFlag" contextRef="P01_01_2024To12_31_2024" format="ixt:fixed-false" id="ixv-2321">We have had <ix:nonNumeric name="ecd:MnpiDiscTimedForCompValFlag" contextRef="P01_01_2024To12_31_2024" format="ixt:fixed-false" id="ixv-4858">no program, plan or practice pertaining to the timing of stock option grants</ix:nonNumeric> to NEOs coinciding with the release of material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div> information.</ix:nonNumeric> Annual grants of stock options to employees are typically approved by the Compensation Committee or our Chief Executive Officer pursuant to a delegation of authority from the Compensation Committee in the first quarter of each year as part of our annual compensation cycle.</ix:nonNumeric> Our Board or Compensation Committee may also approve grants at other times as they deem appropriate. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>26</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_140094662" continuedAt="TextSelectionAppend_140094662_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_140094662_1" continuedAt="TextSelectionAppend_140094662_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><div style="width:790px"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_140094662_2"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The timing of any equity grants to newly-hired employees, or in connection with promotions or other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-routine</div> grants, is generally tied to the event giving rise to the award, although <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-executive</div> new hire stock option awards are generally approved at the beginning of the calendar month following the individual&#8217;s commencement of employment. For all stock option awards, the exercise price is no less than the closing price of our common stock on the date of the grant. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for certain stock options granted to our NEOs during 2024. In the event an issuer grants stock options or option-like instruments within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K,</div> Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">8-K</div> containing material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div> information as required under Item 402(x) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-K,</div> Item 402(x) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-K</div> requires tabular disclosure of certain information related to such awards. The table below is being provided because certain of the stock options granted to our NEOs during 2024 were granted within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K,</div> Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">8-K</div> containing material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div> information. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:40%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Securities</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Underlying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">the Award</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">the&#160;Award</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">at Time of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant <div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;Date</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">the Award</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Percentage&#160;Change&#160;in&#160;the</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Closing&#160;Market&#160;Price&#160;of&#160;the</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Securities Underlying the</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Award&#160;Between&#160;the&#160;Trading</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Day Ending Immediately</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Prior to the Disclosure of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">MNPI and the Trading Day</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Beginning Immediately</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Following the Disclosure of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">MNPI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="ecd:AwardsCloseToMnpiDiscIndName" contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis" id="ixv-4860">Jonathan E. Lim, M.D.</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardUndrlygSecuritiesAmt" contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-4861">632,759</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardExrcPrice" contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-4862">2.03</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardGrantDateFairValue" contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-4863">934,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="ecd:UndrlygSecurityMktPriceChngPct" contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-4864">1.43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="ecd:AwardsCloseToMnpiDiscIndName" contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis" id="ixv-4865">David M. Chacko, M.D.</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardUndrlygSecuritiesAmt" contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-4866">278,812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardExrcPrice" contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-4867">2.03</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardGrantDateFairValue" contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-4868">411,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="ecd:UndrlygSecurityMktPriceChngPct" contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-4869">1.43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="ecd:AwardsCloseToMnpiDiscIndName" contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis" id="ixv-4870">Shannon R. Morris, M.D., Ph.D.</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardUndrlygSecuritiesAmt" contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-4871">137,142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardExrcPrice" contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-4872">2.03</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="ecd:AwardGrantDateFairValue" contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-4873">202,531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="ecd:UndrlygSecurityMktPriceChngPct" contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis" unitRef="Unit_pure" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-4874">1.43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr></table></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The timing of any equity grants to newly-hired employees, or in connection with promotions or other <span style="white-space:nowrap">non-routine</span> grants, is generally tied to the event giving rise to the award, although <span style="white-space:nowrap">non-executive</span> new hire stock option awards are generally approved at the beginning of the calendar month following the individual&#8217;s commencement of employment. For all stock option awards, the exercise price is no less than the closing price of our common stock on the date of the grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for certain stock options granted to our NEOs during 2024. In the event an issuer grants stock options or option-like instruments within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form <span style="white-space:nowrap">10-K,</span> Form <span style="white-space:nowrap">10-Q</span> or Form <span style="white-space:nowrap">8-K</span> containing material <span style="white-space:nowrap">non-public</span> information as required under Item 402(x) of Regulation <span style="white-space:nowrap">S-K,</span> Item 402(x) of Regulation <span style="white-space:nowrap">S-K</span> requires tabular disclosure of certain information related to such awards. The table below is being provided because certain of the stock options granted to our NEOs during 2024 were granted within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form <span style="white-space:nowrap">10-K,</span> Form <span style="white-space:nowrap">10-Q</span> or Form <span style="white-space:nowrap">8-K</span> containing material <span style="white-space:nowrap">non-public</span> information. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Grant</span><br/><span style="font-weight:bold">Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of</span><br/><span style="font-weight:bold">Securities</span><br/><span style="font-weight:bold">Underlying</span><br/><span style="font-weight:bold">the Award</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Exercise<br/>Price of</span><br/><span style="font-weight:bold">the&#160;Award</span><br/><span style="font-weight:bold">at Time of</span><br/><span style="font-weight:bold">Grant <sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Grant&#160;Date</span><br/><span style="font-weight:bold">Fair&#160;Value&#160;of</span><br/><span style="font-weight:bold">the Award</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage&#160;Change&#160;in&#160;the</span><br/><span style="font-weight:bold">Closing&#160;Market&#160;Price&#160;of&#160;the</span><br/><span style="font-weight:bold">Securities Underlying the</span><br/><span style="font-weight:bold">Award&#160;Between&#160;the&#160;Trading</span><br/><span style="font-weight:bold">Day Ending Immediately</span><br/><span style="font-weight:bold">Prior to the Disclosure of</span><br/><span style="font-weight:bold">MNPI and the Trading Day</span><br/><span style="font-weight:bold">Beginning Immediately</span><br/><span style="font-weight:bold">Following the Disclosure of</span><br/><span style="font-weight:bold">MNPI</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan E. Lim, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">632,759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">934,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David M. Chacko, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">278,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">411,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shannon R. Morris, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">137,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">202,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employment letter agreements with our NEOs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment letter agreement with Dr.&#160;Lim </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an employment letter agreement with Dr.&#160;Lim, which governs the terms of his employment with us as Chairman of our Board and as our Chief Executive Officer. Pursuant to his letter agreement, Dr.&#160;Lim is entitled to an annual base salary and an annual performance bonus. Dr.&#160;Lim&#8217;s employment is <span style="white-space:nowrap">at-will.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which his service terminates, Dr.&#160;Lim is entitled to receive amounts previously earned during his term of service, including unpaid salary and bonus and cash out of unused vacation or paid time off. In addition, Dr.&#160;Lim is entitled to certain severance benefits under our Severance Plan under the &#8220;CEO&#8221; tier, as described below under &#8220;Severance plan.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment letter agreement with Dr.&#160;Chacko </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an employment letter agreement with Dr.&#160;Chacko, which governs the terms of his employment with us as our Chief Financial Officer and Chief Business Officer. Pursuant to his letter agreement, Dr.&#160;Chacko is entitled to an annual base salary and an annual performance bonus. Dr.&#160;Chacko&#8217;s employment is <span style="white-space:nowrap">at-will.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which his service terminates, Dr.&#160;Chacko is entitled to receive amounts previously earned during his term of service, including unpaid salary and bonus and cash out of unused vacation or paid time off. In addition, Dr.&#160;Chacko is entitled to certain severance benefits under our Severance Plan as a Tier 1 Covered Employee, as described below under &#8220;Severance plan.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment letter agreement with Dr. Morris </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an employment letter agreement with Dr.&#160;Morris, which governs the terms of her employment with us as our Chief Medical Officer. Pursuant to her letter agreement, Dr.&#160;Morris is entitled to an annual base salary and an annual performance bonus. Dr.&#160;Morris&#8217;s employment is <span style="white-space:nowrap">at-will.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which her service terminates, Dr.&#160;Morris is entitled to receive amounts previously earned during her term of service, including unpaid salary and bonus and cash out of unused vacation or paid time off. In addition, Dr, Morris is entitled to certain severance benefits under our Severance Plan as a Tier 1 Covered Employee, as described below under &#8220;Severance plan.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Severance plan </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2021, our Board adopted our Severance and Change in Control Severance Plan (the Severance Plan) for the benefit of certain employees of our company or any of our parents or subsidiaries as designated by our Compensation Committee (the Covered Employees). The severance benefits under the Severance Plan will supersede any severance benefits otherwise payable under the Covered Employees&#8217; employment offer letters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Severance Plan provides assurances of specified severance benefits to Covered Employees whose employment is subject to involuntary termination by us other than for cause (as defined in the Severance Plan) or the Covered Employee resigns for good reason (as defined in the Severance Plan) under the circumstances described in the Severance Plan, including, but not limited to, following a change in control (as defined in the Severance Plan). The severance benefits each Covered Employee could be entitled to receive under the Severance Plan are determined pursuant to each Covered Employee&#8217;s classification as the CEO, a Tier 1 Covered Employee, Tier 2 Covered Employee or Tier 3 Covered Employee. Covered Employees are classified as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;CEO&#8221; means our Chief Executive Officer. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Tier 1 Covered Employee&#8221; means an employee of our company who has been designated by our Compensation Committee as eligible to participate under Tier 1 in the Severance Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Tier 2 Covered Employee&#8221; means an employee of our company who has been designated by our Compensation Committee as eligible to participate under Tier 2 in the Severance Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;Tier 3 Covered Employee&#8221; means an employee of our company who has been designated by our Compensation Committee as eligible to participate under Tier 3 in the Severance Plan. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Severance Plan, if, at any time before or after the end of the <span style="white-space:nowrap">12-month</span> period beginning on the date of a change in control, we (or any of our parents or subsidiaries) terminate a Covered Employee&#8217;s employment other than for cause (and other than due to death or disability (as defined in the Severance Plan)) or the Covered Employee resigns for good reason, then the Covered Employee will be entitled to receive the following severance benefits, subject to his or her execution of a release of claims and compliance with certain restrictive covenants, including with respect to <span style="white-space:nowrap">non-solicitation</span> and <span style="white-space:nowrap">non-disparagement:</span> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">An amount equal to the Covered Employee&#8217;s annualized Base Pay (as defined in the Severance Plan) for 12 months, nine months, six months or six months following termination in the case of the CEO, a Tier 1, Tier 2 or Tier 3 Covered Employee, respectively, paid in a lump sum. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Company-paid COBRA coverage for 12 months, nine months, six months or six months following termination in the case of the CEO, a Tier 1, Tier 2 or Tier 3 Covered Employee, respectively. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The accelerated vesting of the equity compensation awards (as defined in the Severance Plan) that would have become vested and exercisable within 12 months, nine months, six months or six months following termination automatically accelerate as of the date of termination in the case of the CEO, a Tier 1, Tier 2 or Tier 3 Covered Employee, respectively. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Severance Plan, if, at any time within the <span style="white-space:nowrap">12-month</span> period following a change in control, we (or any of our parents or subsidiaries) terminate a Covered Employee&#8217;s employment other than for cause (and other than due to death or disability) or the Covered Employee resigns for Good Reason, then the Covered Employee will be entitled to receive the following severance benefits, subject to his or her execution of a release of claims and compliance with certain restrictive covenants, including with respect to <span style="white-space:nowrap">non-solicitation</span> and <span style="white-space:nowrap">non-disparagement:</span> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The following aggregate cash amount paid in installments over the following time period: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In the case of the CEO, the sum of 18 months of annualized base pay and 1.5 times his or her target bonus (as defined in the Severance Plan) paid in a lump sum. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In the case of a Tier 1 and Tier 2 Covered Employee, the sum of 12 months of annualized base pay and 1.0 times his or her target bonus paid in lump sum. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In the case of a Tier 3 Covered Employee, the sum of nine months of annualized base pay and the greater of 0.75 times his or her target bonus or a prorated target bonus based on the period of time he or she was employed for the fiscal year in which termination occurs. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Company-paid COBRA coverage for 18 months, 12 months, 12 months or nine months following termination in the case of the CEO, a Tier 1, Tier 2 or Tier 3 Covered Employee, respectively. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">100% accelerated vesting of the Covered Employee&#8217;s equity compensation awards. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The severance benefits prescribed by the Severance Plan are subject to a Section&#160;280G <span style="white-space:nowrap">better-off</span> cutback provision, which provides that, in the event that the benefits provided to the Covered Employee pursuant to the Severance Plan or otherwise constitute parachute payments with the meaning of Section&#160;280G of the Internal Revenue Code, the Covered Employee&#8217;s severance benefits under the Severance Plan will either be delivered in full or reduced to the extent necessary to avoid an excise tax under Section&#160;4999 of the Code, whichever would result in the Covered Employee receiving the largest amount of severance benefits on an <span style="white-space:nowrap">after-tax</span> basis. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding equity awards at fiscal <span style="white-space:nowrap">year-end</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to outstanding equity awards for each of our NEOs as of December&#160;31, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Grant</span><br/><span style="font-weight:bold">date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of</span><br/><span style="font-weight:bold">securities</span><br/><span style="font-weight:bold">underlying</span><br/><span style="font-weight:bold">unexercised</span><br/><span style="font-weight:bold">options</span><br/><span style="font-weight:bold">exercisable</span><br/><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of</span><br/><span style="font-weight:bold">securities</span><br/><span style="font-weight:bold">underlying</span><br/><span style="font-weight:bold">unexercised</span><br/><span style="font-weight:bold">options</span><br/><span style="font-weight:bold">unexercisable</span><br/><span style="font-weight:bold">(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option</span><br/><span style="font-weight:bold">exercise</span><br/><span style="font-weight:bold">price</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option</span><br/><span style="font-weight:bold">expiration</span><br/><span style="font-weight:bold">date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan E. Lim, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">79,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">553,665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/19/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/5/2024</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">312,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,187,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/4/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">687,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">812,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/31/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/1/2022</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">560,291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">230,709</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/31/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David M. Chacko, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">243,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/19/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/5/2024</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">125,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">475,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/4/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">275,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">325,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/31/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/1/2022</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">259,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">106,787</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/31/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/26/2021</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">153,043</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/25/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9/23/2020</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">183,688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9/22/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/11/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/10/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8/21/2019</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">455,730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8/20/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shannon R. Morris,&#160;M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">120,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/19/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/5/2024</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">111,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">424,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/4/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4/10/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">156,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">218,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4/9/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/1/2023</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">73,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">87,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/31/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5/2/2022</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">193,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">106,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5/1/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Stock option award vests over a period of four years with 1/48th of the shares underlying the option vesting on a monthly basis following the vesting commencement date (June 20, 2024), subject to continued service through each vesting date, and subject to accelerated vesting in certain circumstances as described above under &#8220;Severance plan.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Stock option award vests over a period of four years with 1/48th of the shares underlying the option vesting on a monthly basis following the vesting commencement date (February 1, 2024), subject to continued service through each vesting date, and subject to accelerated vesting in certain circumstances as described above under &#8220;Severance plan.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Stock option award vests over a period of four years with 1/48th of the shares underlying the option vesting on a monthly basis following the vesting commencement date (February 1, 2023), subject to continued service through each vesting date, and subject to accelerated vesting in certain circumstances as described above under &#8220;Severance plan.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Stock option award vests over a period of four years with 1/48th of the shares underlying the option vesting on a monthly basis following the vesting commencement date (February 1, 2022), subject to continued service through each vesting date, and subject to accelerated vesting in certain circumstances as described above under &#8220;Severance plan.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Stock option award vests over a period of four years with 25% of the shares underlying the option vesting on the <span style="white-space:nowrap">one-year</span> anniversary of the vesting commencement date (December 17, 2020, December&#160;11, 2019 and August&#160;12, 2019 for Dr.&#160;Chacko&#8217;s January&#160;26, 2021, December&#160;11, 2019 and August&#160;21, 2019 grants, respectively, and May&#160;2, 2022 for Dr.&#160;Morris) and 1/48th of the shares underlying the option vesting on a monthly basis thereafter, subject to continued service through each vesting date, and subject to accelerated vesting in certain circumstances as described above under &#8220;Severance plan.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Stock option award vests over a period of four years with 1/48th of the shares underlying the option vesting on a monthly basis following the vesting commencement date (September 23, 2020 for Dr.&#160;Chacko and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top;text-align:left">
April&#160;10, 2023 for Dr.&#160;Morris), subject to continued service through each vesting date, and subject to accelerated vesting in certain circumstances as described above under &#8220;Severance plan.&#8221; </td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our director compensation program is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our directors&#8217; interests with those of our stockholders. Directors who are also employees of our company do not receive compensation for their service on the Board. We have reimbursed, and will continue to reimburse, our <span style="white-space:nowrap">non-employee</span> directors for their actual <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs and expenses incurred in connection with attending board and committee meetings. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span> director compensation program </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">non-employee</span> director compensation program provides for annual retainer fees and/or long-term equity awards for our <span style="white-space:nowrap">non-employee</span> directors. Under the <span style="white-space:nowrap">non-employee</span> director compensation program in effect for 2024, each <span style="white-space:nowrap">non-employee</span> director received an annual retainer of $40,000, and the chair of the Board and/or lead independent director received an additional $30,000. Non-employee directors serving as the chairs of the audit, compensation and nominating and corporate governance committees received additional annual retainers of $15,000, $10,000, and $8,000, respectively. <span style="white-space:nowrap">Non-employee</span> directors serving as members of the audit, compensation and nominating and corporate governance committees received additional annual retainers of $7,500, $5,000, and $4,000, respectively. The <span style="white-space:nowrap">non-employee</span> directors also received initial grants of options to purchase 120,000 shares of our common stock, vesting over three years, upon election to the Board, and thereafter annual grants of options to purchase 60,000 shares of our common stock, vesting on the first to occur of (i)&#160;the first anniversary of the grant date or (ii)&#160;the next occurring annual meeting of our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December&#160;2024, the <span style="white-space:nowrap">non-employee</span> director compensation program for 2025 and thereafter was updated to: (i)&#160;increase the cash retainer for the chair and members of the compensation committee from $10,000 to $12,000, and $5,000 to $6,000, respectively; (ii)&#160;increase the cash retainer for the chair and members of the nominating and corporate governance committee from $8,000 to $10,000, and $4,000 to $5,000, respectively; (iii)&#160;increase the initial grant of options to purchase shares of our common stock from 120,000 shares to 240,000 shares; and (iv)&#160;increase the annual grant of options to purchase shares of our common stock from 60,000 shares to 120,000 shares. The remaining terms of the <span style="white-space:nowrap">non-employee</span> director compensation program remain unchanged.&#160;The <span style="white-space:nowrap">non-employee</span> director compensation program allows <span style="white-space:nowrap">non-employee</span> directors to elect to receive options to purchase shares of our common stock in lieu of receiving all of the cash retainer payable to such director in the next calendar year. Such election is voluntary and irrevocable for the applicable calendar year. In the event a <span style="white-space:nowrap">non-employee</span> director timely makes an election, such <span style="white-space:nowrap">non-employee</span> director will be granted a number of stock options under the 2021 Plan on the first day of the calendar year in which the cash retainer would otherwise be earned with a value equal to the aggregate dollar value of the cash retainer payable to the <span style="white-space:nowrap">non-employee</span> director for such calendar year based on the director&#8217;s committee assignments in effect on the last day of the preceding calendar year, as calculated on the grant date in accordance with the Black-Scholes option pricing model (utilizing the same assumptions that we utilized in connection in connection with the most recent stock options we granted prior to the grant date and the average closing price per share of our common stock for the calendar month preceding the grant date). The stock options will vest in twelve monthly installments on the last day of each calendar month following the date of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation under our <span style="white-space:nowrap">non-employee</span> director compensation program is subject to the annual limits on <span style="white-space:nowrap">non-employee</span> director compensation set forth in the 2021 Plan. Our Board or its authorized committee may modify the <span style="white-space:nowrap">non-employee</span> director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, subject to the annual limit on <span style="white-space:nowrap">non-employee</span> director compensation set forth in the 2021 Plan (which limits will not apply to any <span style="white-space:nowrap">non-employee</span> director that serves in any additional capacity with the company for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which he or she receives compensation or any compensation paid to any <span style="white-space:nowrap">non-employee</span> director prior to the calendar year following the calendar year in which this offering occurs). As provided in the 2021 Plan, our Board or its authorized committee may make exceptions to this limit for individual <span style="white-space:nowrap">non-employee</span> directors in extraordinary circumstances, as the Board or its authorized committee may determine in its discretion, provided that the <span style="white-space:nowrap">non-employee</span> director receiving such additional compensation may not participate in the decision to award such compensation or in other compensation decisions involving <span style="white-space:nowrap">non-employee</span> directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employment arrangements with Dr.&#160;Varney </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an employment letter agreement with Dr.&#160;Varney, which governs the terms of his employment with us as our Chair of R&amp;D. In this role, Dr.&#160;Varney also acts as a senior advisor to our Chief Executive Officer. Pursuant to his letter agreement, Dr.&#160;Varney is entitled to an annual base salary. In February 2025, Dr.&#160;Varney received a base salary increase from $86,400 to $89,900, effective November&#160;1, 2024. Dr.&#160;Varney&#8217;s employment is <span style="white-space:nowrap">at-will.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in June 2024, Dr.&#160;Varney was granted an option to purchase 60,000 shares of our common stock under our 2021 Plan. The option is eligible to vest in full on June&#160;20, 2025, subject to his continuous service through such date. Dr.&#160;Varney also serves on our scientific advisory board, or SAB, but does not receive any additional cash compensation for such service. Pursuant to his scientific advisory board agreement with Dr.&#160;Varney, which governs the terms of his retention with us as a SAB member and as a consultant, Dr.&#160;Varney is subject to a <span style="white-space:nowrap">non-competition</span> covenant during the term of his service with us, as well as <span style="white-space:nowrap">one-year</span> post- termination <span style="white-space:nowrap">non-solicitation</span> of employees and consultants covenant and a perpetual confidentiality covenant, in addition to his obligations under our standard proprietary information and inventions agreement, which was entered into in connection with his commencement of employment with us. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">2024 director compensation table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes compensation received by our <span style="white-space:nowrap">non-employee</span> directors and Dr.&#160;Varney during the year ended December&#160;31, 2024. Dr.&#160;Lim, our Chairman, Chief Executive Officer and <span style="white-space:nowrap">Co-Founder,</span> and Dr.&#160;Varney, our Chair of R&amp;D and SAB member, are also members of our Board, but do not receive any additional compensation for their service as directors in addition to the compensation they receive as employees. Dr.&#160;Lim&#8217;s compensation is described further above. Dr.&#160;Varney is currently a non-executive employee. For a description of the employment arrangements with Dr.&#160;Varney, please see &#8220;Employment arrangements with Dr.&#160;Varney&#8221; above. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:59%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Fees</span><br/><span style="font-weight:bold">earned&#160;or</span><br/><span style="font-weight:bold">paid in</span><br/><span style="font-weight:bold">cash</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option</span><br/><span style="font-weight:bold">awards</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">All other</span><br/><span style="font-weight:bold">compensation</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Bristol, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">84,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">95,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">179,095</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander W. Casdin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">55,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">91,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">146,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julie Hambleton, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">52,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">85,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138,366</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Harding-Start, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">53,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">91,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">144,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean I. Liu, J.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">47,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">91,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138,585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pratik S. Multani, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">44,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">90,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">134,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael D. Varney, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">85,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">89,593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">175,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts in this column represent the annual retainers to which the <span style="white-space:nowrap">non-employee</span> directors were entitled for 2024. Certain of the <span style="white-space:nowrap">non-employee</span> directors who were eligible to receive annual retainers elected to receive those annual retainers in the form of stock options, as described above. The number of options to be awarded was determined based on the Black-Scholes option pricing model on January&#160;1, 2024, which resulted in a Black-Scholes value per share of $1.34. The grant date fair value of the options awarded to the <span style="white-space:nowrap">non-employee</span> directors, computed in accordance with FASB ASC 718, was higher than the annual retainers otherwise payable to them. See Note 10 to our consolidated financial statements included in our Annual </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top;text-align:left">
Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2024 filed with the SEC on March&#160;20, 2025, for a description of the assumptions used in valuing our stock options. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the grant date fair value of stock options to purchase shares of our common stock computed in accordance with FASB ASC 718 and the incremental value of the annual retainers elected to be received in the form of stock options as follows: Dr.&#160;Bristol, $9,229; Mr.&#160;Casdin, $6,043; Dr.&#160;Harding-Start, $5,823; Ms.&#160;Liu, $5,219; and Dr.&#160;Multani, $4,834. See Note 10 to our consolidated financial statements included in our Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2024 filed with the SEC on March&#160;20, 2025, for a description of the assumptions used in valuing our stock options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts in this column for Dr.&#160;Varney include the base salary paid to him for his role as Chair of R&amp;D during 2024 of $86,983 and a matching contribution of $2,610 under our 401(k) plan earned by Dr.&#160;Varney in 2024, which is expected to be made by us on behalf of Dr.&#160;Varney in 2025. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate number of shares subject to stock options outstanding at December&#160;31, 2024 for our <span style="white-space:nowrap">non-employee</span> directors and Dr.&#160;Varney was as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:82%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">securities</span><br/><span style="font-weight:bold">underlying</span><br/><span style="font-weight:bold">options</span><br/><span style="font-weight:bold">outstanding&#160;at</span><br/><span style="font-weight:bold">December&#160;31,</span><br/><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Bristol, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">222,747</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander W. Casdin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">201,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julie Hambleton, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">326,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Harding-Start, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">387,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean I. Liu, J.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">235,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pratik S. Multani, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">213,701</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael D. Varney, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">554,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity compensation plan information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information on our equity compensation plans as of December&#160;31, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, we had three equity compensation plans, consisting of the Erasca, Inc. 2021 Incentive Award Plan (the 2021 Plan), the Erasca, Inc. 2018 Equity Incentive Plan (the 2018 Plan) and the Erasca, Inc. 2021 Employee Stock Purchase Plan (the 2021 ESPP), in place under which shares of our common stock were authorized for issuance detailed as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:55%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Plan Category</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">securities&#160;to&#160;be</span><br/><span style="font-weight:bold">issued&#160;upon&#160;the</span><br/><span style="font-weight:bold">exercise&#160;of</span><br/><span style="font-weight:bold">outstanding</span><br/><span style="font-weight:bold">options,&#160;warrants</span><br/><span style="font-weight:bold">and rights</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Weighted-</span><br/><span style="font-weight:bold">average</span><br/><span style="font-weight:bold">exercise&#160;price&#160;of</span><br/><span style="font-weight:bold">outstanding</span><br/><span style="font-weight:bold">options,&#160;warrants</span><br/><span style="font-weight:bold">and&#160;rights</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">securities</span><br/><span style="font-weight:bold">remaining&#160;available</span><br/><span style="font-weight:bold">for future&#160;issuance</span><br/><span style="font-weight:bold">under&#160;equity</span><br/><span style="font-weight:bold">compensation&#160;plans</span><br/><span style="font-weight:bold">(excluding</span><br/><span style="font-weight:bold">securities&#160;reflected</span><br/><span style="font-weight:bold">in column(a))</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(a)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(b)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="2"><span style="font-weight:bold">(c)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">33,910,721</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.93</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,835,810</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">33,910,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3.93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,835,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 25,925,048 shares of common stock that were subject to outstanding option awards as of December&#160;31, 2024 under the 2021 Plan and 7,985,673 shares of common stock that were subject to outstanding option awards as of December&#160;31, 2024 under the 2018 Plan. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the weighted-average exercise price of outstanding options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 13,265,858 shares of common stock available for issuance under the 2021 Plan and 1,569,952&#160;shares of common stock available for issuance under the 2021 ESPP (all of which were eligible for purchase pursuant to the offering period in effect on December&#160;31, 2024). This amount does not include any additional shares that may become available for future issuance under the 2021 Plan pursuant to the automatic increase to the share reserve on January&#160;1 of each of our calendar years through 2031 by the number of shares equal to the lesser of (i) 5% of the total outstanding shares of our common stock as of the immediately preceding December&#160;31 and (ii)&#160;such smaller number of shares as is determined by our Board. Additionally, this amount does not include any additional shares that may become available for future issuance under the 2021 ESPP pursuant to the automatic increase to the share reserve on January&#160;1 of each of our calendar years through 2031 by the number of shares equal to the lesser of (i) 1% of the total outstanding shares of our common stock as of the immediately preceding December&#160;31 and (ii)&#160;such smaller number of shares as determined by our Board. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_5">Security Ownership of Certain Beneficial Owners and Management </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes set forth certain information with respect to the beneficial ownership of our common stock at April&#160;15, 2025 for: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our NEOs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our current directors and executive officers as a group; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person, or group of affiliated persons, who beneficially owned more than 5% of our outstanding common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares of common stock that they beneficially owned, subject to applicable community property laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership is based on 283,265,716 shares of common stock outstanding as of April&#160;15, 2025. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options, warrants or other rights held by that person or entity that are currently exercisable within 60 days of April&#160;15, 2025. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o&#160;Erasca, Inc., 3115 Merryfield Row, Suite 300, San Diego, California 92121. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares&#160;Beneficially&#160;Owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">5% or Greater Stockholders</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">T. Rowe Price Investment Management, Inc.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,830,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Life Sciences<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,216,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Venrock Healthcare Capital<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,216,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Blackrock, Inc.<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,358,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Named Executive Officers and Directors</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan E. Lim, M.D.<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">34,743,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Bristol, Ph.D.<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">389,279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexander W. Casdin<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">820,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David M. Chacko, M.D.<sup style="font-size:75%; vertical-align:top">(</sup><sup style="font-size:75%; vertical-align:top">8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,144,478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julie Hambleton, M.D.<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">272,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie Harding-Start, Ph.D.<sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">361,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean I. Liu, J.D.<sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">185,873</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shannon R. Morris, M.D., Ph.D.<sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">803,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pratik S. Multani, M.D.<sup style="font-size:75%; vertical-align:top">(13)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">326,567</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael D. Varney, Ph.D.<sup style="font-size:75%; vertical-align:top">(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">494,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11&#160;persons)<sup style="font-size:75%; vertical-align:top">(15)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">41,854,442</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">T. Rowe Price Investment Management, Inc. (T. Rowe) has sole voting power and sole dispositive power over 16,830,856 shares of our common stock. The address of T. Rowe is 101 E. Pratt Street, Baltimore, MD 21201. This information is based on the Schedule 13G filed with the SEC on November&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 10,590,811 shares of common stock held directly by Frazier Life Sciences Public Fund, L.P., 1,183,784 shares of common stock held directly by Frazier Life Sciences Public Overage Fund, L.P., 1,415,675 shares of common stock held directly by Frazier Life Sciences X, L.P., and 3,025,946 shares of </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top;text-align:left">
common stock held directly by Frazier Life Sciences XI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Mr.&#160;Heron, Mr.&#160;Topper, Mr.&#160;Cha and Mr.&#160;Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Mr.&#160;Heron and Mr.&#160;Topper are the members of FHMLSX, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Mr.&#160;Heron, Mr.&#160;Topper and Mr.&#160;Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P. The address of Frazier Life Sciences entities is 1001 Page Mill Road, Building 4, Suite B, Palo Alto, CA 94304. This information is based on the Schedule 13G filed with the SEC on May&#160;29, 2024. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 2,580,000 shares held by Venrock Healthcare Capital Partners III, L.P., 257,838 shares held by VHCP <span style="white-space:nowrap">Co-Investment</span> Holdings III, LLC, and 13,378,378 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP <span style="white-space:nowrap">Co-Investment</span> Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Nimish Shah and Bong Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.&#8195;The address of the Venrock entities and Messrs. Shah and Koh is 3340 Hillview Avenue, Palo Alto, CA 94304. This information is based on the Schedule 13G filed with the SEC on May&#160;31, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Blackrock, Inc. (Blackrock) has sole voting power over 14,984,602 shares of our common stock and sole dispositive power over 15,358,280 shares of our common stock. The address of Blackrock is 50 Hudson Yards, New York, NY 10001. This information is based on the Schedule 13G filed with the SEC on November&#160;8, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 12,899,360 shares of common stock held by City Hill, LLC, 19,456,216 shares of common stock held by a family trust of Dr.&#160;Lim, for which he is a <span style="white-space:nowrap">co-trustee,</span> and 2,387,506 shares of common stock underlying options held by Dr.&#160;Lim that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. Dr.&#160;Lim, our Chairman and CEO, is the Managing Partner of City Hill, LLC. Dr.&#160;Lim may be deemed to share the power to direct the disposition and vote of the shares held by City Hill, LLC. Dr.&#160;Lim disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 187,500 shares of common stock held by Dr.&#160;Bristol, 181,779 shares of common stock underlying options held by Dr.&#160;Bristol that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date, and 20,000 shares of common stock held by a family trust of Dr.&#160;Bristol, for which he is the trustee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 573,974 shares of common stock held by Mr.&#160;Casdin, 153,116 shares of common stock underlying options held by Mr.&#160;Casdin that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date, and 93,750 shares of common stock held by Mr.&#160;Casdin&#8217;s spouse. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(8)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 262,187 shares of common stock held by Dr.&#160;Chacko and 1,882,291 shares of common stock underlying options held by Dr.&#160;Chacko that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(9)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 6,000 shares of common stock held by Dr.&#160;Hambleton and 266,666 shares of common stock underlying options held by Dr.&#160;Hambleton that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(10)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 2,000 shares of common stock held by Dr.&#160;Harding-Start and 20,000 shares of common stock held by a family trust of Dr.&#160;Harding-Start, for which she is a <span style="white-space:nowrap">co-trustee,</span> and 339,340 shares of common stock underlying options held by Dr.&#160;Harding-Start that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(11)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 185,873 shares of common stock underlying options held by Ms.&#160;Liu that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(12)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 803,203 shares of common stock underlying options held by Dr.&#160;Morris that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(13)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 172,866 shares of common stock held by Dr.&#160;Multani and 153,701 shares of common stock underlying options held by Dr.&#160;Multani that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(14)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 494,999 shares of common stock underlying options held by Dr.&#160;Varney that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(15)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of shares of common stock and shares of common stock issuable upon exercise of outstanding options which are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date, as set forth in previous footnotes. Also includes 21,174 shares of common stock held by Ebun&#160;S.&#160;Garner, J.D., our General Counsel and Corporate Secretary, and 1,290,941 shares of common stock underlying options held by Mr. Garner that are exercisable as of April&#160;15, 2025 or that will become exercisable within 60 days after such date. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_6">Certain Relationships and Related Person Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions entered into or existing since January&#160;1, 2023 to which we have been a party in which the amount involved exceeded or will exceed $120,000 (or, if less, 1% of the average of our total assets at <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years), and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;Executive and Director Compensation.&#8221; We also describe below certain other transactions with our directors, executive officers and stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholders&#8217; agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an amended and restated stockholders&#8217; agreement in April 2020, or the stockholders&#8217; agreement, with the holders of our convertible preferred stock, including entities with which certain of our directors are affiliated. This agreement provides for certain rights relating to the registration of their shares of common stock issuable upon conversion of their convertible preferred stock and certain additional covenants made by us. Except for the registration rights (including the related provisions pursuant to which we have agreed to indemnify the parties to the stockholders&#8217; agreement), all rights under this agreement terminated upon closing of our IPO. The registration rights will terminate five years after the closing of our IPO. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Erasca Foundation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2021, we established the Erasca Foundation to provide support such as direct research grants, hardship grants, patient advocacy, patient education in underserved populations, and funding for other initiatives to positively impact society that align with our mission. Our chief executive officer and certain board members serve as directors of the Erasca Foundation and our chief executive officer, chief financial officer, and general counsel are also officers of the Erasca Foundation. In July 2021, we issued 1,093,557 shares of our common stock to the Erasca Foundation as a contribution and recorded $17.5&#160;million as a contribution of common stock to the Erasca Foundation in the consolidated statements of operations and comprehensive loss. In April 2023, we loaned the Erasca Foundation $125,000 in exchange for a <span style="white-space:nowrap">non-interest</span> bearing promissory note that matured one year following the date of the note. The Erasca Foundation repaid this note in full in December 2023. In April&#160;2024, we made a donation of $125,000 to the Erasca Foundation.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Indemnification agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Charter and Bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Further, we have entered into indemnification agreements with each of our directors and officers, and we have purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Policies and procedures for related person transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board adopted a written related person transaction policy, setting forth the policies and procedures for the review and approval or ratification of related-person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Act, any transaction, arrangement or relationship, or any series of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets at <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years) and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our Audit Committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction. All of the transactions described in this section, other than participation in our IPO, occurred prior to the adoption of this policy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_7">2026 Stockholder Proposals </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders who intend to have a proposal considered for inclusion in our proxy materials for presentation at our 2026 Annual Meeting of Stockholders pursuant to Rule <span style="white-space:nowrap">14a-8</span> under the Exchange Act must submit the proposal to our Secretary at our offices at 3115 Merryfield Row, Suite 300, San Diego, California 92121 in writing not later than January&#160;13, 2026, which is 120 days prior to the <span style="white-space:nowrap">one-year</span> anniversary of the mailing date of the proxy statement for the Annual Meeting, unless the date of the 2026 Annual Meeting of Stockholders is changed by more than 30 days from the anniversary of our Annual Meeting, in which case the deadline for such proposals will be a reasonable time before we begin to print and send our proxy materials. These proposals must comply with the requirements as to form and substance established by the SEC in Rule <span style="white-space:nowrap">14a-8</span> of the Exchange Act for such proposals in order to be included in the proxy statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders intending to present a proposal at the 2026 Annual Meeting of Stockholders, but not to include the proposal in our proxy statement, or to nominate a person for election as a director, must comply with the requirements set forth in our Bylaws. Our Bylaws require, among other things, that our Secretary receive written notice from the stockholder of record of their intent to present such proposal or nomination not earlier than the close of business on the 120th day and not later than the close of business on the 90th day prior to the anniversary of the preceding year&#8217;s annual meeting. Therefore, the Company must receive notice of such a proposal or nomination for the 2026 Annual Meeting of Stockholders no earlier than the close of business on February&#160;24, 2026, and no later than the close of business on March&#160;26, 2026. The notice must contain the information required by the Bylaws, a copy of which is available upon request to our Secretary. In the event that the date of the 2026 Annual Meeting of Stockholders is more than 30 days before or more than 60 days after June&#160;24, 2026, then our Secretary must receive such written notice not later than the 90th day prior to the 2026 Annual Meeting or, if later, the 10th day following the day on which public disclosure of the date of such annual meeting is first made by the Company. SEC rules permit management to vote proxies in its discretion in certain cases if the stockholder does not comply with this deadline and, in certain other cases, notwithstanding the stockholder&#8217;s compliance with this deadline. Stockholders are advised to review our Bylaws which also specify requirements as to the form and content of a stockholder&#8217;s notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to satisfying the foregoing requirements under our Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company&#8217;s nominees must provide notice that sets forth the information required by Rule <span style="white-space:nowrap">14a-19</span> under the Exchange Act no later than April&#160;25, 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to file a proxy statement and WHITE proxy card with the SEC in connection with the solicitation of proxies for our 2026 Annual Meeting. Stockholders may obtain our proxy statement (and any amendments and supplements thereto) and other documents as and when filed by the Company with the SEC without charge from the SEC&#8217;s website at: www.sec.gov. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reserve the right to reject, rule out of order or take other appropriate action with respect to any proposal that does not comply with these or other applicable requirements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Incorporation by Reference </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that this proxy statement is incorporated by reference into any other filing by us under the Securities Act or the Exchange Act, the section of this proxy statement entitled &#8220;Report of the Audit Committee&#8221; to the extent permitted by the rules of the SEC will not be deemed incorporated, unless specifically provided otherwise in such filing. In addition, references to our website are not intended to function as a hyperlink and the information contained on our website is not intended to be part of this proxy statement. Information on our website, other than our proxy statement, Notice of Annual Meeting of Stockholders and form of proxy, is not part of the proxy soliciting material and is not incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board is not aware of any matter to be presented for action at the Annual Meeting other than the matters referred to above and does not intend to bring any other matters before the Annual Meeting. However, if other matters should come before the Annual Meeting, it is intended that holders of the proxies named on the Company&#8217;s proxy card will vote thereon in their discretion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Solicitation of Proxies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying proxy is solicited by and on behalf of the Board, whose Notice of Annual Meeting is attached to this proxy statement, and the entire cost of such solicitation will be borne by us. In addition to the use of mail, proxies may be solicited by personal interview, telephone, <span style="white-space:nowrap">e-mail</span> and facsimile by our directors, officers and other employees who will not be specially compensated for these services. We will also request that brokers, nominees, custodians and other fiduciaries forward soliciting materials to the beneficial owners of shares held by such brokers, nominees, custodians and other fiduciaries. We will reimburse such persons for their reasonable expenses in connection therewith. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="toc897507_8">Erasca&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of Erasca&#8217;s Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> for the fiscal year ended December&#160;31, 2024, including the consolidated financial statements thereto but not including exhibits, as filed with the SEC, will be sent to any beneficial owners of our Common Stock on the Record Date as determined on April&#160;28, 2025 without charge upon written request addressed to: </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Erasca, Inc. </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Secretary </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3115 Merryfield Row, Suite 300 </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reasonable fee will be charged for copies of exhibits. You also may access this proxy statement and our Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> at www.proxydocs.com/ERAS. We make available free of charge on our website all of our filings that are made electronically with the SEC, including our Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> for the year ended December&#160;31, 2024. These materials can be found at www.Erasca.com under the &#8220;Investors&#8221; section. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="width:790px"></div>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING ONLINE, WE URGE YOU TO VOTE YOUR SHARES VIA THE TOLL-FREE TELEPHONE NUMBER OR OVER THE INTERNET, AS DESCRIBED IN THIS PROXY STATEMENT. IF YOU RECEIVED A COPY OF THE PROXY CARD BY MAIL, YOU MAY SIGN, DATE AND MAIL THE PROXY CARD IN THE ENCLOSED RETURN ENVELOPE. PROMPTLY VOTING YOUR SHARES WILL ENSURE THE PRESENCE OF A QUORUM AT THE ANNUAL MEETING AND WILL SAVE US THE EXPENSE OF FURTHER SOLICITATION. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors, </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ebun S. Garner </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General Counsel and Corporate Secretary </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&#160;29, 2025 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:top"> <p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">&#8201;


<img src="g897507dsp1.jpg" alt="LOGO"/>
</p> <p style="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL">P.O. BOX 8016, CARY, NC 27512-9903</p> <p style="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right">


<img src="g897507dsp1a.jpg" alt="LOGO"/>
</td></tr>
</table> <p style="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:56%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:6%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:36%"/></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL;text-align:center"><span style="color:#0c5486"><span style="font-weight:bold">Erasca, Inc.</span></span></p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g897507dsp1b.jpg" alt="LOGO"/>
</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL;text-align:center"><span style="color:#333300">For Stockholders of record as of April 28, 2025</span></p> <p style="font-size:4pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL;text-align:center"><span style="color:#0c5486">Tuesday, June 24, 2025 11:30 AM, Pacific Time</span></p> <p style="font-size:4pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:ARIAL;text-align:center"><span style="color:#0c5486">Annual Meeting to be held live via the internet - please visit</span></p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #0c5486; font-size:8.5pt; font-family:ARIAL;text-align:center"><span style="color:#0c5486">www.proxydocs.com/ERAS for more details</span></p> <p style="font-size:24pt; margin-top:0pt; margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:center">YOUR VOTE IS IMPORTANT!</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL;font-weight:bold;text-align:center">PLEASE VOTE BY: 11:30 AM, Pacific Time, June 24, 2025.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:right">


<img src="g897507dsp1c.jpg" alt="LOGO"/>
</p> <p style="font-size:16pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g897507dsp1d.jpg" alt="LOGO"/>
</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt;text-align:left">&#160;</p> <p style="margin-top:0pt;margin-bottom:1pt;text-align:right">


<img src="g897507dsp1e.jpg" alt="LOGO"/>
</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="color:#0c5486"><span style="font-weight:bold">Internet:</span></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><span style="color:#52c1b1"><span style="font-weight:bold">www.proxypush.com/ERAS</span></span></p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">&#8226;&#8194;&#8202;Cast your vote online</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL;font-weight:bold">&#8226;&#8194;&#8202;Have your Proxy Card ready</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">&#8226;&#8194;&#8202;Follow the simple instructions to record your vote</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="color:#52c1b1"><span style="font-weight:bold">Phone:</span></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><span style="color:#074261"><span style="font-weight:bold">1-866-574-1406</span></span></p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">&#8226;&#8194;&#8202;Use any touch-tone telephone</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL;font-weight:bold">&#8226;&#8194;&#8202;Have your Proxy Card ready</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">&#8226;&#8194;&#8202;Follow the simple recorded instructions</p> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><span style="color:#0c5486"><span style="font-weight:bold">Mail:</span></span></p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">&#8226;&#8194;&#8202;Mark, sign and date your Proxy Card</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:ARIAL">&#8226;&#8194;&#8202;Fold and return your Proxy Card in the postage-paid envelope provided</p></td></tr>
</table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><span style="color:#0c5486"><span style="font-weight:bold">This proxy is being solicited on behalf of the Board of Directors </span></span></p> <p style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">The undersigned hereby appoints Jonathan E. Lim, M.D., and Ebun S. Garner (the "Named Proxies"), and each or either of them, as the true and lawful attorneys of the undersigned, with full power of substitution and revocation, and authorizes them, and each of them, to vote all the shares of capital stock of Erasca, Inc. which the undersigned is entitled to vote at said meeting and any adjournment thereof upon the matters specified and upon such other matters as may be properly brought before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED IDENTICAL TO THE BOARD OF DIRECTORS RECOMMENDATION. This proxy, when properly executed, will be voted in the manner directed herein. In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the meeting or any adjournment or postponement thereof. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors&#8217; recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card. </p> <p style="margin-top:50pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL;text-align:center">PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL;text-align:right">Copyright &#169; 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>
<h5 style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:50%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:49%"/></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<img src="g897507dsp1.jpg" alt="LOGO"/>
</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:right"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL;text-align:right"><span style="color:#0c5486"><span style="font-weight:bold">Erasca, Inc. Annual Meeting of Stockholders</span></span></p></td></tr>
</table> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:20%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:39%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:39%"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<td style="vertical-align:middle"><span style="font-size:8pt"><span style="font-weight:bold">Please&#160;make&#160;your&#160;marks&#160;like&#160;this:</span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:middle">


<img src="g897507dsp2.jpg" alt="LOGO"/>
</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table> <p style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL;font-weight:bold">THE BOARD OF DIRECTORS RECOMMENDS A VOTE: </p> <p style="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><span style="font-weight:bold">&#8195;&#8195;&#8201;FOR </span>ON PROPOSALS 1 AND 2<span style="font-weight:bold"> </span></p> <p style="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:2%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:67%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:3%"/>

<td style="vertical-align:bottom"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:8%"/></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom;background-color:#cccccc"/>
<td style="vertical-align:bottom;background-color:#cccccc">&#160;&#160;</td>
<td style="vertical-align:bottom;background-color:#cccccc"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL;font-weight:bold">PROPOSAL</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&#160;</p></td>
<td style="vertical-align:bottom;background-color:#cccccc">&#160;&#160;</td>
<td colspan="5" style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;background-color:#cccccc"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL;font-weight:bold;text-align:center">YOUR VOTE</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:ARIAL;font-weight:bold;text-align:center">BOARD OF DIRECTORS RECOMMENDS</p> <p style="font-size:2pt; margin-top:0pt; margin-bottom:1pt;text-align:left">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:top"><span style="font-size:8pt">1.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="font-size:8pt">To elect three directors to serve as Class I directors for a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">FOR</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">WITHHOLD</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom"><span style="font-size:x-small">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center">


<img src="g897507dsp2a.jpg" alt="LOGO"/>
</td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1.01 Jonathan E. Lim, M.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">FOR</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1.02 James A. Bristol, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">FOR</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">1.03 Valerie Harding - Start, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">FOR</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:14pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">FOR</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">AGAINST</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">ABSTAIN</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top;white-space:nowrap">2.&#8194;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top;text-align:center"><span style="font-family:Times New Roman">&#9744;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">FOR</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="vertical-align:top">3.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top"><span style="font-size:x-small">&#160;</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
</table> <p style="font-size:90pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:120pt; margin-bottom:0pt; margin-left:7%; margin-right:5%; font-size:8pt; font-family:ARIAL;font-weight:bold">You must register to attend the meeting online and/or participate at www.proxydocs.com/ERAS </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; margin-right:5%; font-size:8pt; font-family:ARIAL">Authorized Signatures - Must be completed for your instructions to be executed. </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:7%; margin-right:5%; font-size:8pt; font-family:ARIAL">Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form. </p> <p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:8%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:1%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:39%"/>

<td style="vertical-align:bottom"/>
<td style="width:8%"/></tr>


<tr style="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<td style="BORDER-TOP:0.75pt solid #000000;vertical-align:top">Signature (and Title if applicable)</td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000;vertical-align:top;text-align:right">Date&#8195;&#8195;&#8195;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">&#8199;</td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:-0.80em; font-size:8pt; font-family:ARIAL">Signature (if held jointly)</p></td>
<td style=" BORDER-TOP:0.75pt solid #000000;vertical-align:bottom">&#160;&#160;</td>
<td style="BORDER-TOP:0.75pt solid #000000;vertical-align:top;text-align:right">Date&#8195;&#8195;&#8195;</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>eras-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-April-2025 [04:39:50] {AM}-->
<schema targetNamespace="http://erasca.com/20241231" elementFormDefault="qualified" xmlns:eras="http://erasca.com/20241231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2024">
<annotation>
<appinfo>
<link:linkbaseRef xlink:type="simple" xlink:href="eras-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="eras-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="eras-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
<import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
<import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
<import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
<import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
<import namespace="http://www.xbrl.org/2006/ref" schemaLocation="http://www.xbrl.org/2006/ref-2006-02-27.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
<element name="DavidMChackoMDMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eras_DavidMChackoMDMember" substitutionGroup="xbrli:item" />
<element name="JonathanELimMDMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eras_JonathanELimMDMember" substitutionGroup="xbrli:item" />
<element name="ShannonRMorrisMDPhDMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eras_ShannonRMorrisMDPhDMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>eras-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-April-2025 [04:39:50] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecd_AllIndividualsMember_117320640" />
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_JonathanELimMDMember" xlink:label="loc_eras_JonathanELimMDMember_117320650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember_117320640" xlink:to="loc_eras_JonathanELimMDMember_117320650" order="100" />
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_DavidMChackoMDMember" xlink:label="loc_eras_DavidMChackoMDMember_117320651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember_117320640" xlink:to="loc_eras_DavidMChackoMDMember_117320651" order="101" />
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_ShannonRMorrisMDPhDMember" xlink:label="loc_eras_ShannonRMorrisMDPhDMember_117320652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember_117320640" xlink:to="loc_eras_ShannonRMorrisMDPhDMember_117320652" order="102" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>eras-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-April-2025 [04:39:50] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_DavidMChackoMDMember" xlink:label="loc_eras_DavidMChackoMDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eras_DavidMChackoMDMember" xml:lang="en-US">David M. Chacko, M.D. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eras_DavidMChackoMDMember" xlink:to="lab_eras_DavidMChackoMDMember" />
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_JonathanELimMDMember" xlink:label="loc_eras_JonathanELimMDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eras_JonathanELimMDMember" xml:lang="en-US">Jonathan E. Lim, M.D. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eras_JonathanELimMDMember" xlink:to="lab_eras_JonathanELimMDMember" />
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_ShannonRMorrisMDPhDMember" xlink:label="loc_eras_ShannonRMorrisMDPhDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eras_ShannonRMorrisMDPhDMember" xml:lang="en-US">Shannon R. Morris, M.D., Ph.D. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eras_ShannonRMorrisMDPhDMember" xlink:to="lab_eras_ShannonRMorrisMDPhDMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>eras-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 29-April-2025 [04:39:50] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
<presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecd_AllIndividualsMember_117320637" />
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_JonathanELimMDMember" xlink:label="loc_eras_JonathanELimMDMember_117320650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember_117320637" xlink:to="loc_eras_JonathanELimMDMember_117320650" order="100" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_DavidMChackoMDMember" xlink:label="loc_eras_DavidMChackoMDMember_117320651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember_117320637" xlink:to="loc_eras_DavidMChackoMDMember_117320651" order="101" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="eras-20241231.xsd#eras_ShannonRMorrisMDPhDMember" xlink:label="loc_eras_ShannonRMorrisMDPhDMember_117320652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember_117320637" xlink:to="loc_eras_ShannonRMorrisMDPhDMember_117320652" order="102" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g897507dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MJNTI;I2>B7HC]2_"_P#P3#M+WPS97VO?$F]M-?N[&"Y:VT[2;>?3K66>%)!
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M=W9;*^NG7<_H/A[,)9CE&&Q3?-.2:>RNX^EDOE8^9_B)_P %#_"WPW\:^)/
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M*34*CLOA]+:/H?9>'F9)5,7E\I-05I48M]M[=S]B,#T'Y5^:7/U0,#TQ^F*
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4X%:-KHMC]#O[L>['T#"@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g897507dsp1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507dsp1a.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /S5\=^._'
M%EXX\96EIXR\5VEK:>*_$-O:VMOXAU>"WMK>#5[R*&""&*\5(88XU5%1%"JJ
M@  "OH:%"BZ-%NC!MP@VW"-[\J\C^6.(>(<_H9_GE&CGF84:-',,9"G3AC<3
M"$(0Q-2,80C&HHQC&*2C%))))))(Y3_A8?Q _P"AY\8_^%-K7_R;6OU>A_SY
MI_\ @$?\CQ_]9N)/^B@S+_PNQ7_RT/\ A8?Q _Z'GQC_ .%-K7_R;1]7H?\
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MZ'_/FG_X!'_(/]9N)/\ HH,R_P#"[%?_ "T_56OF3^OPH * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H _*KXA_\E \<_P#8X^)O_3U>U]-A_P"!1_Z]P_\ 24?R
M!Q-_R4G$'_8RQW_J55./K8\,* "@ H * "@ H _86ODS^VPH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H _*KXA_\ )0/'/_8X^)O_ $]7M?38?^!1_P"O</\
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MM.I55FIT6?L77Y&?L8TNBLJEE5FR$4L S%1DA03DX')Q1^GY;!MY=%Z_TAU
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MQ&;XNFJTZ59T,/"6L(*$(3G6<6K.I*4^2/-S<D:?-!IU)6_4\*JA0JJH080
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MS4I+H?F_B9B:2CD&7I_[10CB\7./\E/%O#4J*?:4OJ<YV?\ R[G3EM-'N/\
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M<Y.4G;S;9_6!X _Y$/P3_P!BCX;_ /3-95_/V>?\CK./^PW%?^GZA_0/#O\
MR3^1?]B_!?\ J-2/YVOVS_\ DY[XN_\ 8=T__P!1W1J_4N _^26P'_7[,/\
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MNK4@HUXV]V.)H3]G62711KTY2AY*,ET9^ <4Y6LBS_'X3#*5+"RE[;"V<_\
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M@!1*4I.\I.3[MMO[V*,8P7+"*BET227W(GJ2@H * "@ H * "@ H * "@ H
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M7/&DX>M_9U-MN76UU?ZGKXX^:"@#]A:^3/[;"@ H * "@ H * "@ H * "@
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M8KSE*T5YM'\PGCOQMXN^+WCW5_%_B&2;6/%/BW58RMO:12R8DE,=GI>C:5:
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MR@XI7C!]694JV#5:C&KC*%.DYQ4Y*K2GRQYDI2M&;;Y5=I;NVA][U^:GP84
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MUK+;RL<TI2E)RE)RE+5MMMM^;>K&TR0H * "@#]A:^3/[;"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#\JOB'_R4#QS_ -CCXF_]/5[7TV'_ (%'_KW#_P!)
M1_('$W_)2<0?]C+'?^I54X^MCPPH * "@ H * "@#]A:^3/[;"@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#\JOB'_P E \<_]CCXF_\ 3U>U]-A_X%'_ *]P
M_P#24?R!Q-_R4G$'_8RQW_J55./K8\,* "@ H * "@ H _0OXK?$Y_AWX]^$
M5K?:G<V'A7Q)<^-[?Q%!::'=:Y/>/I?AV.\T=4ATS2[W4(1%?-O+6JH"#B8E
M!@>+E6%AC?[:IRBI5<-@*5;#WER*-9YAA*,I.3E&/\"=6*51\MY:+VG(S^R\
MTQ%3!T\HJ4Y<L*^:T\/B&H\[>'EE6<5^11M*5_K.&PL[TUSI0:NJ;J)XO@[X
MQW7BWXA?%Z#PZVI>)_#/A#P7\/=2T#0&TF+PM?/K>K3^-QK2QW/BVUTB4+<1
MZ5I0\V^N!;1BW8Q%290_16RWZKDN$Q6(C"GB:^;8O#NK[53A'"T\)E4H.:HR
MJ)*E5Q&)J2M!UY1E91FO91.>./\ ;9XL)0E.6&AD\,3*E[)QG/%_7<=3M3=6
M,&Y5:-*A2@G..'4[.4J;]K-7]/\ V@=->+41K/AF]TFZT'QAX,\*^(5M-8T7
MQ!INEV_CV1;7P]XA76-(N)(+K3/[1DCM+E,136S[V=#$H=YAE$ZLL"J%>,H8
M_P"OTZ3G"=*7UG+\.L5/#\DTFY5J,H/#SBW"I.<*>DVXQN>:PH?VA&K0DJF6
MT,'C*D(2C5_V/%XNK@_;W@WR_5GA\36Q,)>]3H8>=5.4'%N_XD^/.@>']2\0
MZ1%I-]J=]H_BK0O FG;+[2=/L]<\8:QH4GB:[TJ+4-2NX;?3K?2="$-W?7=T
MZJBR^7$DLP$3X8;+:^*HX2K"48+%K'5DI<WNX3 3A1JXJ7+&3<)XJ4\)1A!2
MG.O"S48/G73B,=1PM7$TIWE]4I8)U'%P?^T9A4J1PV#47)-5G1A#%U.?DA3P
ME:%:[BI6Z'P5\4K3QQX<\5:IIFBW::[X,U#4]$UOPP+_ $R]E&MZ?IMMJUO:
M:?K&GW$UC?VE]8WUA+;7<<@4B["RI%)')''EF.$>7T<+BG/VV$Q=*5:G-0G"
M7)2K5*%>,J4TI1J4:E&JG#532C.G*4*D).\!B8XW%U\#)+#8G"5*,*JE)2II
M8BE3KT:L:D=)4Y4ZBYG92A.%2G**E!WP;CX_>#+;2/!NNM'?'2_%7@?Q#\1;
MRX B#^&/"OAC2K6]U:\UB MYGVB/4;^RTL6T2M(;J9EQB)RO36RC$T<5FF%3
M5:66SPU*,J?O+%5\=B5A\!1P[T4I8N*J5Z,I.,/94I-R7-&^&'S"G6H995E3
MEAZN85JU&5&M*%.>$^IT:U7,*F)O+W:>7RI1H8F4.?DJUJ2^&3DJ+_'>32+>
MXF\8_#[Q%X0-SX+\2^.?"\5[J6@:@_B#3?"NF)J^JZ3*=*OYET;Q''I\T,_V
M.<O&4,I6X9K>1553+.7V].EBZ6(Q&"K8>EB:<%4M36)Q,<)&M3G*$56HPKRC
M3J22C*+G2:A*-12+PF,6+K99%49T<+G%14L+6J."YJCHSQ%.%2DI.I2E5P]*
MM6IIJ7NT:L:GLZD5"7?S_$.PM_$7P_\ #IL+PW'Q!T37];L+@/"(;"'P_I^E
M:A/#=J6W/++'JT2(8PP!B?. 1GFJX.='^W+RB_["IQJ5+7_>)XEX9*&FC4ES
M>];3S"CC85<)E.+4'&&;5:-&G%VO3=7 XK')SZ-*&%E!VN^>4;:7:Q?A1\4+
MWXJ:7%XDM?!&M>&_"M[:O+I.KZW?Z2+C5;FWNGL[N.WTFRN)KB&R2:*<1W=Q
MY0F$)=(_+>.27HQ^7++K4ZN*ISQ+5&:I04GRTJU+VL93FTH1GRN#=-.34:D>
M9QFIPBZ.+=?$8FC2H35'"5\9AIUI6C"5?!XF6&E&E!OVDX2E"I^\<8Q4J<HK
MF3C.7CWA+XV>)/#\/Q&U'Q5X6\2ZQX,\-_&;QCX;OO'!U+0EMO#^D'Q)!INF
MBUT>>^CO[[0M*6[MENIXHPT*>:8H[CR) O93RRCBL-PS2IUZ6'QN:9?1]G!J
MI)XG%2JXB,%4G",HTIXB4(T*+D[.HH*?LZ<HU'R8K'SP6*XDJ>PJ5\)E,L/6
MJ.+A"-##+)LNQ6*=/VDHNHZ*E7QE:,=X3:I2J5KT5ZQKGQ<?PSXUT?POK7A.
M[M-)U[Q!IWAC2_$2^(?#%U-/J6K0.^FW3^&;34Y-3@T:>[0V@NI(ED20JTEN
MD)\VN#!8#Z[3J^SKQCB:='$UO8N%1KDPD9U:L955'V4*KP].5>G'F<90M!SC
M6?LSHQN.C@5"K.DY85U<)2=52@KRQM?#X6C*G3<O:5(1Q.)IT:KY8N+4ZD8S
MHQ]J_ ])^+6M:%XVBOO%7BC45\):/XR_:BDUN*5S+"N@> WT*?18#"B;I4TZ
MWENA;QKSF8@9+"O1H82E4RNG*GAO;8NMDF45*2BKU*F,Q><U<)>-VE[6LO9T
M;MI6LFTKLC$5*D<PJTHUE1HPSS"49.4N6G3PKX0GF%93D_AI1Q$7BJC>THN6
MRL>[Z%\7-1OM7TW0]?\ A[X@\):EXGT'5/$'@B#4=4\.WO\ PD<6D6]M=W>D
M7$FG:C+'H7B!+6\M9C:W+M%Y9F9;EC;R*OGXG+_84<?*EBJ6)KY5R/%4X*HE
M"$ZCHJM3J2@E6HPK)4ZDHI3C*=)QIRC43*H9A"K++YRHSH8+-)^SPU>?)=S]
MC/$PA4HJ3J4Y5<-2K5J2:?NT:L:GLJD5"5_X->/?$OQ#\$V?BCQ+X6B\,S7G
MVB2U6VU&UOK6^@BOKZWWP1Q7$TMJ8DMHD<7# R.6=%5"%6,WPV'RU1]EB'B'
M'#4:TX\C@_?PE#$.2NDN6I*I-TX7<J<$HU)2E[SO XBOB:F,A5P_L%A\9C</
M!\T7IAL=BL*H22;_ 'E.%""JS5J=2<I2I*,+17&Z-^T/:ZAX"N_B?J/@;Q%H
M/@I8+2+0[S4+_0AJ?B76[W68?#]II.F:4M^#;0W&KSI;PWU_-:0OM:9MEOMF
M?JKY/4H8K"Y?'$4JN88R5'V=&/-RQI5</+$NK6JN/)35*A'VU2$?:3C2=[.J
MI4DECX7S*I*E.&!RF6.IXC$M+E]I@,0\-.%"G?VE5U:D94Z3Y8*59*E'F4HS
M>GHWQO;6H/%MC:^#IV\8>#X]!O-0\.Q>+?!\NG2:/XB>[33]<A\6?VLNG"PC
M?3]1CN8R?M4,EDRK;RK+"\V=;+?94<)B8XB,L)B*];#2J2IU8.C7H4J=9P=-
MP=27M(5J/L)04HSE4M-T_9U?9S2QZEB*N$G0E'$PPU/%TZ<94Y^UH5*\\.VI
MJ:IPG1G3G*O"<TX4E&5-U74IQG%:_'S3;WPS9:E9>&-5N_%6H>/+OX:6'@RU
MU+1)YKKQ986\VHW2P>(([TZ;)H<6B6\NIMJ*RD"W0CRC<?N*J64U?;X:G2JQ
ME0Q&"JYA[:<:E-4L+0J2H5I5:<HNI&<<3'ZM&"4O:59T^67LY^T40S.E[+'R
MJP<*N78K#8*=.$H5'4Q.,I8:OAJ=&:E&$^>ABZ=:;;BZ5.%=S2E1E%\MX:^,
M>M:?K/Q/U'QGH.OZ7IVE_$[X?>"WTB\O=+O4\&P>)/#/ANU.K+<Z?<S077A^
M77=2@N&FC=7$>I>;+'$8Y(X]X9;1KX7)*.%KTZM;,)9NX5>6<'4GA7.I2PLX
MR2<:S5&="DES0E5=.,)S52,G-?'U,/6S&K6PM6E3RS 9=5JTTX3BXUL9BXU\
M92E&5I4Z.%E3JXAM1G&&$KQY.:FN;W3P]XUL_$GB7QMX=L+.Y\OP-?:3I&H:
MNS0_8KK6M1TN+6;G2[158R&:QL+S2WG9U5=VHHBDM&^WRY8:4,#A<=)J,<94
MQ,:4->=T\-.-&5?LJ<L0J]"&MW+#U&THN+?;]8C]>JX&*<IX?#X>M5FG'EIS
MQ+JNG0:3<E5]A3IXF2<4E1Q-!IR<WR\;I_Q<=_B!9> ==\)7GA^YUG^WQH%Z
M?$/AC6GNI/#L(O+B+5=-T/4[FXT%[C3M]W;>?YBLD3)*T,V(CHL(I9;C,?3K
M*<L!AX8FM24*BY:<ZD*,E"K**ISJ4:U6G2JP3M>7/2E4IQE)95\:L-C,)A:M
M*488W$RPE&IS0O*JJ&)Q4)>R4G4C1K8?"5JE.I)*2M"%6G2G-1.8\+_M"Q^(
M(/ ^M7W@#Q'X<\&_$#5)= T#Q/J>I>'Y,ZU';:M<1QWFC6>H27EMI=Q_8E_'
M#>E2698V>&.&593UXC*5A7BZ-3&TOK6$P3S!THQJ.^&A2I5ZG[Q0Y(UH4:JJ
MNG=KDC*/.JJ]D1]>DYU/982K4H4,QEEM2JN2*598Z670J0IRDJE2C/&>SP_,
MHJ:G44HPG03K'.WGQG\0^*=5^"][H?A7Q+X>\%>-_B-#!I?BB;4-#>V\3^'4
M\->++J*/4=)M;Y[[2K74FM+2_LUEB?S(K93.;>0K$_1ALICA\5C</C:M-8S"
MY9BZ]3"-3<J53DP\H?O%'V<J^&=11K0YK0G*2IRJJ$W''$9CS82K5PM&=7#R
MQV#PE/%4Y0<.:.:4:-:HH\_/]5K0IUZ5.LD^?VE.\(*K&1Z[X\^)5QX/\0^#
M_">E^$=7\7>(/&\/B.72+73KW2].M+?_ (1FWT^[O)-5O]4N8DL[0P7^1*JS
M-OC$:QL\J ^5@L(\8L?+VL*%/+:-&O5E._P5:WL(J$8IN4^>R44M>:[<81G.
M/?BJ\<)3PTW"51XO%1PE.$%>7M)8;%8E2;;48TXT\+4<Y2DK+X5.?+3GYEK_
M ,6KO7+/X8W^EC5O"%XGQWM/ /CS0+V:R:[L9=.T?Q)/JVC7UQ83SVUYI\H@
MTZ]BGAE*RP2V\GR,S(G=A\%1P^*=2K4AB\!7R/,\?0JJ,XQ:HTG%3<)J,XU<
M-7IUJ4XM/EJTY\KG'ED^.IBZE;!YC2ITI8?,,!F&482I3YH3E%XK,\J<>24'
M*,J>*P.,A.%^67LZ_+.$*BE&.UX1_:(\/>*_$'A?3(]%O-/T;Q[-JEOX%U^3
M5] O?[:FTNRN]3"ZCHFGZA+J'AU;[2K"]O+(WD0\R.#9.+:>1(7)Y)B:5+%\
M\E'&8##PQ5?#\L[PHRG1IR2J\OLI5J$\11C7I1D^7FFX2J1I5'%3S7#PJ4>5
M.>$KXN6!AB(RBXO$)5[-4TW/ZO4EAJL*6(MRSE[*\8QK4Y-FO_M!6O@[5]4T
M[Q=X+UK2X;71_%^LZ6^FZSX8\2ZGJ<7@VP?5;ZUN=%T35IIM'NKK2XY+FT%R
MYC98V2>2WE&RL,-ESQ>&=7#XBFZT/JG/3FITJ5-8O%4,$G+$U(QH_P"SXG$T
M88EWY81<JM.56G"4CHK8Q8;%4,/5I3C2Q-:M0I5(VG.<Z.$Q>-3AAZ;E6E"M
MAL%7G0M'VLI>SI3I4ZM6,#83XT+8>!-4^('BCPM-HVBVXT@:"^E^)_"OBB'Q
M3/KUZFFZ59:5?:5J8MH+N34;BRMW:[D@MD-XK_:6CCE>*JN63AC,+EU&JJF.
MKUIT72G3JT/9.G#VDJLY5(+]RJ<:M1R2]HH4)OV5W34\L-F-.MA:^/G3='+Z
M&&6*]NITZEX6;=/V=.;E[?\ AQC35XSJ5J=.-1RYN79^'?Q5L_'>J>)/#EQI
M+Z#XF\*PZ/>ZCI@UC1_$%E-I6O+>_P!E:CI^LZ'=36US&TVFZA;RQ-Y4L,MH
MP9#')%)+&)RZ6'PM'&TZOM\-5K5<.WR5*<J=>A"E4G"4*D4W&5*O2J4ZD;QD
MI2B^6=.<(U0Q\:F+E@:E)T*ZP\,5!<T)QG0G5JT;\U-M1J4ZE&4:M-ZQ4J<X
MN<*B96U#XQ:3IW@OQ-XUDTC47L_#'C>[\#W%FDEL+FXO;3QE;>#&O8&9]BVK
M7ERMP Q#^4I&-W%3A\OJ5\3D>%C.,99Y"E.FW>U)58U9)3LKMI4G?EZM&^(Q
M$<-3SJI*+DLDH5*]1*W[R-++J69.,+[-TZJIKFLN=-WY=2*'XMRW_C[7_!.B
M^$;S48?".H:?I_BG5IM?\.:5<::E_IUAJ@U>T\.ZA?QZAJ>@06FH1;[Z-(Q)
M);W,5LEP\!!4,'".6K,\3B8X;#36*]F^2I4]["2JPE"JZ<9*C4J3I-4H2O)T
MYTJTU3I5%,BKB91QRR[#T)8G%*.&G*"<:?N8EVA*C[1Q]NJ<;NJX>Y&49T8R
ME7A.G'G_  C^T1X>\5^(/"^F1Z+>:?HWCR;5+?P+K\FKZ!>_VU-I=E=ZF%U'
M1-/U"74/#JWVE6%[>61O(AYD<&R<6T\B0OUSR3$TJ6+YY*.,P%"&*KX?EG>G
M1E.C3DE5Y?92K4)XBC&O2C)\O--TY5(TJCCS3S7#PJ4>5.>$KXN6!AB(RBXO
M$)5[-4TW/ZO4EAJL*6(MRSE[*\8QK4Y/O?&WQ!?PQJWA_P +Z)X<OO%WB_Q-
M#JM]I>A65]IVE10Z3H2V?]KZQJ>J:I.D-G8P2ZCIUNH1)Y99K^%$B*^8\7!A
M,++$_6I\RHX; 0ISKU9)M0]M.5.A3C&*;G5K2A5<(^['DHU9SG%17-W8BO#"
MPH<R<JN+JNC0I1LI5)PIRJU97DTHTJ-.*=6;;Y7.E",93JPB^ _X: AO)_"N
MCZ%X#\3:OXL\3:AXWT*?PR;S0=/F\->(/A^;$:_8Z_J5SJ)LX;14OHY8KRUE
MNEFC>!HD=KE$KLCE,I^WJPQ5)X.C@\-CX8A^T4:N'Q->6&CR4^3VBK0K0E1J
M4G%<M6,TY*G"55<DLPC2CRU:%2.*CF$<MG0BX3E&O/!5<PISYU)4_83PE..(
M524XOV-6'N>V_<N(_M$Z4]EH]K:>&+X^--4UGQ?H5QX1U'7?#FD+H]WX"O8M
M/\3W%_XCO=0&G-8175S8);R6[SR7)U*WVPH!.;<_LJ3?M:5>-7 K!X;'>WC"
MI?V6*G.G1IQHN*J/$2J4J\'3T@EAZTW5Y%!U&\?[.-2G7HRH8R&+>#C0<Z;Y
MJBPT,:JBJ1ER+#O!U:-=U'[\'7HT94E6GR+U?X>>.M(^(_A/3_%FBQW-M:W<
MVHV5Q8WOV?[9INJ:-J-UI&KZ;<M:3S02RVVI6-U%YMO-+#*J++$[QR*QYL?@
MJF KQI3DJD*E*AB*52*DE4H8BE"M1FHS49Q<J<X\T)QC.G/FA)*46:X/&0QD
M*W+%TZF$KU\+6IMI^SK8>I*E4BI1;C.#<>>G4BW&I3E":MS67:UQ'6% !0 4
M % !0!^57Q#_ .2@>.?^QQ\3?^GJ]KZ;#_P*/_7N'_I*/Y XF_Y*3B#_ +&6
M._\ 4JJ<?6QX84 % !0 4 % !0!^I'B'P1_;WC?X>^,O[3^R?\(&_BEO[-^Q
M>?\ VK_PDVC+I&/MGVN/[#]FV^;_ *BX\S.S]W]ZOG<)B?JD,TAR<_\ :.$I
MX6][>S]GC,/B^>UGSW^K^SY?=MS\_,^7E?\ :&,POUO^S/?]G_9V/CCOAO[3
MER_,L![+=<G_ ",/:\_O?P>3D_><\/-/B#\!Y?&NJ>/]8@\406,WC/3OAA:Q
M:9?Z =5T:.3X9Z]K6O1VGB&T76+8^(O#VLMJXM+S3E:Q/D0R 3OYV(^O 9I]
M1I8"DL/&M]1S'&X^\I6YOKF787+^2*Y7[.MA_J_UG#XB\^3$.E+V7[KW^?'Y
M;]>K8JI]8GAUB<IAE?N+WH\F/KX[VO-S+FIU?;?5J^'M'VN'=6'MH>VO3@T'
MX!-%H_Q4T_Q5KNAWS_%;1=(TN_M/"'A#_A#M!\-2:1INHZ?;3>'M-;7M2F 1
MKRWNE:>Z:47-J\OF;9DBMKQ.:?N<OI8"-:A4RO'U<PH8C$5EB:SK3>"E3]HE
M3HP<:53!JT8J,71E&E*\X3K5HP66NGC,5BLP^K8JCC<NH9;7PM'#O#T)X>E5
MS.=:/O5:\G]9I9E.E4YFW%PE.+4)PHT8'_9X#_#_ ,->';GQ19ZQXV\-^,KW
MXAOXS\0^%+?5=*\0^+]4;58]6N/$/A!M6C6ZTJYT[5[BQ6UCU.*6WBAM3#<J
M]NI-SSB,<QIXK"X-87!4L$\NCA(U7[N%E&G*:A74%*%:6)IK%^V5-_OG/FIS
MA.47%'*9K+L1@\7C'B\9B,32Q;Q;I0BXXC#.,,(W1YI1G2HX2G#!2IN:E5PZ
ME^]IU91JP]1\%Z+?^!?#&HR>)Y/!QN(I+O5[YOAYX%O?"6CPVD%G#NCAT)=:
MUR]U*\1+:5C,)WEFWI'' NQ5;AQ^(P]:5+V"Q$:4(\C^LXA8B3E*I)W3C1HQ
MIPM*,>7EE;E=24_>:CVY?AL53<XXB6&G6JSBH?5Z#PT5%)*,9^TKUG*7,Y2Y
MN:$8J2BH>ZYS^??A7\(M*\4VOQNU/4H-?M?!/Q)FU_PCX$T_5K"XT34M'\!:
MK-J&KZ_=:7IVHV<-UIEKJGC37]=O;9+R!7:VLM.<IY/E*/3QN*K8/+<BP4:D
M(9I@94,77JPE"JXU,#.-+)J-64)2ISG@L%0H\T(R]V5>K3FU552W%@H4\1G6
M:YC&FY99)3H4:,Z+HPJ5<;1HRSVO!.$*KAC\5",9U)6]I4H3K4;TYPJU.X;X
M)>*/$S1Q_$WQWI?B&UT;P;XJ\%>%E\,>#YO"US!!XNT:'0=4\1:_->^)M8CU
M/7O[+C:&..SATVS0SW$GD,98TMN:OF.'Y<;4P.$EA,9F,J$JTYUO;4::P^*C
MC8TL/2]E3G&G/$TZ-2I[6M6J<E*%*,X^_4J;8#!8C!ULJ5;$PQ6!R.O#$86'
ML?9XB52GAJV#IO$UU5E3FZ6&Q&(IKV.'P\9SJNK*"484X6_#7PE\>0>+O OB
MGQK\0]!UU/AYH'B'PUHNE>'_  -=>'8[^SURQTRP.JZQ=WOC'5F?61'I5NSB
MUBM[;YG6.%,[Z>,S#!UZ.>QP^"G0KY_2A"M*==584)0Q#Q%L/!4:<G3<I23C
M5G.H_<?M%R-5,,+EF+P\,GPU3'QJ8/(ZZJ481P_)4K1C@:^"IK$U'5G%U:4:
MSE"=&G1@[UN>E+VM/ZOZ3\,O!/\ PKGP'X;\$_VG_;'_  CUD]G_ &G]B_L_
M[7ONKBY\S[%]KN?L^//V[?/D^YG/.!RYCC/KV*EBO9^QYJ="GR\W-_ H4J%[
M\L?B]GS6M[M^6[M=^G0H>P^L^]S?6,9CL7M;E^N8VOB_9[N_LO;^SYM.?EY^
M6'-RKQNZ^ GBJYM_%OA23XAZ5)\-_'WCG6O&OBG17\%SCQ0L6KZY!K$_AO0_
M$B>+!:6>ESI;16]Q/<Z/=W!W7+P-#]HC2T[<)FN'P\<EJ5,'.>,X>I4(8.I&
MNH4YU</.I6I5<32=*<I^RKU/:PA2JTKJ$*=1R2E*?!C\NKXN6<1I8J-+"Y_3
M]AC*=2DZDXT9Y;A\KK+"U(U:2I3JX>@TY5:=>,)5'.$5*'O9UA^S=JMIXBL[
MV3Q=X8.BZ5\4/^%H6UQ'\/B/B#K5Y)KMUK3Z'XI\;R^*734-+MH[MK*U-OI=
MK)'%9V <NEH8KC3#YS2P]#")X:I*OA,NK9:HQQ'L\(X5,#5P?UI8=4G)8N4J
MCKUI.M*G4J2Q$N2,Z\9T.;&9-5Q-7'*&*I4\-CL=@L>^?#NKB:4L'C\%C5A:
M>(=>,5A$L%&A0@J*J4*3I0YYPH2CB-2\_9JTW5;K4/[8\337>E:KJ'QLNM0L
M+?2!:7#VGQECL(IK6"^;5)A!-I*61V3M;R"Y:4$Q0!-K\M'-:F&PU&C1A[.O
MAL%EN%I5>9/DJY;F4LRI8ATW&TE*HXP=%RT47+VDN;E7JU,+&IBJE>;4J=;'
MTL94I2B[3IPR&>15,,Y*2=JM.<JSJ))Q3]DH-_O3J_#'PQ\8Q>*/#7B3X@^-
MM%\5'P'I.JZ/X-MM \(7/A5LZS:66GW^N^)9KGQ1JZZEK+:=9_9UCL8M,M(_
MM-Q((&,L:VSQ./PE2CF2PN#GAL1G$8T\5*5=5:4*4:SQ#I8:G[*$X1G65*I*
M5:K7FE2A3C+2<ZO#A\MQ%+^S\/7Q<*^!R>HJV$C[#DQ#J0PM;!4I8FLJLJ=1
MTL-B<1#]S0P\:DZKJ2BDH4X=#\+?!/B'P!H-SX4U3Q#I.O:'87=V/"3V?A^Z
MT;5['2;N\O;]K7Q!=2:_?6VL7D4EXL*3VEIIB^7;!GB9Y3Y?)F5>CC\/0BJ4
MJ&+6&IX:O/VBG1G[##4L+2J4J7)&=-N-)U*D95JJ<I\L.2,+R[<+0KX;%YA4
M=:%3!XK%8C%T:?LW&M1J8O%8C%XB$ZRJ.%6FJE=1H<M&E.$(OVDJLI7CRP^!
M=A-\$M,^#=]KANQH\.G26/B'^R( B:MHNO)XBTB_FT&ZN[F&YM8M1@MQ-92W
M#I/$DD9=/,RG56S6I+-\+F]&E&E5PGL5&G-N<)1IX18*K&32INU:BZBO'EE3
M=1.,G*"DSZG3GA<UP59RE0S6MF%6?):$Z?U[&UL=#DDU./M,+5J4W3G*+C.=
M&,I4^63IG&:I\ _%VM6.ERWVL_!R#5_#_B6RU_3-.TGX,WFG^!]86TTW6M+$
M/C3P\_Q#N+G7Y4&KI?6;Q:C9I8W=C%(D<V2PZ:6:X3#UXU*5#%N%2AB*%55<
M;&I4I+$2PTO:8*:PU-4*T%AYTI5)PJNMAZ]6BU33YCS:F68VOAJN'K8K"J4:
MN&K494<%*DIRPTIR=/&P>+J>WP]9RA-T*<J/LZ]"C7YZCIJF:6G_ +/^JZ-H
M$*Z=XSTI?&FE_$_4/BMH&M-X-^R^&+#6-4T,Z!?Z%-X3LO$:22>'7T^XU"")
M(=5@N((KB#$\DMLTMS+SB*JX+V>'G]6PV7XC*ZL*E?VE;$8;$8RKC'4E7]E%
M0Q,:LJ,^=4G3E4HR?L84JOL:=T\IDJ>:JM7INMF&-P.84Y4</[*EA<3@,%@<
M'2Y*+JU'4I..$J*4)58S=+$R@ZOMH+$NMK_@V/P=X(^+]Y\4=<N_'5U\6Y(X
M;RQ\%^ M;A:+41X2M_#VG:/X=T73]0U^\3/]E0O;W-Y<GRYV0RSY*FN>6(G6
M658'(Z+PF*RVO6Q.$JU\12YO;O$T\5"K6JSAAZ$%1JQ3>D8^QC;EER3E/MP]
M)TJN*QV=UJ>*PE3"4,+BZ-/#3]BL)"6(IUZ5.A&6(Q%:.(AC)JI2_>U)U)U'
M#EISA1H][\%O FL^$?A3I.B>*+VYE\::[:WVO>-]6$D(OY?%OB8R7NKS>? @
MC,UG)/'9Q,B[%CT^$(-J@4^)*V%QN,Q&&R^U'+<-3^IX3V?,HJC34DZL%)\R
M]M5E5Q+YGS<]65]3EX;I8G!82AB<<G5Q]>I#$UXUHPYO<C3I8>A55/W+X?!T
M</A9\KDG[)^]*_,_//AU^SKJW@O7/ >IW_BKPG=67PYMM<T_2H/#OP\/AW6/
M$T&M:+-I$NL>.->F\5:@^L>)B[I<R74%M:Q22O>,T)>[5[7JQ^<TL;0S>$<+
M4H5LXPD<+4C[>^%PG)B<-7BL%AE2C[*BEA_9^RG5J.,/8QIU(*C/ZQRT,DK4
M*N7\V,A5H99F,\?"<\.WC<0ZF$S'#2CC,4ZS56HGF#J.M"C3YY4Y.I3;JP^K
M];8? V.R\#?";P5+XD^T1?##Q19>(I+[^QC#_;\=I;>(+9]/^RC5F.E>8NND
M^>)KO;]FQY9\S,?)B,QCB<=B\7.ARPQ>6ULNE3535*M@J6#=53Y->54O:<G(
MK\W+SJW,_76'E"ABJ5.KRSQ&9K,HSY;^SDL\AG2I<M_>LX?5^>\?^?W)_P N
MC%\/_ _QAI,GPWT2Z^(>CW'@+X2Z_;ZMX1T6T\$W-KXBOK&RT?5]%T[3/$WB
M*7Q?/:W1LK+5VCCGL=(LC(;9))D9F('5/.*-6OB<PK82<\TQN$K86O4]LHT.
M:M"E&>(IT%1YX59RI*4HRKSIKFJ1@HJ473X?[-KTJ<\#AL5##Y7]:HXJG15%
MRK15+&K&?595W5Y)89324&J$*Z<*'/5FJ558F3XMZ-XRU+XN_!2Z\%7]IH^H
MZ9I/Q4D.JZQX>O?$7AV)I]+\-Q16.MV=CJNES+#=8E\MHM2M9!);JZF18WBD
MPR:I0I4N(OK$>>E4P>!BX*:IU)I9@F_8S:FE4AI/6G4CRIQE!*7/'IS2G4J4
M,IC1FZ=:&;1G&?+SQA;*,XCS5:=XN=%N<:<DJE)\U2'+4C+E3O6?P((TS08]
M5\4K?Z[!\69?B[XMU2+1#:V?B+6;G3-1TFXTK3M-_M>1] TN.PNK*WMR]WJ,
MD<6FH)#-)*TBQ/'T>:G2I8:4<#A\IQN4T:4JJE55/&^TG5KU:L:<8SJRKUJU
M:2C2IQ;FH1Y(Q3<T<%6A#'U:M>']H9EC,MQM6K2IRA2A+*ZV6RH4J5*=2I)0
M6'RRC0O.K.7-*5>7,VZ;I_#_ .!FJ^ 9['1[35OA]-X-T2SO[#1+FW^&0T_X
MGP6EQ:WEI807?CN+Q6]I+/8Q7$(^VQZ%%-<K;A9=C,\DMYAF<<RPN*6(CB89
MABZ*I3J4L2H85RM3C.N\*Z,I*4U&3=*.(5-5)>TC:*5)1A,!4P&-HSPKPLLM
MHXB6(CAZV%=2M!.I*LL/#$*O"'LH5)+V<IX>52-&*HR<Y_OSEO"'[-_BKPG=
M>$+RT\<>![:Y^'NG^(--\-7&F_"J2UNM<DUO1)M)_MWXB71\=--XGUWS72YG
M>UDTM)WDO20LEXLMIV8G/*.(^OR^I3C+-*-&A7I?6/\ 9:-.EC,)B72P-!45
M]7I3IX9T%&I*LZ494>3W:$XXGAI9)7I2P<?KT)4\OQM?'4:LL.WC:M6K@<SP
ML7C,2ZUJTZ=3,?;N<*5'VSHS52*=:#PVC:_LWR7^A?$*Q\3ZWX7M-0\>7GA;
M5%M/ '@F3PSX*T;7?!NI2:OI?B)O"6K^)-936-9O;\6G]IRS74"7MO86]LR*
M8S/)C+.(T/[)6"I5;91B*U>F\966)GR8BA##5<'"4*6'=+">R5;V=./O0K8B
MK6A*+:A'IAE4ZM3-)X^K2DLTPBPE58.@\)S\E2I6IXRK[2MBO:8VG.5/V=65
MXQIX>E2G"I%._K/PW\&Z_P"%$U5_$,OPXEN;TVL=M_PKSX=S^ 8%@M3<Y?4Q
M=>*]<DU*XE\Z-E"O;QP;'55?S"]<>-Q6'KTZ4,/#%0Y92E-8C%K$1O)048TH
MQP]#EY>65YR<I34DK0Y->C!87%T*E26*JX6LE%0INAA)8>>[<Y5)2Q-=2YK0
MM""A&+BVW/F2AY;X@^ _C/6+7Q1X4LOB1H^E_#_Q+XZ7X@O8/X&N+_Q9;:I+
MXGL?%=]HHU\>+[>QDT&75;-G4_V.+I5N?+\\K$#)U9?FF&P<LDQ%;!3KXO(E
M&G1<:ZIT:M*'MU!U:;HU)^VIPKN"E"K&FY0A4E2?O0EEF.!QF,_MFEA\=#"X
M?/,,Z-:]#VM:C+ZC0P#="I[6$/95:6'C[6%2E.?+.M&E5IRG3J4.A\;?"'Q'
MX[\:Z)K&KZ_X*@\/>'M<TW6](N-/\!7]K\3K&&PFBGN?#EOX]'C1K>+0]2*S
MP7H70U,]I>36K1[F%RO/@<9A<'AL53E0KU*^*H8K#55'$1AA*]/$TJU&+Q&&
M="4JDL-"K"=+]^E]8HTZZ<+.F],?A,5C*M%4\11HX:A5PU>FY8>53%X:KAYT
M*LJF$Q/MXQHSK3I3C*3P\G&A6J4FZBDFJ_PT^"FJ?#?4='L;74/AS?>#?#D5
MS!HC#X7BR^) M'BNH+"SU'QQ%XK:TN&M(IH4:\CT**:ZCAVR[&=Y).G%YO'&
MTJU3$0Q"S"O"$)SIXE0PDY1]GSU7A71E).HH2YJ4:ZIJI/VD;12I+&EEE3"X
MA1PM3#QRU5JE:-&IA7/$4E4G.HJ-+$JO"'LZ522=*<\/*I"E&-*3G->W.S\>
M> M=UO7_  SXV\%^(-*\.^-/"MCKND6DWB#0;GQ+X>U/1/$9TV34]-U/3+'7
M-'NTD%WH^F7,%U:ZC"T;VS*Z31RLE<&!Q4,+]<HUJ<JV#S"%"->$)JG44L-4
MJ3H5:51QJ1C.G[:O%QG3G"I"JU:$E&<>[&X>6*I8;V514,7@*TZV'J2A[2"=
M6DZ->E5IJ5.4Z5:'(WR5:<X5*5*:E**G2J<SX4^"#>'/$?A+Q7=>*?[4UO1]
M1^)&O>)9ET1;"W\2:_\ $@:2+RYLK==5F_L#3K"+2+>"WM&;47:%(Q+<-*KR
MS=4LSA&CB<)0PSIX26 PF P\)5>>=&GAL7/&2J5)JG!5JE>M4JSGRPHPC*H^
M2*@HP7/# 5&XU\16A+&3S*&95YTZ3ITIRI956RBE1I4Y5*DJ<*6&G02G.K6G
M+V#YW*55SAR^I?LY2B]/B+1=?\,W'BFV\8_$;Q+8CQIX&'B?PK)I?Q&O[+4=
M0\/ZEH:>(K*XDGM+G3-/>#5;6_M9 T+[K<QS/%3PN;?5Z.'PLZ,I8:&7X7 U
MO9U?959O"8C$5Z.(I5.2:I2C]:K0E2E"K"<)--QER3@\;E_UJKB,1"K&EB98
MNGB\.YTE5ITG'+,)EE:C5I\\'6I5XX2%9N,Z,Z52-+E<HTYQK>^^#]$O/#OA
M[3])U!_#\E];_:'NI/"OAP^$]!:6XN9I_P#B7: VJ:DUA$J2(A$E]<N[(TC/
MND(7AQE:G7KN=%5HTE&$8JO65>K[D(Q;E45.E%\TDY1C&G%034%S<O,]\'1K
M4*/+B)495I2E*3P]%T*6K]U*G*K6E>,%&,I2J-S<>9*":A'IJY3J"@ H * "
M@ H _*KXA_\ )0/'/_8X^)O_ $]7M?38?^!1_P"O</\ TE'\@<3?\E)Q!_V,
ML=_ZE53CZV/#"@ H * "@ H * /TN\=>./$.F>*/"G@#P7IFBWOBKQ3IWB#7
M1=^)+R^L]"TG0?##Z5;W]U,NFVLUSJ%]-?:WIEO#:QF 8EFF>51"$E^?P6%C
MB(8_$59.&%RR&'=7E2=2=3%U*L,/2@FTHIK#UZE2K*Z@J<8J$Y5%R_VEB\0L
M*L%3C%2Q&85JE&A%MQ@E0H^VQ%6I)*7NTXNE"--+FJ3K1LXPA4E'YN\8>,?%
M_P 4_$7PC\*2Z5HFFVX^)'Q!\)>/?#TGB3Q%'IFH^(O!'A?6;HHE]HUG:7%Y
MX?\ LK6FJV?F%'-Q+;QW$"FU+GW,MPF#P\\7C^>I4H3R6&88.3IT_:T8SS7
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M5"3JTJ;FZ2G#$T<13]I1]I.-*K&$9*#4*GM80I1I]?XI\&:7XMF\)SZE<:A
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MC[12A.G)3ISBW2:4H3C&46TU=+1GW5+.<?1G&2X7S"2CO"=3)W"<6K2A./\
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M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\JOB'_ ,E
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M27<)+D]FI>[[52E#^]&#49-=U%RBGYM%^D 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 ?-GQY_Y';]F7_LN,?_ *KSQW7M95_NN>_]@*_]2\*>-FG^]Y#_ -A[_P#4
M'&'TG7BGLGY5?$/_ )*!XY_[''Q-_P"GJ]KZ;#_P*/\ U[A_Z2C^0.)O^2DX
M@_[&6._]2JIQ];'AA0 4 % !0 4 % 'Z!Z?_ ,G5>+O^S??AU_ZL;XHUY=3_
M )$&$_[&&+_]1L$?V)2_Y'^-_P"Q?@O_ %(QY]!5XYZX4 % !0 4 % !0 4
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M-FG^]Y#_ -A[_P#4'&'TG7BGLGY5?$/_ )*!XY_[''Q-_P"GJ]KZ;#_P*/\
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M*L3_ ."I?Y!_K!D?_0VPG_@^G_\ )!_PU;^SA_T67P+_ .#B/_XFC_5_._\
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M'$?_ ,31_J_G?_0JQ/\ X*E_D'^L&1_]#;"?^#Z?_P D'_#5O[.'_19? O\
MX.(__B:/]7\[_P"A5B?_  5+_(/]8,C_ .AMA/\ P?3_ /D@_P"&K?V</^BR
M^!?_  <1_P#Q-'^K^=_]"K$_^"I?Y!_K!D?_ $-L)_X/I_\ R0?\-6_LX?\
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M\-6_LX?]%E\"_P#@XC_^)H_U?SO_ *%6)_\ !4O\@_U@R/\ Z&V$_P#!]/\
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M3=6?1M;TVXCTJU\6:S::-::S>3B?RUTN"2Y:6696*@6TJ9\Q2HT46JM"G/\
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MOVC?/'EM+^W9RE+"5,+"3I.=?#5G--_#AY3<J=E:ZJQFXMWLE>\9)V/"=?\
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ME&I",9251<M.3C:JXT_-1^U=>'5?[ '@B/\ M3[8?!P/]L3?9/\ A:8\8_\
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MRUQ-JO\ PC/VP:DEI!+8B$6&QY5,X<1*4J*SYL/BW1J./U&CF<L1.W*[Y?+
MT[X=.ZE[7^TL/4C[1Q]G&%53N[&,)QY*%62<88R&73P\4N:47F%7'THQKI-)
M>R>75FW3<O:.I1IQ2DW(Q=5\=_$$_LO^"?%>D:K&/&'B%/ %AJ&MW-VD-Q$/
M$OB32](O;FUFBTFZB:Y<7JPB7[,OE)-)<1AI(4BEZ\71MFF3X*E>-'%5,)&I
M:\)3O@E7DGI)P]I.#=1J\E=P2?->-TYJ-+B"O.,8RP/]L3I0B_:TZ?U?$XB%
M-1E[GM(T*4?W5TE4E"'/:,I,P-7^.OC"+X>ZV@TZ#27O? GQ.F\&^([;Q#)K
M'B>VU7X6SIHNJ7GBBRNM!LK>WGN[LFYADMVF",!'-&K2#:4>7%5\ [>R^LU,
MAQJIQC^Z> S3,<'15"4KMQKJEB(1J17-"5ZZA4O0YJCI4W1J5J4_WL</6QV
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M_P#ZG[_RUO\ \(Z/[4_Z<?\ D_\ ]H'_ !!S_JH__,?_ /?H?\,G_P#4_?\
MEK?_ (1T?VI_TX_\G_\ M _X@Y_U4?\ YC__ +]#_AD__J?O_+6__".C^U/^
MG'_D_P#]H'_$'/\ JH__ #'_ /WZ'_#)_P#U/W_EK?\ X1T?VI_TX_\ )_\
0[0/^(.?]5'_YC_\ []/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g897507dsp1b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507dsp1b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M'T?ZG\.?]"[_ ,N,5_\ +@_USXE_Z&7_ );X7_Y0'_#>/[5W_15?_+&^&_\
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M^%_^4!_PWC^U=_T57_RQOAO_ /,?1_J?PY_T+O\ RXQ7_P N#_7/B7_H9?\
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M#_7/B7_H9?\ EOA?_E ?\-X_M7?]%5_\L;X;_P#S'T?ZG\.?]"[_ ,N,5_\
M+@_USXE_Z&7_ );X7_Y0'_#>/[5W_15?_+&^&_\ \Q]'^I_#G_0N_P#+C%?_
M "X/]<^)?^AE_P"6^%_^4!_PWC^U=_T57_RQOAO_ /,?1_J?PY_T+O\ RXQ7
M_P N#_7/B7_H9?\ EOA?_E ?\-X_M7?]%5_\L;X;_P#S'T?ZG\.?]"[_ ,N,
M5_\ +@_USXE_Z&7_ );X7_Y0'_#>/[5W_15?_+&^&_\ \Q]'^I_#G_0N_P#+
MC%?_ "X/]<^)?^AE_P"6^%_^4!_PWC^U=_T57_RQOAO_ /,?1_J?PY_T+O\
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M'T?ZG\.?]"[_ ,N,5_\ +@_USXE_Z&7_ );X7_Y0'_#>/[5W_15?_+&^&_\
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M_P"<O[>/_)UWQ5_[D;_U6_@^ON.#_P#DG,N_[F/_ %*K'P?&?_)2YE_W+_\
MJ+0/D*OICY<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@#]>?\ @E3_ ,UX_P"Z7_\ O1*_-/$3_F3_ /<W_P"ZQ^H>
M&_\ S.?^Y3_W:/D/]O'_ ).N^*O_ '(W_JM_!]?2\'_\DYEW_<Q_ZE5CY?C/
M_DI<R_[E_P#U%H'R%7TQ\N% !0 4 % !0 4 36]O-=3P6MM$\]Q<316]O!$I
M>2::5UCBBC1>6=G95 ')) JH0<YPIQLG)J*N[*[=E=O1+NWL*4HTX2G)\L8)
MR;[)*[^Y(_:3Q+^SY\)&^%6O?L^Z5X/\++\=/"?P/T+XAOXGMM*TY?$VI:['
M?74NIVO]KB#[6Z3:A9):E&F(%OJ\"8"(*_(,;G^8/,,3Q-A\56CP_EV<T\%.
MESS5%X9X>[E*DFH2DL(Y8A^[=XF'-\1^T93P[E4<MRSAK&8;#?ZP9WE>,Q,9
MU(+VU&NZM-8>7MW%U(TX8VI*C9._U;#58<CIMQ/S[^!W[+6O?''P7XQ\9:9X
MP\.>%[7P7JUA8:HGB7SK2RAL)HDN]2UBZU4/Y=E:V&G_ &BX=7C8N+<J"I8$
M?>YWQ!0R*IERKT)U:6/=9<U-KF@Z<8<D8T[7JRK5*E.E"*E'WIIMV/SSA_AO
M$<0/,J5"LJ&)P$:+5.<&U4E5E63C*7,G25-49RG)QEITNB]\:_V5+OX5?#_0
M/BGX:^(OA?XI> M;U/\ L9M>\-1M!%::@3=I& %O+N*ZM3<6%W;M*DZM'-$(
MWB&[(Y<MXG^MYM_8V-RVME>,G2=:C&J[^TBHQFTTX4Y0DZ<U4@K2C."F^9.*
M4NW,.$OJN3U<YP&:4,UPN$G&&(]DE'V2E45%3C)5)QJ1C6E"E->[.+JTY*$H
M.<J?J\?[ L]E<^$D\5?''X>^$K7QUI6BS^$AJL4D>K:[KNK*DC:!IVCW&I6[
M7+6RW%@K7*3G?)?PQI"6-<U3BYK$9E@\+E%?%XK+*U>-2%*5XK#T+IXFI.-.
M7LHRE&HHP<9.U*<G))*^]#@V,\!E>98G.*."P68T:$U.K!1<:^(@JE/#P4JL
M8U9<CO*2E"VGNN[:\MT+]D'QAJ/[0>J_L]ZIXATG1M:TS3+O68O$*VEU?Z7?
MZ;%96]_9W-M;J\$R_:+>Y0%7(,4B2(=VS)ZJ7%.&K<.U\_I8>;CA9>SJX>4E
M&<*JK1HRASI232YXU(2M[U.46U%OE7+B>$L3@^(<%D-;$Q4<PINMA\3&%XSH
MJE7GS.ESJ49*IAJM"<'+W:D).,IT^6<\#X6_LTZK\3[[XRV-IXIT_23\'=/U
M*_OI+C3KFY&MKIL^L0-':+%<)]C+G1Y"#(9,><O!VG)F/$]++\CRK.WA)5*>
M:*@XTE4494_;THU5>7*U+E4K.R5VNA>6<(U,QXFS'AI8Z-"I@*]>A[=TG*,W
M0Q4<*Y<G/%Q4G+G2YI66FNYJ?"/]G'P9\2O#N@ZIK'[0OPX\#:]XFU2?2-&\
M&7\<]_XA-ZEZ;"UBU&W-[9_8#=SF(P,%FCD2>/;(7+1ITYKG&,P&)EAL)DN(
MS)4Z,:TJM-N-))QE*45)4ZEY046IQ:C*Z?+&4'"<N'*,DP6/PCQ6+SO#Y6E6
ME1C3J)2JMQ5-\W*ZM.\6JD6I1YHI/WG%J2C]!_LF_"+6?A)^V;>?#?QG!IM_
M>Z+X3\12K<0)]ITS4;.[T^RN]/U&T6[A5@DEO,ORNBM&XD0\ID^)FV<X?.N"
M<RQ^%4J-G3I3IR:YZ56GBZ49P;B[-;2A)6YJ<HRM&_*O;R_(L3P_QMDV!Q,X
MUH556KT:L-(UJ$\'C(QERO6$HU*<Z=2#ORU:<N64X<E27P!\156/X@^.T151
M$\9>)U1% 545=;O@JJHP%4   #IBOHN'&WP_D3;NWE^";;WO]6I'@\5I1XIX
ME27*HYKF"26B26+K6272Q^K_ ,>/@%\,;S]EBTU;P9X&\.:%X_\ "_PZ^'GQ
M&O=5TC2K2RU/5]+N;/[+X@^U3VZ"6Z00K>7<V_(\R.%LYS7PDLZQ^#XTKPJ8
MRK++%G&+RZ="4Y.E2C7J3AA&H-\L+5U3ITWNH1K):,^\P&1X#&\!8*2P5".:
M8G(J&.I8CV4?;5*N"P^$Q6,?/%*I*=2C.5.5[J53$4VTVKIW[)?P$^%\GP%M
M]4^(/@7P]XC\9^.M'\<>.='N->TBTO[S2O#6AG3]$T_[-)<1,UM#+<30WL6T
MC?\ ;BP/R\''^<YAAJ^,HY9C*N$AD^$H1KRH5)0OB<9#$XBE=Q:O*-*DX6^S
M*C-;MW7ASDN7XFEA*^9X.ABWFF82AAZ=>E";^K825*C7E&-1-N*Q$^6I))1<
M:U#I*+E\+?"?]EZY\>?#^Z^*_C;XB>%_A)\.DU4Z'IFO^)8;B]FUK5$D\F2.
MPL(9K<-;).LL)E,^XO;3A8BD#NOVF;Y_#+,7A,MH82IF&9XN'M(8>FU%QI^\
M^:I)J7+=1<E[K2@U*4HJ4.;XC).'*N:X7&YA5Q4,NRS -1JXBK&ZYFZ:2C%R
M@FN:K3A?F5ZDXTXJ4^91UM2_8N^)]M\8/#?PGTB_T#78?%NAGQ7H/C>SGG7P
MS/X3BV_:M:N76&2: 0M);QF&-9][WMJ(G=;A7KGPG%6!JX#-,9BZ53+ZN2S5
M+%X>I;VD*DVXTXPORJ7.XS2YE3<72K<ZC&G*1T8WA+&8?%Y11P6(I9CA,]C*
M6"Q-/W825.$*E;VD4Y^S5.G.G4YHRJ0G3J4N2<JDI4H3_$+]D9O#?@/Q1\0/
MA[\6/!GQ;TKP%?+8>.K3P[#/9:AX><R"%YQ&]U=1WMK'(26D$D.421XQ((GV
M<^$XM]IB<NHX[*J^6T,W?+@\14=X5)NW)&2<(.'/S04;<WO5*:DHQJ1D^W%\
M%.E0S3ZEFU#'X[)(RJ8W"1BH5*-.DJCK-2]I-.=)4JLI0FJ=XT:RBW5@J4O9
M7_8\^%<7[.7@7QMJOQ=\$>&?%7B'5+C4+CQO>ZO>7?A;4;1K/4C#X,T>"2YM
M('U2VEM!YT_E>9Y]G=Q@F-5QY^9<49E@^(L1@<+EF(Q=#!X.H_J4*:6(KU(R
MHSCBX/DG-490J*%-*T9PJT:C2E)H[,GX5RK&\-TL=BLTH82MB\912QTZE\/A
M*4H3A/!U(^TITW7C4A*=2[<Z<Z=6DI-1..^*7@WQ3>_LX?LKV-ZWP]MM&\3:
MX-,T.\T/PO=6'BB*35GFB6;Q#JK:@\.HQ@2F246]O T\B1RR$NF3VX2K0GQW
MFE)?6(XK^SX-IU4\-R06"VI<G,IKGCR-S<:=ZRC&U2T>/&4JM#PZP=52H2P<
M,UGM2:Q#G?-4FJJGR>S?LJG,G3<IIX?WE[&7M.C;_@GE>V?BV3P-K/QU^'.D
M>*M0B:Y\&^'IHIGUWQ1906)N;F__ +(.H1W&G6D<\-]"&1;QF73YY0@5,'EA
MQNZV#J8K"Y+B,0L)?ZURS_=89.IR4E.LJ4H\U2+IU.5QBH*K33DVW;KJ<!1P
MV)H4,5GE'#PQ=HX9RI6J5YQBG5C3I2K1NJ;:CS*;YG=<L=+^$?#W]E/Q=XN\
M5?%/0O$7B#0_ >B_!;[7_P +"\4ZHEWJ-EIPM7OPATVSLT274_-ATVZN%.Z
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M8-.DU6PTO3Y;&YOKO6IK^+4XXUD$)"2V<EE)Y$:JWLYM2QE7BG,Z6887'XS
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M^-?PR\06$OP^\23:SXCTWQ#I=CX6T35[F0VUOH$FN7^I+!/?O#;QS;'^SO\
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M_C!7Z^?B04 % !0 4 % !0 4 ?KS_P $J?\ FO'_ '2__P!Z)7YIXB?\R?\
M[F__ '6/U#PW_P"9S_W*?^[1\A_MX_\ )UWQ5_[D;_U6_@^OI>#_ /DG,N_[
MF/\ U*K'R_&?_)2YE_W+_P#J+0/D*OICY<* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H ^E?@W^T;<?"_P?XE^&WB'P#X7^)GPZ
M\5:G;ZWJ/AGQ%)=V3PZQ:I9QQWEGJ-IO,(,=A:$J]O(0]M&\;Q_.)?#SG)(9
MM4P&*CBJF!Q^6<ZP]>EO&$U/FBXW5U^\J6:E'2I4C+FC)*/OY'GU3)HX[#RP
MM+'8#,80C7P]5+EDZ<E*$KN,EHU%M2C+WH4Y1Y)0NY/BA^TI?>./ \/PN\'^
M ?"'PH^&ZZK'KM[X;\*17$T^LZQ$%6*[UC5KLA[OR_*@*JL,;$V\7F.XBC6/
MFP/#OL,PHYIF.8U\UQN$IRI8>56T*="$U)2]G33D^=JI55W/E2J3M!2E*3[,
M=Q-&KEV)RK+,JP^3X/'3A/%>S]^I7]G*$X1<W""C!3I4I.T.=NE"*J*GS0E\
MS5]*?*!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M<?\ 09_Y2H?_ "H/[3QW_/\ _P#)*?\ \@'_  HKX5_]"M_Y6_$?_P MZ/\
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MA_\ *@_M/'?\_P#_ ,DI_P#R ?\ "BOA7_T*W_E;\1__ "WH_P!8LX_Z#/\
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M_P#_ ))3_P#D _X45\*_^A6_\K?B/_Y;T?ZQ9Q_T&?\ E*A_\J#^T\=_S_\
M_)*?_P @'_"BOA7_ -"M_P"5OQ'_ /+>C_6+./\ H,_\I4/_ )4']IX[_G__
M .24_P#Y /\ A17PK_Z%;_RM^(__ );T?ZQ9Q_T&?^4J'_RH/[3QW_/_ /\
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M\**^%?\ T*W_ )6_$?\ \MZ/]8LX_P"@S_RE0_\ E0?VGCO^?_\ Y)3_ /D
M_P"%%?"O_H5O_*WXC_\ EO1_K%G'_09_Y2H?_*@_M/'?\_\ _P DI_\ R ?\
M**^%?_0K?^5OQ'_\MZ/]8LX_Z#/_ "E0_P#E0?VGCO\ G_\ ^24__D _X45\
M*_\ H5O_ "M^(_\ Y;T?ZQ9Q_P!!G_E*A_\ *@_M/'?\_P#_ ,DI_P#R ?\
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MY6_$?_RWH_UBSC_H,_\ *5#_ .5!_:>._P"?_P#Y)3_^0#_A17PK_P"A6_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
6* "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g897507dsp1c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507dsp1c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( "8 + ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /TJ\7>)OC#X_P#B%\5=)\%>*O$'@KP5\%_^$?TF;3O GAKP
MAXC\??$+Q3KNBV>NW26DGC6:/3M+T_3K+4+9$B,D1G+22-(2%2'ZK"X?+,%@
MLNJ8K#T\7BLT]I-2Q%6M2P^&I4YRIJZH)SE*<HMMV?+HDMV_D\5B,TQN.S*E
MA,35PF$RGV4'##TJ%7$XFM4IQJ/E>(:IPC3C))*ZYM6WLE>MO 7QHN-6CTMO
MCA\>+6%O$.K:$=8N? WP0728[?2]&35H?$DDD5C)<_\ "/:A,YTVTD%LUTUY
M&RSVD$&+@Q+&95&FZG]DY?)JG"IR+$8_GO.?(Z5G)1]I!+VDUS<BAK&<I>Z7
M'!9LZJI?VQF,5[6=/G>'R_D2A!356ZBY>RF_W<'R\_.FI0C'WCL/^%,?%S_H
MZ7XD?^$=\+?_ )D:Y?[4RW_HGL-_X/Q?_P N.K^R<S_Z*/%?^",'_P#* _X4
MQ\7/^CI?B1_X1WPM_P#F1H_M3+?^B>PW_@_%_P#RX/[)S/\ Z*/%?^",'_\
M*#(UWX1_M!:?I=W?^#_VF?$^H^(K")[O3=)\5^!OAW<:!K%Q;HTB:3J3:;H%
MI<VEO=NJP-=0REX1(9%1F48UHYEDLZD88G(*5.A)J,IT<1B54@GISQYJDHMQ
MWY6K2M9M&5;+,[ITY3PO$%6=>"YH0K8?"NG-I74)<E.$HJ6W,G>-[V9[/\)/
M'+?$OX9>!?'TEDNG3^*_#.E:S=6$;%XK2\NK9#>V\#LQ9[9+L3")G.XQA"P#
M$@>5F6$^H8_%X)2YUAJLX1EU<4_=;71M6O;2]['K99C/K^7X/&\GLWB:4)N*
MVC)KWDGV3O:^MK7/EKPC\%/A3\4/C1^TOJ7Q \#Z)XJOM,^(/A6QL+G5(II)
M+6T?X;^%KAX(C%,@"&9F?D'DU]#B<US'+\JR&G@L74PT)X>M*2@TDVL552;N
MGTT/G,+E&6YAFW$%3'8.GB)T\31C%S3O&/U6B[*S6E]3M?%?[./[*O@[3!J6
MJ?![PO(9KB*RT[3K*QO+G4M5U&?(M]/TZU6\!GN9"#@950 2Q %<-+B#B"K+
MECF=9<JNVY12BENV^71(G.,#PID>$6*Q>5TY.<XTJ-&E"4Z^(K3TA1HTU).5
M25M%=)+5M(\3N?@7X+O=1\36^A?LW_"6U3PKI]MJ.J:?J)UO4M0A^UP-=V^F
MK<V&KVUO/JYLD:9H(E9$&$,IE*HW:L]S.,:7/G&)?M&U%KD2T=F[.+:C?2[^
MZQ\%5_M>OB<UI9?PCE%%9/1A6KT:TJ]>M'VD74A04Z-:E2EB723J2IP3C'2+
MGSM1?;>#/@G^S?K#Z'8>)_@/X-T&_P#$5A'?^'K^U-U=Z#X@C:)9I(;*Y:Z6
M2RU*-6P]A<CS!CAF+*#C5SS/8<[I9M6G&D[33LI0Z:JVJ_O+0][(JN18V67X
M;-N'L/EV(S2C&M@JU.3J83&1Y5)QI5&U*E7BG[V'JKG5M&VTG[UX9_9K^!/@
MW7=-\3^%_ACX:T77]'F:XTS5+."X6ZLYVBD@:2%GN64,899%Y4\.:\ZOGN;X
MJC/#XC'U:M&HK2A)JS2:=G9=TC[O#Y!DV#K4\1ALOI4:U)WA.*=XNS5UKV;1
ME_LH?\FW_!O_ +$?2OY25IQ'_P CW-/^O\_T,N&O^1#E7_8/ S/@I_R5K]J;
M_LI?A/\ ]5CX4K3-?^1;P]_V"UO_ %*K&>4?\C/B/_L+H_\ J)1.M\2Z''XM
M^*FG:3?:CJMA;>'?!/\ PD&EMH]\^GW::IJFMW&EW-RMQ'&Q&VRLHX^""/M!
MQP3GS:4_8X:4HQC)SJ<KYE=<L8II6]7^!XF:X".<\7X7!8C%8C#4LKROZY0>
M&JNA45?$8J>'G-32;]VE24-+/W]-W?G/AWX%AU+_ (3BZD\4^-+>>'X@^)M*
MDDL/$MY;274&DSQ6=I)J+*A-U>^0HW2L3E2N .@TKUG#V*]E3:]E"23@G:ZN
M[=EY'E\,\/T\5_;]66;YG2J0SC'8=NCCJE.4X8:<:5.59I7G5Y%K-[JVVQP-
MGX7TN?X?VUM!XNU-?%]CJGB>[\ >&Y?$T2_;+WPGK]W#!-H.@W+![J>.)HE=
M[9,J]XI;;YH!Z.:I[64_87H)4U6J*F[152*TG-:1O9V3>MGV/$PG#\<3PKSX
M;,<9/,\!B,;4RW#?6VZ?M<#BZL:4J&'DM9\JM>"3YIWTYC[$MGEDMK>2=/*F
M>")YHO\ GG*T:M(G_ 7)'X5Y#LF[;+8_9J4IRI4Y5(\LY1BY1[2:3:^3T/ O
MV4/^3;_@W_V(^E?RDKV>(_\ D>YI_P!?Y_H>/PU_R(<J_P"P>!D_!.2,_%[]
MJB(.AE3XD>#Y'B#*9$CD^&?AA8W9 <JC-#*%)&"8G ^Z<:YJFLLX==K+ZK62
M?IBJM_NNOO1GE#7]J<1J^JQ5#3R^J4;:?)V]'V.Y^*7@[4=5FT;Q1H,%Y=ZG
MH7G6VIZ5I^KWVAWNO>'KADFGL+?4+"XAD2[@N(EN((V<(SE@P<[4;R\-5C!3
MI3:C&=G%N*DHR6B;33T:T?Z'D\79'BL9/ YOEU.I6Q>7<T*^'HXFKA*N+P<V
MI3HPK49TY*I3G%5*47+EE*Z:D^6+^?--\1_#S0=3\>0:C?\ C2SA!37- TZ3
M6O&&D:F^I7-L$U31=7@AO8_^)JNI)&3=3/+YD<A=ISY>!WRIXB<:'+&FW\,G
MRTVK)^[*+M\-NBM9]#\UPN:<,Y=BN(J>*Q&:4()K%8.C+%9EAZ[KSA:OA<3"
M-6/^T*ND_:U)3YX2<I57RV7CWQP^&FH?$GX-_#S5/ ?@74O'GBKX8ZM*\D&H
M:;J<&G^([?X@I>P:]'I5S;7UIJ>H2:1X@DT6^DN87MUA2P>9)P%9E][A_,*>
M!Q^,HXK%K"8;&TU[RE&].6':E#F4HR@O:4_:0LT[N2CRN]CV,OPRS+A?*H9=
M@,1CL1E'O3JU:-2%#$SQTJD\1&A-SA7K/#UY1E.HE&*45*-1[KZ6_9*T#X@>
M"OAYK?AOXK7OCR?Q1X;\0WEE>7OC75X]:\/R:=;6T3V%[X"UR11/=>$WL#$Y
M%W(TEO<+<0E8A%L'E<25L%BL;1KY=##QP]>G&48T(.G44FVI1Q%-:1K*5U[J
MM*/+*[O<_0^&:.-P>!JX?,IXB6(P]6492KS52GRI+EEAJCU=%QL_>=XRYHZ6
ML=7^RA_R;?\ !O\ [$?2OY25S<1_\CW-/^O\_P!#IX:_Y$.5?]@\"3QE\!DU
MGQK>_$7P-\0?&'PI\8:W96.G>*[WPJ-&OM-\6VNDPM;Z1-KFA^(-.O;.?4[&
MW/D07B(DB0LT9# @HL+G#HX2&!Q>"HYAA:,I2HQK<\947-WFJ=2G*$E&;UE%
MMIRUTZO%9,JN+GCL'CJ^68JM&,*TJ/)*%905H.I3JQG!S@O=C-)-1NM3+_X4
MQ\7/^CI?B1_X1WPM_P#F1K3^U,M_Z)[#?^#\7_\ +C/^R<S_ .BCQ7_@C!__
M "@J3_ CXG73K)=?M,>/;AT&$>?P-\)Y70 YPK2>#B5&>>*I9MET=L@PT?2O
MBU_[F,:F0XNLU*KG=:K*.SGA<#)KT<L.VOD6A\%_BVH '[4GQ'4*  !X.^%H
M  X  'A'@ 5/]J9;_P!$]AO_  ?B_P#Y<;+*<S6BXBQ22V7L,'_\H,_5/V>_
M'GB6QGT3Q5^TM\5]4\.WZ-;:QI>G:7X"\-W&I:?*C17.GMJ^C>&(KJVM[B%W
MBE$;?,CLI'.1I3SK!X><:N&R'"4Z]/6$Y3Q%50DM5+DG5<6XM75]F14R/&5X
M.CB>(,94H3TG",,-2<HO1QYZ=%22DM'9ZK0^CM T'2/"VAZ/X;T"QBTS0]!T
MVRTC2=/@WF*ST[3[>.UM+=&D9G<)!$B[W9G8@LS,Q)/AUJU3$5:M>M-SJUI2
KG.3W<I.[>FBNWLM%TT/=H4:6&HTL/0@J=&A",(16T8P2C%=]$MWKWU/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g897507dsp1d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507dsp1d.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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7Z*;DXQ3UD]Y2DVY2EHE>3;LDKV2/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g897507dsp1e.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507dsp1e.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M9<KEMJD<U_PL.Z_Z)S\2/_!-I'_S05?LX_\ /Z'_ )/_ /(''_:F(_Z$F/\
MNP7_ ,V'G_Q ^,NM07.C_#_X7^'?[8^,?B>Q.HVV@>(O]'TOP#H(G^SS>,/B
M+)IUS*=/TJ-L"VLH9C=:A*Z0VXR6*^A@L!3G">,QU1T,MH2Y93@OWE:I:ZH8
M=25I5&M92DN2C%\\]XQG.*S*LE1PN"P_-FF)@IJC6:4<-3V=;%NG*:C"+TC"
M$W*M-<E-V4IPP/!/QEUS0M7T;1_BCK_A;Q%X6\=7S6/PQ^,'A73+C0?#.M:W
M#)-:7W@;Q/I=UJ5^/#GB:/4+2]2PF-VUMJ2P/"ABO8&@EVQ. HUJ=2ME]&K0
MJX6/-B<'5DIU:<-&L12DH4W4HN+BZBY%.C=2?-2ES1SPN85L/4IT,PK4J]'%
M3Y<+C*,73I5*FJ>'JP<ZBI5E*,E2?.X5DG!<M6/)/ZGKQ#W0H X#QEXE;3A-
MHG_"->/]26_TUB=6\&Z?'*;+[0T]OM@OS?PO:ZE%Y8E&$.T21-DY(&E."=GS
MPCRO:5^GDDTT>5F.,E0YL,LOQV)C6IN]7"*G[G-S1LIRK4IPJ1MS)Q7NWBT[
M[?/7B3Q7J_A_5=&\'?"N^\>>*OC+XITB>\L_#'C[Q#/<Z!\/="G?[++XW^(U
MK#YBV-E;,0;.S#O<7T[)# A)8KZN$PE.K">+QS6'RVA/EE.G!*I7J)75##II
M<TY+64G[E&'OSWC&?D14L'.C2R^KC<3FF+H\T</C<55JT\+3DU>OBH<\XPY&
MN6,8MSJSO3INW/.'M_PI^$^C?"[2KWR[NY\1>,O$EQ'JGCSQYJX637_&&NA"
M'N[R7)%IIL&^2*QTV$BWLH,1QJ6,DDO)CL?4QLX>ZJ&&H)PH4(7]G1IWORQ3
M^*4MZE25YU)7E)M[>[@,OI8"G.TG7Q-=J>(Q$[>TKU+6YI6TC&*]VG3C:%*%
MHP25[^6_ #PGX<\<?LT:!X4\6:19Z[X?UB7QQ:ZCIE]&7@FC_P"%@^)WC=64
MJ]O<PRI'+#<0O'+#+%'+$Z2(K#LS*O6PF;SKX>I*C6I*@X3B[-/ZO27S36C3
MNFFTTTVCCRO#T<5DT,/B*4:U&JZ\90DKIKZQ5?R::335G%I---)ECPIXL\1_
M!GQ#IGPP^*^L2ZQX3UV_72OA'\5M1<&>_D96:S^'WQ!N=H2V\80PKY=AJLFR
M+6HH2&*:@DD<Q7P]',*,\;@*2I5Z,>?%X6.T$M)8G#K=T&]:E-:X=O2]%IP,
M/B*V6UJ>!S"JZM"M+DP>*EO-O6.&Q+V6(25J55Z8E+6U9-3^GZ\4]L^;OB]X
MUUW2/%^C^$/A>-2U_P",'B/P_,VEZ!=ZA<0^ /"/AW[9<6MQ\1_'5O'&52TM
MKII8+:-&:XO[BUCM8$)C8CU<!@Z52E/%8Z?L,NH32G**7MJU2UUA\/?><EK*
M3]RC%\\]X1GX>85JE'&4Z> =2OFE>BXPHRJ36$HTN=WQ>(IKW5RR]V#2]K6:
M]E#13E#O/A3\)]&^%VE7OEW=SXB\9>)+B/5/'GCS5PLFO^,-="$/=WDN2+33
M8-\D5CIL)%O908CC4L9))<,=CZF-G#W50PU!.%"A"_LZ-.]^6*?Q2EO4J2O.
MI*\I-O;MP&7TL!3G:3KXFNU/$8B=O:5ZEK<TK:1C%>[3IQM"E"T8)*]^]U_Q
M!H?A71[_ %_Q'JUAH>BZ7;R7=_J>IW,5I9VMO"A=WEFF95'RJ<*,LQP%!) /
M+2I5*U2%*C3E4J3:C"$4W)MZ))+5OT.NK5I8>G.K6J1HTJ2<I3FU&,8K5MMV
M22\SXV^ GP+.L?"3P=KFH?$'XU^&9_$%OJ?B*'0]"^(>M>']+L=/\0:[JFLZ
M3]ET:% FGF;2[ZSN)(A_RUGD)R6)KW\TS)T\?7I0PV$JJ@XTG.6'I5&Y4H1I
MR?.TW)<T7:756/GLJRM5,OP]66*QE%UU*JH1Q-6FHQJSE4@O9II0?)*-XVT=
MT4O'O@Z'5W\6_L\^ O$GC#XE^)_&&B65MX]U+XG^*]0\:^%?@YX9NY))+;Q(
M\%WM">/)R?.T;3+>2.Y::UAOYF@M;0/-I@\1*@\+G.*I4\)0PE23P\,/2A0J
M8RK&UZ2<5_ C\->JTXQC*5**E4GRK/&X>-:.*R3"5:N+KXJG%8B>)JSKTL%2
ME?EJVD_]XE\6'I1<92E&-63C3AS/[GM8/LEK;6WF23?9H(8/-E.Z67R8UC\R
M1N\C;<D^I-?,R=Y-V4;MNRT2\EV2/J(KEBHW;Y4E=[Z::^9\Z_&;X>^(9-6?
MXE>"](M/%]W+X5/@;XC?##5VA&F_$OX<K<ZE?-I6G2W*F+3_ !38W&KZK+9O
M(R072W\]K<DJT97ULOQ=)4XX/$U)8:$:OM\-B87Y\+B+07.U'WI4IJG353EO
M.#A&I2NU*%3Q\QP=7VCQN%I1Q$I4O88G"SMR8K#)S?(N;W8U8.I4=/FM3FIS
MIU;)QG3Q? ?P7_9/^)'AJQ\5>%/A-\/KS3+LRP2PS>%[2UU+2M2M7\K4-%UK
M3Y8Q-IFLV5P&AN+695=&7(W(R,VV)S/B#!5I4*^9XN,XV:MB:CC*+5XSA)3<
M90G%J4)Q;C*+33,L+E?#N-H1KX?*\'*G*ZL\-3C*$HNTH3BX*4)PDG&<))2C
M)--'GGP!^ WP7OM<^.4]_P#"[P1?R>%?V@?$VB^'?M_A[3[U-'TFQ\*>!;ZS
MTZRANH7CBLX;R^O)DBVE5>X=@,FNW-<VS2-#*%',<3%5\!&51*M47/)XG%0<
MIVDN9N,8Q;>K22>B.'*,HRIXC.&\MPTGA\PE&E>A3?LXK#86:C"\7RQ4I2DD
MK)-MK5GM7Q&^(GB+4M>E^#OP9DL)?B(UI:W'BGQ-=0K=^'_A%X=OLK#K.KP#
M]WJ/BFYA#G2= W!IBOVNZ$=C"3/Y>#P=&G2689BI+!)M4J47RU,74A:].#WA
M2BVO;5[-07N0YJK27JXS&5IUGEN6.+QMHNK5DN:G@Z<]JDUM.M))^PH73FUS
MSY:2;?H_PZ^'/AOX8^'QH7AZ&>66ZNI=4U_7=1E-YK_BKQ#>;6U+Q'XBU*3]
MYJ&K7<P+N[$(B[(H4CABCC3CQ>+K8VK[6LTN5*%.$5:G2IQ^"E2AM&$5LEJW
M>4FY.4GVX/!T,#1]C13]Z3G4G)WJ5:DOCJU9[RJ2:U>R248J,8QBN]KE.H*
M/G'QUX!\3>!_$MU\7?@SIT-UK-[(DGQ,^&ZSI8:;\3=-A0C^T]-+XM],^(MD
MFXVU\1&E\K-;7K/F-E];"XJCB*,<!F,W&E#_ ';$6<I863=^627O2PTGK."O
M*G+]Y25W.%3Q\5A*^%K2S#+8*565OK.&NHQQ44K*46[1ABH)6A4=HU(_NZKL
MH3I^)>"/'<NN2_$'PK^SMKZZ_P",/BK\0=4^(_B?Q%KGAR\TO3_@'I>LZ-X=
M\.WUEXGT^^D;^V?'4%WX<NTL-%'E&6<R272)9V3R7?J8G"^QA@JV<4'0PV P
MZP]*G"HG+,)1JU:T949Q5H8=JM'VE=<\5%+V;E4FHQ\O"XKVL\=0R6NJV)Q^
M(>(JU)TI1CEL72I4)1K0D[SQ*=&7L\.^23E?VBC3IN4OK[X=?#GPW\,?#XT+
MP]#/++=74NJ:_KNHRF\U_P 5>(;S:VI>(_$6I2?O-0U:[F!=W8A$79%"D<,4
M<:?/XO%UL;5]K6:7*E"G"*M3I4X_!2I0VC"*V2U;O*3<G*3^BP>#H8&C[&BG
M[TG.I.3O4JU)?'5JSWE4DUJ]DDHQ48QC%=[7*=04 % !0 @ 7. %R<G QD^I
.QWH_0-O(6@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g897507dsp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507dsp2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M8\,W>A^'-/\ $&AZ?XM\0Z]8::NNW/AS3;"*+4VT_1G:XLY(I2AGAS]FE2:
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6ZS]J4PZL;<1"* 1K;(=[YPIL&Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g897507dsp2a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507dsp2a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M3P?X@TWQ!#IS3Y,$=[-I=Q,EM)( 2B2,K,%) (!( *GQ;^"7PJ^.OAB7P?\
M%CP1HGC/1&\U[5=3MRNHZ1<RQ-"U_H.LVS17^@ZCY3,GVJPN;>7:S(6*,RD_
M0/T/P$_:B_X(^>.O!*ZCXM_9OU2[^(_AU',[?#[6GL[;QWIENS+O72M2'V:P
M\4Q1!G<1&/3[ORXPD<=Y-S( ?DEX=^$_Q-\5^.%^&?AWP!XNU3X@"\-C-X.M
M] U)?$%C<1RQ0S_VIILMNDNDP6[S1FXGO5@BMU;?.\: L #]Q_V8/^"-MI$M
MAXK_ &I-::[E_=SQ_"OP=J<D%JH*2AK?Q5XOL62>9OGB)MM"DM]CQ974948K
M0!^YO@_P7X1^'WA^P\*>!O#6B>$?#6EIY=AH?A[3;72M-M0<%V2ULXD3SG8;
MI)6!>1B6=F8DDV\@V\CIZ "@#/ATG2K;4;S6+?3-/@U;4(;:WO\ 5(;*VBU&
C^M[(.+."\O4C$US# )'$:2.RQ[VV@9-&WD&WD:% !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g897507g02g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g897507g02g02.jpg
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M*"@H*"@H*"@H*"C_P  1" !Q K0# 2(  A$! Q$!_\0 '  !  ,! 0$! 0
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ML(UJB$&0#XL@V/'G KN+.2BXMIFGC)22:"(B\/0B(@ B(@ B(@ B(@ B(@#
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MU,9@DC@C#&"1NT'(;,R#_P!*IQ7JK%;!30ONJ=4W!^05^\&#$&RZ8?F?R5<
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MB(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@
MB(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@#XUGZK+]$K*>E+^\9NDHB8;/]
M]B[:/N$'LGZ^Q:YT6_\ AV-$5C:/NHJ[,]YDQ1$2<=A$1 !$1 !$1 !$1 !0
M#2G^I=2(I:/?1#?[C,V7?]</TE.M&_ZU#]((B=6_#$=/Q#25%^JQ]"^R(D!H
L5T"(B#T(B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (B( (B( __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Erasca, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001761918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th">
<div>Jun. 20, 2024 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Equity Award Grant Practices </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have had no program, plan or practice pertaining to the timing of stock option grants to NEOs coinciding with the release of material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div> information. Annual grants of stock options to employees are typically approved by the Compensation Committee or our Chief Executive Officer pursuant to a delegation of authority from the Compensation Committee in the first quarter of each year as part of our annual compensation cycle. Our Board or Compensation Committee may also approve grants at other times as they deem appropriate. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The timing of any equity grants to newly-hired employees, or in connection with promotions or other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-routine</div> grants, is generally tied to the event giving rise to the award, although <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-executive</div> new hire stock option awards are generally approved at the beginning of the calendar month following the individual&#8217;s commencement of employment. For all stock option awards, the exercise price is no less than the closing price of our common stock on the date of the grant. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for certain stock options granted to our NEOs during 2024. In the event an issuer grants stock options or option-like instruments within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K,</div> Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">8-K</div> containing material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div> information as required under Item 402(x) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-K,</div> Item 402(x) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">S-K</div> requires tabular disclosure of certain information related to such awards. The table below is being provided because certain of the stock options granted to our NEOs during 2024 were granted within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K,</div> Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q</div> or Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">8-K</div> containing material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div> information. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:40%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Securities</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Underlying</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">the Award</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">the&#160;Award</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">at Time of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant <div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant&#160;Date</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">the Award</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Percentage&#160;Change&#160;in&#160;the</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Closing&#160;Market&#160;Price&#160;of&#160;the</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Securities Underlying the</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Award&#160;Between&#160;the&#160;Trading</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Day Ending Immediately</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Prior to the Disclosure of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">MNPI and the Trading Day</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Beginning Immediately</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Following the Disclosure of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">MNPI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Jonathan E. Lim, M.D.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">632,759</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">934,458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">David M. Chacko, M.D.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">278,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">411,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shannon R. Morris, M.D., Ph.D.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6/20/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">137,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">202,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(1.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text">We have had no program, plan or practice pertaining to the timing of stock option grants to NEOs coinciding with the release of material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-public</div> information. Annual grants of stock options to employees are typically approved by the Compensation Committee or our Chief Executive Officer pursuant to a delegation of authority from the Compensation Committee in the first quarter of each year as part of our annual compensation cycle.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=eras_JonathanELimMDMember', window );">Jonathan E. Lim, M.D. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscIndName', window );">Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jonathan E. Lim, M.D.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardUndrlygSecuritiesAmt', window );">Underlying Securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardExrcPrice', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardGrantDateFairValue', window );">Fair Value as of Grant Date | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 934,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_UndrlygSecurityMktPriceChngPct', window );">Underlying Security Market Price Change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.43)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=eras_DavidMChackoMDMember', window );">David M. Chacko, M.D. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscIndName', window );">Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">David M. Chacko, M.D.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardUndrlygSecuritiesAmt', window );">Underlying Securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardExrcPrice', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardGrantDateFairValue', window );">Fair Value as of Grant Date | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_UndrlygSecurityMktPriceChngPct', window );">Underlying Security Market Price Change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.43)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=eras_ShannonRMorrisMDPhDMember', window );">Shannon R. Morris, M.D., Ph.D. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscTable', window );"><strong>Awards Close in Time to MNPI Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardsCloseToMnpiDiscIndName', window );">Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Shannon R. Morris, M.D., Ph.D.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardUndrlygSecuritiesAmt', window );">Underlying Securities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardExrcPrice', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardGrantDateFairValue', window );">Fair Value as of Grant Date | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_UndrlygSecurityMktPriceChngPct', window );">Underlying Security Market Price Change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardExrcPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardExrcPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardUndrlygSecuritiesAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardUndrlygSecuritiesAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardsCloseToMnpiDiscTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardsCloseToMnpiDiscTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_UndrlygSecurityMktPriceChngPct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 2<br> -Subparagraph ii<br> -Sentence F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_UndrlygSecurityMktPriceChngPct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=eras_JonathanELimMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=eras_JonathanELimMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=eras_DavidMChackoMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=eras_DavidMChackoMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=eras_ShannonRMorrisMDPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=eras_ShannonRMorrisMDPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>14</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="d897507ddef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d897507ddef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d897507ddef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="DEF 14A" isProxy="true" isUsgaap="true" original="d897507ddef14a.htm">d897507ddef14a.htm</File>
    <File>eras-20241231.xsd</File>
    <File>eras-20241231_def.xml</File>
    <File>eras-20241231_lab.xml</File>
    <File>eras-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g897507dsp1.jpg</File>
    <File>g897507dsp1a.jpg</File>
    <File>g897507dsp1b.jpg</File>
    <File>g897507dsp1c.jpg</File>
    <File>g897507dsp1d.jpg</File>
    <File>g897507dsp1e.jpg</File>
    <File>g897507dsp2.jpg</File>
    <File>g897507dsp2a.jpg</File>
    <File>g897507g02g02.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>24
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d897507ddef14a.htm": {
   "nsprefix": "eras",
   "nsuri": "http://erasca.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "d897507ddef14a.htm"
     ]
    },
    "schema": {
     "local": [
      "eras-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "eras-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "eras-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eras-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 14,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 3,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 4,
   "entityCount": 1,
   "segmentCount": 3,
   "elementCount": 269,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 20,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d897507ddef14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d897507ddef14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d897507ddef14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d897507ddef14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d897507ddef14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d897507ddef14a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r31",
      "r47",
      "r82"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r34",
      "r50",
      "r85"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r51",
      "r77",
      "r86",
      "r90",
      "r98"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15",
      "r27"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15",
      "r27"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15",
      "r27"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r27"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "eras_DavidMChackoMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://erasca.com/20241231",
     "localname": "DavidMChackoMDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "David M. Chacko, M.D. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r54"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r54"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15",
      "r27"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15",
      "r27",
      "r78"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15",
      "r27",
      "r78"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r31",
      "r47",
      "r82"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r28",
      "r44",
      "r79"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r51",
      "r86"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r51",
      "r86"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r51",
      "r86"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r51",
      "r86"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r51",
      "r86"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r38"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r15",
      "r27"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r51",
      "r77",
      "r86",
      "r90",
      "r98"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r102"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r102"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r102"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r43"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "eras_JonathanELimMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://erasca.com/20241231",
     "localname": "JonathanELimMDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jonathan E. Lim, M.D. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r43"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r35",
      "r51",
      "r77",
      "r86"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r33",
      "r49",
      "r84"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r52",
      "r87"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r36",
      "r52",
      "r87"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r28",
      "r44",
      "r79"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r29",
      "r45",
      "r80"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r30",
      "r46",
      "r81"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r37",
      "r53",
      "r88"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "eras_ShannonRMorrisMDPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://erasca.com/20241231",
     "localname": "ShannonRMorrisMDPhDMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shannon R. Morris, M.D., Ph.D. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r32",
      "r48",
      "r83"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>25
<FILENAME>0001193125-25-103868-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-103868-xbrl.zip
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M.^7GC61_SBN>*7X[XS!7CQ*0,#+N7__<V][>>OT!&0YL\\GT.^1_Z='.:WW
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MYW-(&22S)G5?N].,C/, 26*PKG"!<2FJE8I;!U.RZQJS8!&%*/NB>K6M6N,
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M':5Z% YD:!-. K!R..M('5T5)=<.@ %!"_@E2B ,5;<2!IV46K-HUS38"O"
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MI697M8&NDDRZ)O0I RD5(&.4"MS4RP-"+YQ@DB4>>4DI).R],K8BSXOT\/O
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MTIA'L>R2!ZS2OP^#Q65S"2;-Q;7:S$;89A!3DB6%6U,<"NGKB]^-9AEX5:@
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M^]P?#)!T6E6FCV G.><E5+":,9+*8??<MV'@Q/[M%*XI1HX:Y-P5NDM4[<S
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M 8D"@>5*)BZJ.&A,TX+3F99-7]#@"'GC.%*FV$/<,W=E$^-&6[VU:=%-9?R
M9@W@ <*Z,W6>E?8$L1^BY-6I^?!6[9F8JY=, P?@77"4 Q=G3RC4%?DT>4@[
MWC6P8W%EC[A4 **$<RD\%0##(/SK7EH,J. K&D8GA$AJ0XV1H< IH<NCYX8=
MX_$?$@O?/(](NCVT'H<6:@9?U.:1?Q6R5GW>A\5*A6]I!PMT#C0>)@5., X)
M_M3IV^TO32*L3?U.Q((=$0:1'+%.;<IW+PDM6R];C]AW\6KMN_B;^"YJQ]5*
M.9=\&GY#AY]5(V'1?D_2J'>-,*%'>&J/]*EU\@-R?=;>1TD73JW^Q95 G02"
M-IQ)/#2O6G7^(;:,=ZG_7T0L9JDT0 E(K 5RM<AP)?= U#JY/_$TUAHV@@9R
M*!']?2TYH\N4HCF8+^IW/GX\;,,0*K82$JW8WXOK ])-.$:Y#UBH#R)70.(?
MR) L,CE"@I;-G'O!'3+\<DVR:_7F<,T(QBI 6DI=@S_T:=_J@JAYL8,O_NS'
M\MYVIX&+F\4*XZLDNM(5R=ERJ?>_RB]AI"2O(G/7>B7:UEF\(Q^%C4EX=W30
M\JP>]C$<AQ3]\'&2AFB<P<9/NJEOD421^!R'F/6=8ZA,PWW1,*TP<U!NZ4Z&
MB7C ;$0R8(<75<\&X3;@@@; UHAIB-G,+?XS=I0EYQYI$B QPRE$>\&33R<?
M2EJ6Q^H3 _/ZM'7>Y5]%V.U:Q8CN4ZU0Z=/5M&_ _I!Z&!0;<7#11@$B#]R;
M(W@$=LU@R);'AUSB QQ4T.)$V_!9Y(1&#LLOOZ7U/TRB2 U4?1".TJIEMJE7
M+/E\4+( K@C?EO5<5K;"9%PZ5NBH+&@PW[F(-A/O7 2U>7):K,1(>TE?N.S"
M9;ZE+ER5#*1DT$S&/BO4/C-;$L3H269X>*UJ\P-Q3)&8@.&5.,V,+BUS=7F=
MV<BI=Y.AS!8:B(L^G%FV0;+_G>+G,N_)X>GATQ)_O015!.\6H$9^GKNU-:,;
M+*:.M:9FS9LVF_J(S],$F0=<H_V^0@86:NFU3.676CG$DV^OX.DY>?H.%FX_
M96BA6#>JFBJ:%HI8>,$8>5\H,03 *@L$X1Z+W1W'<SGR(]"')[C=I&F&<9Q<
ML:TX\#'X-Y]L=HLPZNF">E,'I#G6VS:O0'L:@_H(7%> KAW^5EDUX+)I BR#
ME+EIG X.+/0_]*<.JH&#+<68^)Y(^:4\S.@=H,'E.59V9RQK-0Y#/&)A7. N
M.]%@WXBW<!%W84/\\H/[#!M091;E]T8O/]6$+>^7)5BN!["(&PE]#EC?I"!K
MOK$!3C%WU\Q]V\^;AT(!'Z1?<VG.  -,I7;6&$,XNB%%L, NZ>ZKAK[MK1:*
MEQ1)W#"Q=R'&6Z'UUYT8_W8&QY+#M.0W9.WJ*J1@BE9MP-?2L%BJ*AZD>6N)
M!<OZ202+QP9[2:V.50)[RP&0I]:2__&<V99S:](MZLY;+MA+-<Z-677;./Q<
M8^OSYLE83Q&(]RK+*40Y*)SB+T.K=F5T@J1/Q\[:,3V6!S)]_:9M#);( 5X*
MVURQ-!_"NO1"]+&QW:Y(2_3F7,CE]ZL#*&]6^4YNR8#(/G PFD2U2\4QY-=Y
MOO&P:=<620XIZSDB$&^>3I QBDPO3BZRI.LZ"D.I"-0OK_'6J_+6=SK.E"D0
MR2G$,&WLU<40'QYG!M!!P/(A_)MHTQG?Z]=4?1!O(,<5@HI1K@9H115I$,9B
MS:9R.8)P *]I$49?C&WO+=</-:[X2K_S:&<*MS(G[-2>L,,$)\?1 3J^H"7R
MBDO>? +H[/5A4,WLBD0FVJ&Q\ FS].25.%=_%4G>=)Y)3$O5I%]DKK%R)H.6
M,]C@9B*KJC9FE]?8;(&K53<:#G;8O2GV@J-?+P^J1%-ZGHF0_;*U01OA[8"D
ML3'L I\+&9<HC"F6]G.D,.-[H!?I&5 GBU$WA+:T!X']A@X9#E*_5Q"YOE6Y
M[[WW1Z![7(:#D5\;68,$US=\9ZUD.GZ )D2HQ:0-[?I' Q)=#@?% -:,KBA<
M*OM[25&2GMP8##2CAB-'ZI@3!7& #<\.@6@44&2<6BW>PU$>P!N1B!/76(,G
MH]IG:-[O-8[[>IJM5(<?:#.-@1@G/9,,A25U[>3H^."/ ]<1:*;AN%*U/_@1
MNQ<Z6VO_PM_$OU ^:"7!\"7S!,=4+<$Q$D#TPOG]Q1R.018'BZ9M91+'G(]W
MI?;T3;DJ99BZ4Q(D2T-NL0(^Q9PC)_O72W/DX50WR7S(F ;L&9DJ059Y*(O]
MI6"T.8MB6>5"? D'^PZ?!HFR%MTT5<,3#\8R#)#WV55+MHGQVIGJN0LK[M#U
M\2FY<I6*F5.OC4.[ RHL]S!*T#E\)LRU9<E0QV=A[XV=+:JQ@D0!'%WW@)V:
M:,GVU$ED)9F/;2C722W29DJLPKYW\OZTZ1[A>]HNM$3^7J)5=_![DG[)&F]1
M?;U/1-ML&#7V#7\IMG,-U<C/:5";YMZ"(7/DXT+A-._0T8..)2WN99(Q7)&)
M^WX QUM,>YU7KV3/MG8:1VG%4_9CQ$5*6\8$67Q1C3*ICID!25)YOX-RH-*8
M[*XHS3DO2%Q;(@0/=S0O+PH([-,(T/I'&5TH*YM%HJ=(Z(G)ZL0O-\V@T1"I
M3WESBN?BULF1'-.2E3(Q1Z-I4QL'OFJKYJ)1B \N2T\#,6P0I]V(^Z^&VJN>
M<Q"_.>V_)K*[EKDM&]FR.S6R12R*VRY/Y+GIF82443A(,8<8N2%Q2)?K::XR
M2F!PF&%&/ML9]Q4-7LO,I84Y]E-XU5F>BL^\[-*PZ9=.2H3)OL2VT:O3LB,U
M]#KV4XZJK9J9G$D)!]I[J8.%IRT0C*P^F=P[&,#F)+-M3?4+V(M\"E%TC$PE
MK\^[LNUPNR,[J_=Q9^H^3C<ZH-,*OE19HZK2=$E-L9%5;(PYW*"Y(7*!QY!4
MM:L0'>,ZT+5]JT%3Q2;V25D&3:OTQ%T_3FOXD)"O*O,.WC\UEA)]+HR,NE<?
MR36+HP<CA7$+L8XEO4Q@H>"2*$4(],G13X*(MG94(S*K5]9<O[U[DWY,8/SQ
M0$6"/>#XR;))S)D0LR(";%M.Y 'T\=G086W^J[NA2D&?Y7C!6AB!O<(>SERS
M(@?;-/2<&0ZM*H[.@SNT:FB:BX69&M,,6AXS$X9<5(S"']6@ZN4QG/]2@9R>
M(S-$)X/R*1VEF7&U1$5KL845;S5RU,_*[* P+.81W/BT  ()CP/2=Z_@'>=J
M06*<K6Z:U"MD)1@RGJEHX025V4J$GH^K<W6J2MASN5Y [-X35:G#(\;]H/BP
MHP+)LQR5N_ (K.#OB!;&RCY+Z7)-WF4Q8PD*<?:"I]&J$QT).Y)O9F(D^-Q%
M_C4#F=!]B6 )W8+#4H!MH21O(R$OBSQ-O"<Q7 7F0>]WD*N':3+F,#"=&?D1
M6GV?)L58<TT?5X 7(X?;!(:)!QT3TH$!@G@ JS7P347PP$P3EC[.?,KGS2JG
M:2'/ QNW8MS=MYIQVTOS8PA2%1ZA!3=;,V^"&M!B +LW/E-:VF8/@6K0RM./
MT,R?H\Q;S7NQ F^G,B4&,A#MU$2Q0;M%Y#,!G(*<&M"GMQ(M0@2L,0^@*^"<
MG/X\Y>+5 7TMZN14.GGKQIXTY&48[>MGJV?690'G++"_]@-(OJ@FA]D7S"I)
M0.M"]1/&7YZY<QWK2Y@32@?+^CWP-><%6AT\=0(992EK8+%-8)]RM'H]8)C+
MO2AZ4V!8EP[2,+*4-%.+,VZRIF%&U,7)X73%H7H"K4G&W@_5D(V2V7.O$L%7
M"C)NU4?=% O1,.J2,U*KGMJYN/N8\R?@KEP[./X>#HX:\5]//:AH7T<&V2R6
MS7 $5&3"QBX;0F&GV+Q_\:/).)OH+  R*$T-IVULPSAC&V;X"PPHFY;Y4!NY
MC:/P,15L)+EX)GJ_%%0Q(X_X%)0B/Q@6F<I!;- RL4X"=D(&KAO3=V.\JM(4
MY"\2B\81^HLP^I62/1S;MN PIC'G-D//-OW8&+@).ZMJ$\4T[)F#-$JN8<_]
M4A9U)57ZF<'(@.%U*46&S&ZE(-:&:V2V1#<,T6QQ<PMCCKXXG+NAY"HP0V%[
MAFM7;]Y725AE*4J-0Z2.2ABO?M$:WL\Y+DQ2U\M)"]:^(3",MK$__$@U)[G*
ML$E0>5$3HPS1WLJ:,=/>+G)AW>3^G1DTO+ '5T 2[+UZN;OU\C\[*$P)[-DV
M88IU.J^]"S\W\'.$.S8>)W#$=)*1Z_I-U2!$#PV>!TGN#8($57()/%^U[0/!
M> ] ]<P=VS*%C/&885R_G)^^]SY^/-=&_^6&WQ?8UGZ8(?$0NK  !FI3 I/N
M#BCC< AWJ^BMO/4:2);PR]SU["H$?:&!&P(C'%Z-"(P#2)T-:7L'$><$E+[6
ME%79*S/Y,"-\-@VH!SQ:>5=^5"A&6P-54*OYM1'0^75A9YU?YXX!IRO@NTTJ
MBU;C5Z]46#(HHTO<"4ED'H,%-Y+$<UI!MC=]4B%!M9(MH=)NC*D]#'",@#<Z
MH)^H&75V(B2$?T6H2/K;QM31#8B:,^6<T?,!VPMP7TA[+,A^0K](BHC QE**
MN*R$CT>)(D$Q73!DC!8Z7@OA6" N(#VN+8P"89L!U<+*CC$1+<Y]00LH42>R
MY4 . >JQ E=2QA-K::QA2FS$.*TQQG=SYDR.(=Z@G_L5:&(-B>A?^6&D\9#9
M@L6]86KD. V1-/\J8!'I)-!-Y9Z#>X:Z-O"0\TZT+SYN2>QTA]SB):RP1UH/
M#=3(' D3MSC\#G>:.V1U<K7<\D7;.R8[4W_>5/4TFZ>$)L0PSDR"+'I1&3E/
MFJ0[6#*^EIR3S[#C.4;IA'@TO9Y"XS^!Q# _+-"G:)#C312V.93&(_I0;HQ[
M!E-U,#HK2*D+P-]#_W\FJ<3R-"'9NY"BMKV(4/YC-9!/P'&Z6<XNS>RA\$G?
M*H:<9US5C-NR!(J".R=#"_^RS:C:S3KC@-!MWDMHALQ'B61OC>;*Q0]*M\=C
M UY=8O5N)06T'[.];'MM+_L[V,L:07Z7NLZ51#*PH*C]"_> !&Q!R*6>4C&"
M9J$!2054' =J&>#2![CE=8&[&UQ@0MQU*F)$>"-@$&A)RJ>B'R1[:,%6K!M.
M2V@_6:@A7E3=4"U7UUFS[?&<DE5;%6ZBRU!5BD'5BD7=:9DJ.4LO?J@7K.+1
M[F]IDO\'5:5Z\X^&LE,OMW_ T[](63AZ?O<'74JV^K^[:&,%%0_WYA4\_*KZ
M;K67@/'BI?[3Q@NSW97B9NTMO)S*]<WFUF\SO+#FJROQFW=$]#RH/Y#R^<]C
M!\;TQV[Z;%XS->5!OWN+XG</MZ6-A0R7+8.VP.:AA#F._,D^,8%-//25T2Y[
M;;Q3&)V6JT&23NZBVJ4ARNV'($JTR7P% 3WF>>]\[<$1UGUG1^?[J%?-]@@X
M)1F50[S'<K"ZG?]SIV4Y]UX];^WLO;KWZJ3?VCKL;KUH;6]OK<LGW]TIV;Q0
M$261XVEYD*.R@C*VY#G;AK'M=5X]7\G@UFNRRB/T^&^@S_[-^D2M3]0W<Z(>
MS<'!&J)G9(DA\6W[8<2W%5!+I_5R[ZXDE_52S#@O#KFA%7F!M7IV!PLZY:5;
MFA/(RH^Z9Z70O6M5_+;&<+?DN5[-M8PU7\9*<H*+?B IZZY5_!>MSHNUBK^[
MM=>"8[&^'>;PDAWF);VD0,?2 S&T)0;QK=\/CWD]V1(,_T7_PEW[+._4)UGS
M1-IP@[HWM.(M7>@.K)QH;O[Y#U56 4M0#0_8>$.VXCF;W/CBLCM^RW@1[LS:
MMCEZBN/9^KI,+1=TP$<D^A<?0H&#C'PV0M7$9$I4(@)Y0J?B)2]B:D/U#!KA
MW&9L);Z0L_S^*OP4WJ6P((P*)52G=TFZ0)G+SM;F_W7+B5+T7I85&I@6!T-]
M2ADX+$SL18K#(1JBI3CZ0*IWVB%ST) ]0N8$_0UI?_M1T'[).%"C?XG[H*@0
MJMV*U?%,Y"EFET24C&0C3TPE#@G[F$H1]QE;5XVFG7M<QJG:U$7OG<)Q=Q$H
M?A_!14WY(BK#A>=*X3X!Z0:"*NTCO)&9V1@C?[,LQ-/Z%;/DZ'J.VEX^ T%'
MM"^Q4;9JK,2)5Q9!H 6QEG-AR1/1G=);]H/)!A1,ZYL$=@XBY;65PA\-T>)3
M\R@HM293=G C?Z)O@4I85HL_;Z;B;++?Y_Y-.7BK'(;%Z3M5"M%APQD&R9L$
M#MK$3 ),*>;KUA2!4>.4VI<39=%JC7RX"R7)L1R*'YAZCSI?HSV_Z_.&0PN]
M]C!T/I+\<:XTCZ5&0D9GT,,##A=(_ =V75I :$2JQ,+5"USP3\$HP&K$*B#<
MM&[1&ZB\[9TM3>K8@5M6.G7BV*$/S -,**_/7/MZ%O4<@0$7&>$D"\0VRDMS
M<<_D\JD/T\A]*6;:J@HA)3'+CE2E\-V(EP EI <(R+[@Q1;YK;K8I<JO#\32
M6<)4/3?WP@($B;@Y7\R<DM,R.]N+,_^RH,@R'D"FFEN7DUX"K&\:[Y+!Z=/6
MA)+?##P+YCA)=3<S5AQ0Z^N'8+!_I;*1U'9S$F:6/%Y9^=SS69URUEU (OQ9
M!RZ[+725,VDX\39G#/@YM8=O(X1,CS!A/R62H]S9V>IX3P[+TZ)MK(PBXYI7
M?B\9YY:K2,ZT+K![8.=)A9;QA,FQ>4*/'QZ<O7W:O*&2 :9&XRB9V!Y,K7%,
M*.PE6  B-PN&?7(&-(PM*U+6<%+\O8\8DE297(!3)7NBS#BK5#'W #6//<6$
MTJQ%"X<%ZUUJ@'4PO;=T.@P0!(PVL""H@U20@)A7(T/D\6H^WA+$ )MUB#LU
M\GM '[!4=W_H5IT?^/FK#R4=?W//-2<'8B:_1ZL9>=<I?NNHL/8((:H:TJ9W
M48# LK.[_6*Q0X$Y&4!?)-6<.!+-4Y!$4'_J4LIIA(EC$;<S#,=8$"^_QIIX
MRU_,E<VM\@9D E&24653=W*2,(15*5$BDY^8:0O1\?S+QV.IL3F'J+YP3;L3
MV+5[Q.E'.^OTHY+)Y#M-/X*V796%J@ZCQ8G9>A-YEZ60VPCA>596DRB+^SCU
MLT C7S5=1L06G=105\F[W8$NJ89XG?IHI*1&E]<1JTJLEGJT##%'=R1IJS2Z
M\K:L^MIZZSNHPRR49Z[022P/CH]*133SN\F5FI;H+0F?_*35,6RZ_,*"?5>5
M3,A- H"@#VA=9PES\B]Z\Y95'Z90J%QB/%G&<?*O2NO1<G5O%Z+#*)>W28S]
M>D4 %X"!458O'Y&6,$LO%9$9I[*]]1H))&!!?X3 WD @+?JI\]K+ABB$X,.H
M*2B%VK:\UD=[B7[.<*K+XT,N3>B^" 2F84](JB R)\[4G9 L+I831\*RK^"X
M2N_H).R;2>EY,C9/8+4C?(.+)-*(%(C,,#U8I8. EJ3S:F>'E1)-,TGMT>,;
M 3*P[SPOOZ/9(XK2'M^\!#K2SZ5C/'2(LJG0*(SB>BK0E8+[X4[<F2X09 0]
M%_Y ::@2X5T187^HFT"-C7U'+#A<^4\96Q-9@IQEYT5S]0-W25N5+2,6?8W@
M4';7:;ME61GJ(<CO 0V$TV#A?"7L.""R-K6A^P6(@62M;K;GKGI\#9$4%[S'
M_4+L@ QJU%KU0*KB6,/(:@Z.^Q)Y=?_UBK(M;Q[**16GF%];8S4CGE:7[IY'
M404N?\Q:S_.UUO-WT'KF8^[Y&V]J914?!%2!<$<158GQ3RS88J('Q5CG5 B
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ML5+  EX[6HK)"(<S5L+1\[)@J'J4$VK9%H)#!KE4B^!"<GZ84>J?3<Z<#@#
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M=<V0LST>!CEWR*0>'Y4K-GD_7/S#]G!.H*'& -%LGY>A5SX^%SZN],H5!+G
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M0 '_D!D(> =JOC?."T\[^%+_=\7;])?EQ@?CFUPYC1<'I87?1<Q3Q)D M:%
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M)*(YHM_!CL4_'?2%!:PYD^/L._J6#)S4;O3#P!X(.6+5[2>Q7!A!(' $^[=
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MJM7K*?3^IT[_*2I-\J5+W',[=>_^!?)LIX"JX)U7M&P/])@<Q/OASQ^-!]O
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MTP,)$8<N(!*S1"Q (4;8JEMOO[_C85 9TB&F4D]98)NJ+RQSV\]A1%7&,OF
MDS7Y5TU3(BG-O?PQ21&RC\,@!C0O%' <F'1?C&QOJ$A">U%;-:!MF8KV &^]
MZ7XV)CZWPY#FZF#/2<<+HB04/$FTV*@X>M!.Q9/0I8;$P#/&:BQ';D]J  </
MN(!-]TEYH?9_YB+>B;?'K6VX;[&<:\CKX#C7;/X9SAU*QRD"1OABZ,:$AW(\
MF1H8Q#R1IG'PM [<&4] U*8Q L]D-:"/&(QS/LI:&#\U#)%:F ;>31!!=_X
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M-R/W'Q:QOMBN3"_Y ]MDJ]S;2@B\1+2\3!L&I>U^?/5W5Z8JP?4\(G(<<VA
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M88-YA+K+L XV@H@>% ^CC! ;/6\W<+E>$.'^<.,"0PW,,\JYMY*0"GX41]
MFW_7.^;DA2TB=: 21YSC3GBW(@U'N'X$]KK']UERBV2K%5Z>#UZP0C?D33R\
M6G:L<WRF[HV-XKG./\TIJTEFSP7:(.AM\:V1(),9P"W9?<JO:@8Z*MF(16F
MWJ4D'@4AH;/F*X(;!)IPA].=*:FH6B!C)X#@GW*OXH<('9=]C+B_?@((+Z+(
M^$\RN$%< [W9_LY^;'9P!PE2%K*EH4WRUBSZM4G](^=^:#-> Q-Q8Z0=0.^!
M$*A6>.(626%F8^:BJWNPFS/>L@21"$-TB=Y3%,%3<N'ZTTW%++(W\A$3>\8%
M-7O9L3&"$D\SQJ;\N,AG..*VE^%"JPH7/J5PX:[N'M9F"AJ1#R$BHX54\2A/
M@^12G18#,NY@.T26$_1Y-2HO&^=JD"X:"$-!S@YR>T0@N8\BY10>S+ .CGRL
MR/1!QP86[(C,.J$W,K,;D@6A8DJ;6D6H OZ(0QM4-3#4P<S(<6U3>4%7V_A
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M3^R\<"MR=FN92EO2@![5WS#Q1&I17Y\<FUHG^DQQ=MEUX8-M'44V*,'8O7D
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M?K $]C,[>Y [* $6;4<)K+4OX=]%D/,GJ\ Z?38/Y#P4&<YSP?CO!P+?O_/
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M9KT.?X7M?7;%#?8H OD(A_==VSAL6 V+V!EJ97!0(F [5CB<CRXW*;S<4>%
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M0'>4,I+AM-B3/Z4E+8#(=BP&#K)P*0$[UB&=0Q4$A(0"GAA!":S%<Q4/4R%
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ME _Z0DJF^MTOXY?-HX9_EV3<HD!/?P-02P,$%     @ -8.=6E/4Y&J7 @
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M1U53&5Y6ANJ],U\J__\N_@%02P,$%     @ -8.=6C8&,..- @  IPP  !4
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M:J*H+2LJ/',K2WG31Z<-@[6>C8[.="_,](VRU-751'.'VPN8?__EYYO (B>
MNAX?S\+TTXXG)WU53>./8VMIR37]7$'36Q9O RT<)5XX%9N;4_W#']V&LVH[
MDW"Y3@%\EVL[6@T"(:'A%(  T8#T-C*6^*I3YXQKN6V[@SA]*+K3@C]8/ G&
M+U2L2""8S; /OD*?'_[C>-^W*Z%C?8O+ Y<5[MC+W/^4R&_A<@)/M1[Z9HT[
M*B_GZX-M.FB]P(! !+HAW%X(SQM.\6.Q"Q?O ^6:TTB7F(4VW-&@(GQ0N)6#
M BB+'W?C/UD%\5( -[?**8"/)4A2%]EKA@+H?(1X@C(M:'E]M+[3<^'L&#F2
M30'$!6KX776&.A'"'Z,G@-@((X:_#0Y[H\.Z"3R/W>ZV!D#6"6^BU]];%=DB
M/9QM@I,RZEQ,\BD )G\3S9.2YXJXO;=?QRPST9CLQ0E$4:ND/ZX)R_[BDD\6
MIKH3PC==^"X)6Y"QR3B2G%]P<J#]1F&,ZL.910$Y=6A5[;7&:P[JUQUU6ARQ
M(W%4#'5T2J0[JO7EXRM[:'I5"F!VIJUU_?"%M?".^\0J5\4ETP3+Z)5Z%)*H
M"7XG:Z3L&OZK&\HA+AKUX;L*C\:0GM_1N,4XX7H568?NI"ORFYY2L^.H#^ZW
M3N>3(?A$@^M>]8E!7L97\[@R/)=%,.VSX/T)_MKE^OX87#T72SEVUS))5=_<
M>DO#4"B[$3C;,M1;,).UDH3J0<7;14J-*6XG*3RHJ4:/*GI+]S%,(W=#F.M<
M)$/M76S5;E7TVB4;W(W\V!'ZZ""WU=ZP">NU;Q/SN+\Z(N4,<<?SZ# 7)F=M
M)\V%:*)W*%,].G4I.R_X!,(]D:'>"E9G[^3G<Y[M]RG=MN/R?%/\N'<##7>5
MG]NR+&^4MA!*'7P8I>_0@\LF)&MWC4(31?BV@L1DPN1"5G=:P62Z>>BKMV5&
MR1JW%%?T*UP&?P.W9MK2GI! OSG_ NKOGLS(FID2!B.AE:F;P3NM+TCW--#\
MJ]L$L@&VC<@RAHUZGB^#*VWOIQ_YC&N).3FI+SS8+H/<3P+[B%.A \->L!V*
M;6E/&KP"E;]DL]]8QJN],^&%=*<7F.IC=\<"+PI2"3$?RS ='D<%\H5>%E(%
M\I:@-_(4P-/]U\J+-YM9\5F.DU+%$)-7#^IQ^JF[!_!BIW:,PIQC*_S=I.K'
MURNBK"A.3Q1U7)^85=[6<"[$VMBX?5.U*3 \Y5?H(W^"TPS2*+C$,J?(E"22
MF>J2PY\'3,JL6$*P+MH;C4Y#7%@Q7K7!NIM"[.=ZRZ]=E#G\CG$2=.1M,=83
M7+I<?6C Q9%<^AC:@)VU9++Q>4V(]JWRAD@IEZ/MI7(@R2HQNR4_>UH+L46]
M!.]T!"7P7X?=6KD WUH$C4B5C+->I6W]X7TC&NV3W"YE.XFG,P5HW8#KK$'%
MGBHPNG!6V7<7YRE5O8=?MYLHJ6K<?G4N*-K=PYOEZB_N-)HN\(4":$UM&M,K
M<N3B9X/QP>"X[6X71GUZE5B8QM?-R3\]SX57VD?MSY*(<CE?L8R+[51*G#Y!
M43W+WVV;"N^C-\.U+YR/% =>MCG_=)-%DX5%4@\G>PX6L7XWMEOI\"*ERX-A
MW?M&&$7N,Q^9N]EJ4NOH_!E=S0V,YS+G#(KGWQ6:FY!S!@:79 6F[]8>7-]0
MIF-VDX,^?IL%?^SCE7 ?XLP[=:W%S<N@&GY]1R&U-;6(5C(3!?!+7_LNE-UL
M3%-G9? JIOM<NL#/QXNMR$=],_]>_)]Y6X[3'Q+ K=NQ-E<^WBC3H ]E4(:L
M*$A?:W^69U2OWMKNNY\&78RL.C\O\,_T_Z-#QV'1Y3HIDIDPX_)'7'S10_A\
M(S*/R$>JU&:$^68OFN+^M+[0--IRYV/%T[@]F63.5#&58C-0/D_3XPCE<7!R
M8DWB1/2%$G@Z8EXY52PB#?O24>"']A5^X4(8$Z#Q#QW=?M4LT8'/FY:=)38!
MA[I Q?E=3Q)?S^CFZ<M;6=[MZQ"^?];OIO[C2Z_UTNS)G4-\C953IG'06?Z%
M;6V! L0PN*YGU:QKGR!ZBB"+$PWP((2?MA AC)GP.,C!=W?7O7J"=^<%>1=9
M*$'/*!!+R[$4C!H^^*/4OOK10[*50^0,&-+F@@I?W#-8#T518P]Y^KZHK2 '
MLHWZ3?OUAL_33DQ)'WS@7B8,SO$7YM\QS1:H^2+G;>7,@\X4<.9RY* K5;W%
M72L1]_1 R92TU"(^]EMXAB&)T;?WQ%7#9$T>M*B=M&9M[+;UGD+=8MQ27+<N
M;,N?E8KDF39G-3JCC0N/>VUXKVI$.DNLWZZNMGU\GB"Q6$ZNF^)DC9XTMZ-A
MU8RZ]HLFA$/K!H.QHZES].CDUJDMYINX.(#%A^$G];\:@842H"%_H51#B?L[
M;]_#8KYNCM6I6_H'U%BMSI#S[ :9U](<5:HCM%<.BE9$=YCQS-C33A0K\4$;
M(66YP@NCQ"S?-U@9I,\5F>?!$@ST27_W3#!@^A>UFB7[ #CV8EJGT$,3\N8W
M3E%6XLJJ:5)-VTQX'Q&SZ P7/'2:?8V?;E6OD__BRA065YPZ.5ECDUI7D#(%
M[3^AY[M'N(=K6\[\B(W0[NC,O]**\9,^/MNINI&/I #HA<<6MD8:]?ASZC0^
M['2U'JLF\9<$N*KVV3_!\"?GB8T7Q<5;?$$&HJJ!IR$1E4'/ZB6VU;1!6>W^
M);'MAHT9O,<C,R>'==U^/^'3=%C^G4'L14'L=^B8+IXO[6I2A ^2$-8]9H%N
M&M^)K_SJXYXMQU'_;N*C9CO+E?E!<#Y>FT&[_2$]#R]06AKG.YG8?-R2K'GU
M0?*R_;-#.Z!JK2Z358F9X43\6(:S@Q:<>J.-\-R$_2Z\7:X\D"XGX1_KI=Q;
M;56T,/3)B_&GRQ*B;4=[H69=S0PM!]GXP-4^C*8*\+( HTM&VC;LQKOE*  9
MVR)N4P/\&'FPC+CX+P6 E7YJ1^RKV"01Z(A*RBG)FG)EZ^ASD\N.>\/!1^^D
MCIVH-W![5J(26;O. -L=&S[QBZ8 ;M50 +'9-G\*/?R4TC.S3"#^D)?6O6_O
M![Y T2B^^%*_/9S!ECFIO1VM6L#0.06>[#"8[DNK*8RPV%2*.UI?1A%9]LE&
MF*BVG2=^)#5GNVT7/@J@M^T6!>#*_UF'!\],UJ_W.\=1 ,JPY8O[,-J1-F\_
M_FUMILGC>:N.DVR_=WM*A*JCKSY>V<8)X23QGIV!+/_&LWM^0ZI#?:$H2)Q"
M=@,3,W-\:;1]EOI<TJ'J?' -T-AG] FNWDVT*!^[O>P5"_6XKKD94*8DA0H%
M[;T@,?+CC/T S&=E"_(KY,)&4;\+#Q#GY3Z9+U%'MY&!O%A&]IJ#=ZKT9Q%[
MQL?(N:,4P%_F(K@7_S1W1]N/S";L#8@NWO>23_!,&5>S_/TJ@)O?# #H)N/:
M?-$?[WA2S:5'C9;.,6_R\;POSO.X;&3[;W#=J)\Q!=9ZX97)INO#[II*!O?*
M+)&25BCQ%(N,%8Z+LGD)/0?'QA]:V]@A?@;RO9.>J&:3W41O3.W*:J,G9XBC
M72F*U(SPNCP64R)=QT[O4 "C#L0O/&)^C<6I#!I4'!(U7=$(?U/0FD: [ ,E
M$M=\J6W13)Y&1%_/(= D7+7'T#JOU6XG@@X//P$38G".'0NW\ 9QLWJMPT37
M*X:NH9_FG1<2#($L#8XFC^>F'*_Y/KG=;=6?:O.,YZK/VP)FR2'9AGR!NJM9
M2N($?>RB@M-<MK.PA,-L]9'63K]PUU^"D[9TR99Y5[=\\DF,?*/)J=T6D)1)
MI,.-84%=>0R_*( [2E+ CB<3.7VC;J,S' (308K:[NJV)6'+:[7QZ^ DEVOC
MT:KR(@]*.CF(/3)]V\^JY]11EF+= 6%]#%X26CO:/#\]Z@?^Y+/+=:K?]#$2
M)^\L/D:?.!Y\)XE O3K4Z=X&\BITY'..(A6=F1_7)/>;CDF:=_E _#A5K2T-
M/3TEAP0O+6Y"[\" (5$ &5:?7=UI^W7+-JTI'=WVV5#"Y[/!?HWLN.SXO>A"
M$ZM"6N]NE=G)W:;]"O>9/50I(<1@HG;>$OX#',:7%U'Q_,[[Q^CO8TB^DSW;
M]<\/:&(.6&\6J1]_.P*#U0:%#S/:5,:>;4V6QA0!*V>2Q&_ZAFQ[?&E-$CQS
M)92N(!]B09TR;(052]@0EO?YJ=7CZ$W+A4GC*$FD50H908O.X+!]JJL/4$5M
MP-#T9K2O?[K>8P(&EK5ZSQ--&E3"%T/"718%SSKDNL:[5^2F/O9G6Y9Y:\A$
M:6]M^KV3>K$X0!(B75*US^)K.$TK"P'R4P>70"!'&+5S^@95]//J= Q!@BKG
M>SU:ZFO!L ?<I ]UPSGC3YDR< WH:^NAW=I5TJQ@5=%^II"^\7O%-AF9"<BJ
M\P)X"C[2..VIV%,OHTH/UD'I1S,!F2@[Y/Z8QXC@TOZ,0D\D'>$CWJV33P-W
M-0^YJ6X6FSIY<M+O%-4]LR7EZB;K4B,'1J-E$^P>2^7RR\J]NB<N3W_Q!$&;
MU"_+\O)#7TJ>D\9S)K;JZ&2)P=+!EL6^GH[U#P-L'A_LNI8V^U@JI@=--QN0
MW&@]7^?*F@C?R/>7D"&G+4:J>(A'MS-<O%[W/KU%&.J(_?NC+B?B)$(!A-:%
M/O9!/1LMO:[F-;'N!J+J.8,5.=[X,(J0],Q03YVXZ+-,'9F7XC<.U'F .Y5?
M+P5)E&D]G;>78OV\PC$+:7&;7-\ZH=\*!3#)MVC)]2SP99S-&FJ=!6Z2@04E
M!B:6S45?&D5@%  ^YN0YX0&^6T:E.Y\G$>+?]1<(K=#/JQFZZ0A0+J\];GS1
MG!1N$,K;SOCT/LI-8NB5Y!?CK8Q5<0MPO8E>B6^<(;C4K6M0G@>MG& _H.D&
M'-2W2/^\.W]0BVDXR\!;D>F+5K2N+%S8$%RQ%6;L,XX&0OV?MLWA[I#=ZX'1
MHV2I$SO,/7F##W7B78 5D=93F16BMD"QV(IL_J^ZM.S9B1((+.5LSVWY1/"&
M48D3F]3$VR#K\UFT+?D%<3+>V:TC;%13'K01=O*N7$(H]I2-*QI1N9DF8N-N
MZ^ C[;-_;Z%43)Q#?ZDX!03O-^"-]D^U[,#8&A[O>C6BTUPBF(>*U.L9;5,"
M\1Q@T$?OHX5M+[0UQNW\*>F#]GT0#$007"K@>=X%KT-5>GV?S+.]3]QUU&^N
M'T55P>H%'W]6F -JS@KJ/5A;NL]CMQ1Z0GVAH-RY++@W]L94K&E:JS8DV%%B
MN]1Y:$.;;T#XPRK'"RO86"IXIVIET[W55MN+$$<!T#+CT!UP+D+:SYFA#K,[
MAF4$+^N&,9%,+9!9,O<;WUE;:,ALJD#*2P,7B<6?+[459'^-=@]WZ\I60*1M
M2@?.=D)X7 -V/)[POA ZVPQ:R_H;P7RA3AZ-O$TJ/#+QLAQ^(:,H9?!/2S+&
M8B1((L&A:I3AK3QP4>B]0)Q4L???)^^XC0 ]DA(=0_*:IGHN+!4R$$X#P_O3
M(#RF[]*HSO?^F%,.UR\!FDU;OR'X(>NF-PF@@7-#T_!\A91NJI6IP-US3&SV
M\VV]J=/:A-5%9)=;#9/_'RWU*]"E<\L BU73[8\'%2&+1WR_FV#B^U\*<-=.
M"Y8UHA4F@A%/;BKL+R0X'!RB[]=D@R-CLT0:(B;Z)L;3QDQC7I.'"VK8+\]L
M+Q2]/2&G4]UG[8=(6;E!"?A<O\"?MJ5KO!*A6$WOJ4_/8XMO?KNKUJV>XC)I
MDOKL5;-QQW+I3KK 7 FDQ.-S1,YF&7;]XQ[[O8[V.H&<BC^CB6Z>"RVUC<YF
M271$5N:?U*7M%  +(WP<8L*KD$@!?+XH^--:" WY*.R1F-3VLVW@3 4K;3\#
MMZC,#3*1\-EXSTP0%_U77P<[!?WDACB[ 6YV*^7W**4 ;N[+@PXY:?WV9 ZY
M\?Q2/N@HU+[?P:RN&@6P])6?>2W:WIT PD8GVR^(/D2"B^4;TR70.T5?57<G
M8PDA'[H-2<$261=MN,=E6#X[V_2-YANF#ET]"T8S%<]W@@L86[EGB"]Q28A.
M.!W$=L8%@3*!4@!3YTE-3B!OC/^?]@CEO?!02S6A6'F>S\F<85&0C@&>@T3C
M_FV]QII17T?P!B*F=+GEQ9;"@*SJ#!2F+5"4_>:M>R'R^#0TK\EIGP)8SH0]
MH  >:J=1 /^&\!.#Z]MJBHB5&/*]JSKD&%40\68'F=.KDZ.'*'1N1J::XQ\;
M^/+C_I<6S*>592;MVPD.W6QX<,D.R 1A2;##(;ITF((2$KY@:BI:I,E"\>=]
M&N$U[SGBY#1I5Z<JZ=6$O'@" 4Q.IN(<,3B'(SBN!_/2BW9M3B*^TSK?(Z8B
MNE.C+Q?\Y_3 S^8@^$ [L8KZ: 6'(5\/H0"$(;] )R(JY-RJBF,4,_PO*)8"
M^(88X4^&QEQFJY,*"0K/T8:24B,U-OA_['=*N75SD3/@%3.+!.#I@RB,2>9]
MC]M#96"[!#$%"?_J;E.MKG GP[1G"G.TDLILGXO+S/)$%P;]VJPZEG/7;Z2X
MK<=U6JV_BA&$G$4HZ^CI+*\7W* C]K:*K9 +))O@LRTPG?/7"- AKYG9'OR7
M]CY90)H6/L!S1,9O+M+!?=NHB6[XDY2E&_SM+O?&_(Z#ZN5<7)R!_3X<=;%]
M%ZGW)UHW4#KR2\1@ARAD(M)!/; XXY+L:8ZJDQ5^>=;/J'*Q.(E:2M6=*Z$?
M;A4D\!\8M]Z#3V5@_?S.WKB<H/+[V_ZZ95$ F'/XN:4V0KZQ_Y!IZRT%<)0)
M%^MIHR;$##/RKX-&TD;O( S;2U7Z_<Q2B-,#*Y8Y0'5_2T3:26Y;"DF:@%EV
M^8A/. FJP=D6LOCXARZ1Q%<>-?AG?I_<#=Q8:,<J_SKXG77ZQ$!#)(QX.]K-
M2GQH"UMFV!4>JE]JO3SH5=0X6[5^Q"8J6?K1G067(3AX$6M4H%_2FSWA,-OO
M=M8U+JFT#R!4;9O5.R;Q=T:R3G*)*>\E8R<O3.O/A,PR['DWJAJVBH.5+A*]
M'G+KLCY%1J.,1DYS;"'E+3G'.G09ZE.,CS;Z2>O,MKNJQ6,)&Z= 1[=S.5)Z
MJQ:0&$AP_;+UHY^+\..!<01WUR3DW^VO!ER5ZN]U Z3VG^FG\^6,/I5EN4[4
MB#V(^UN_:1$54.A\:)E78Q%6>Q"B$[*<B^7LOI*G?P997OEMR^6R=0+YFSEO
M)DD!1+V#F5( ;]F7W,F\WQL/E%"QC>E &HN*]((+IE[IPJK!FW1KEA6ET[WJ
M+..Q2ALX3Q?\Q\8*U4.+=FD_@^K9B.+C \U6M1Z2F7#%N\0S"'8^<_%Z&"K5
M$(;H7'P#8@B")[;=/.('>*/I7;6_"Z&TBZ2:LV3!F;8CBC\6C!G-.*?^-> X
M:P"_M]OFK//B*:6VXP9FU20&OLNK&YVTG>GY^U'?V4ZE>^2714'UJ9UF97X=
M)@(Q<N\R<VHP+W6P^V"&(US+TETWCMZ)<[=:V!.8WI=:\A"XINYK*MJ$)U![
M%>KCN.-I6'P^UMI2 W'KC-2);(\4)G O,;3%TJ\8\[-.@S&3;.<9&5^2M/.$
MD2VD=J#P^D?AG>4,:>'8FRPO._,S-O_.@6(&\"F_2,[+\V;O&@XAIQ)\MD&_
M/C07T4EZ3=I +5T.+%:K0:%+!3]4.M<)AGC4SWSIS*5?)=+%V2JQKST?)[]#
MOAL[%LFE/F1X(!127AHU$W9NUU"P9.N:X29;C5#$;?Y)G0"69#;Z5J;^&,81
M0F0SJ15_85UEO*Y76V^%ME] ZO9MRDB R.$VCF6"'*X B)^S_;%E]_E:Y=%]
MJ4_@0O4OA3Q1W>$-MQY']VF&)N_(!I>_=*>)E$A=3>M9L_XVX5G(L:FQ^2-"
M8P=9>.$9D6,@V>>54&)J$YKZUZ+EV-B9N1OQ!H0.Z4)$JR-/B4)W^'FAKVS&
MO<;]%)&V(>S*KYP?NW\\BOC'+_SQ/\]NSZ,?R6H[8;9""ZZN3LUIJ;J")ORM
MW?I*V<X\)O=45B/K&LX\[;H;DJ]7EC^[@WJ'DO8RM7 :KLNT1,L?-9S28H@L
M8\OV(WQ;_>TNXEDNR@,^1Q^3TFV_K+X_\S<L2]7M=J)JZNW1JEB]9*!G:VE=
M[8%+I&W]H;Y!AR/M$L*;K'*KU0Y35G<DS?SDS+R. CZK*_+N."QT12J\\Y3M
MTU:D-)ZII))7NYN>\\;>#[C6^I0D<CS+<VZ7"S4PE[]RXSSR]EM9>TEEKB"M
M/$D6IZI%]QJ??;35P8!-V-1<L$!CZ9"F=;JEH81S:X*)--R  J@NZ'!^N&SV
ML^ *P=C>3- ^NCO"SN[?W!QG Z?F^HFJ%SEIAXZ_H:Y"?#!4=QLCULG]E=,B
M9UQIL6C_-0I@3J-B<_'5:3Y'_WJ&.^&)E!E6[U7;1=B?10E^NDL@?@CWXC7=
M-P<EM=X<^]ND7QL]U!UL:Z$QR#_]7KBN^OM=X?>?IL7,M?=.?BN=\+#F6Y2:
MK')D)\LGY4F@/6=G2)*(]RNP**11A5+[F&5T.3+51PC]_:P"5X1=3&IE)%0Q
MLT/YK939<:BT(-^.@;%:1WVUS#_DP>39)D]QIL>,B=15D^:0_1\O?M!]&+5_
M ;%,M4O*GW'0]JC*VHN,R/#\4%E>@7IM*GZ2,;'O%=S@\7GVLXZIIM8EQ!E\
M-]$6QANT;Y<%/4HX_;$!_.MO_V3I"ME)I>Y5_^U5>+SM]D_4T#8T*#:  G#O
MZ59$A1N)M<G4DZ['Q!ZYFD1 :,5LXFNQ.ZB-%F8.0LOE&[D(22M)XOL/<-(Q
M/DM2ZN>BT=OFC@@TX=_9ONNQ2+_K0L$O>DT]XH52X.^ZPJ9#J)=E;>Z!V'60
M]<^+@E.S#+QG3G8N\O7=>NJ;/<2&VQ]NE8>IN"]*H^W ,^?/F_@+V[Z==C45
MQ!?0*M9.^'HTXNG>BL)O;-N]JJGN#Y[<$JINRL0^.3LT>=[[YU?.FA ?9+D>
M+9GLD-WF<;\1FKZE9["C-'+IX4\U^;/[%?H:Q'7]RZ)A2;_;P@=!A6>7-IF6
MG9!# =![=5WHT-K/TQ\- 3;;//.%-,PAV7$.>Q,34*]XFG</^?[)^+?;-'+_
M=?69J_SF,P]VK@]U5<= F9@QE]FB)<*VG'UEGRK4[%3U\8P8&!S18HLR1?C&
MY$8.+%;3Q<*]![D[@21TW*ZF:/&&RDFC-;M=F--Y]A;Z\*%PUYSYF9UYJ.XD
M:XU;WO1%I,Y;M[98U<_1>H[,,2<!*%N[5T8^WIDY"_,G&W^D^99AIN'Z+1Z.
M4U9)Z4(3Y]LE$T=CO>>!E_DHI32L\Q<%YH&/(T-GR=CCPZ%.\> Q*@G4>03\
ME^"&#I;GF5U7]OT2"L!T]ZP.IG:A1P1,7G(K@@M(L+*9N(OQ01WU*FFIV$6-
M&G-489^YU?-[I8*-:NRNXU?@.*^6B&##O![UCL:CKXTN/2L(C6#T &'G0@B9
M:EL:4^8X*]YD-&F[75IX&D.\(XK]$'_:57#MF*&RY)):VXV7>XM?'0Q>HR^?
MF>V&GBUU[B+.ED'\V*L@Q6\-N=IB2M>3^Y>/ZA"%)RY\GH;67:L':>:V&1SH
MV? 0G6>R6G2KH&PGDKFLEMSYLW\/IO[Y%,E7G/LL;_?+Y&W;K<6*^JV'V@RD
MKQ2 6]/^C&C7N6B\5+.KS_+&400C6,<CO\_XS;V+)Y@;LM#S*T+4?!/',*VN
MP&H>3=QHH7AU^MG1F*/P61&6D/!.N.#9MZER:-O3(C[]W,C?AS)$]44;_D/K
M0#P%\/)CMZPROH?';O@_/^,^YTV"[L_6[, .< O%-JW-!97F\ [D\267*CTT
M6R$7JO"V7=?!"IA3 (6!;3A9"B#6SP(^$+DXKY6P)+K#^17&3L@KA#W(Z:G+
M[@Q3=ZFPURLUI.Z31LXLKJ80G'P'0QLP' 8J/ZU_]5S;##>&#)5,]E2DXJP/
M8!&2CEUEXI!'A56M7AOLB8HJ>)6WS8;+O7NTQ=E[[\J]-P-_KS&$C+]8JW;X
M2+=X;72O!V;7N0R15())BU@T>ULGYL([A,D&L]BOFGJ,IFSR-156_I8'SQ=?
MGRE0 $SU$^KP]J'OHHS^I Q5H2@[7KE-4'%_I[JO- -@?%>8?; D_]1@#8YG
M*O6VAOYM $D6]9]8H]Q)8055VMPC\&_-6I\WJI^(1D@85X\M!-&RN4%\W]>\
MUGDK]V1EH4VMR\8^_KC\X$"_>%6)#Q-22T2,X<9=N)*XG.;^) HR','*,>A>
M@LI)$NEMX'X2GY8?KS>?4!TN::WP>0HD>-_SL L>ROZ;]SPVYK>&7D?::2S-
M$:KRMVI[J/YU>R<]NKBW0&O2_KM D'1/MU<N.R.&Z[O]"]WV/T;'6K/S"1>J
MY!X^>5(!++A59*Q5"+C5J#1?V>@7&\C_S8PQ+"GW35!3A4I?EJR3Y"N)8]*L
MC(&B5Z[-VS\O SHF?JD'>=?^5L0T[EZ"BY-..W0@@9/'1O-9'E>6U1O'69-6
M(#>HEGDG :LS(]-UKE\'BX 4>D?RC<"KC_+XC#GW&%7L5&X[/P][HX[SK!?Y
MHX!8^H$8_;&\=[_PO47V>1I2_=+6-2#)W,$U+]KXOLP9=+ 2WK!'?_T>_TZ<
M_J CRP>DM.CLB_$HU36;#C]10),*-.VJH"@+O'!;7"TW25Q+U-1;<F%J<[AF
M5VF;+6V?4W=6AE<3%384"RWS^A"F*A[H$9/HF)ZE-#:YM2CZ]>7B=?A3#"JQ
MS,'.=XL+.,^7W\0?(BZM'GA\@DH#2DBQ!%X@JE<=9^9F2.NW\/R_N/PZS6@(
M!3\;/S&X8GVX3HT^GD1#7H50=[&._W.4S6ED5/K5G29 HI0N <KH>8>==V/<
M1/C+S.Q:@-O+='S]$]OK+ONUI7Y2?G[UQ I^G'&>^=/+%/O&[9A"2E.EB8H\
MK;)[20&\KHU,).J5<BKBF$Q133*A,M5I(R\B_2Z]ZAJZB6.ER'#$R+S&S\<9
M=<I?FL^ $YK4N:'(#R"<8'NZ_;YLO/0.*YF8^!H> =3PUNX5KH]^&?)X^.M<
MSYJD\4O(X8ZI3 $OB#7:LJ/,Y+>PE,W.0EOAN0CSM:*HHJBN "S/W2(1+/*R
MP-KA;)<&.,?E.EYX<.\'KM^YH%TEK29-^EU8]+Z>?)WI;"C=OH_ _,_$*Y_L
M,*NPT-A/A='=YDE0_=^F$IE@:=+%'&$.\^_+XU++5J:F0I6*-R%O(B1;!^N^
M'Y"RB'>,5ZS1%:P+WY<U'.6Q:M)=*X.Q#V_\N?N/4VX ^V1K''[!CF/>LK*$
M%5?BOIASH!W Q[^6FM&"9&4Y2@N!C/!#8=2D-ZW<Q'OC.\U65?,F*PBV*4VK
M*>?G-XO573)>)JW15^ZP"SB^?2\H-$KLK\$?\L B_;L(.W]ROXU__C;EX.>7
M=.(T6Q%4=WJ@/2:\-,!D8\F1/0I-?**\>:VU=6^HI,EQX.+',\0+1H J-:_J
M"2H%J+)^SN^>T0!O"I=QC+25F)L!SOU2JAVX-><XIX\WH^FKUE/T;7(6,J!U
M,$J])E NGZY%4.$TL!$N<DF,X5#<[-,<SMMG+S\<*2B <\"7\N$,Q/"(T"J"
M\L'*3^#@;'/US'0GFHMGK"Z@WWU*V37A=K?DWQ,4J@\ZRQ[U5NQ9F0&[H7=N
MUCX[J04S3,B=?2UKO]E7QU;Y+<@%J7>!Z,_RV(*!X)<%.4(8NS&78@^)9&VJ
M8;*4R&R&!$/'OUGBZO\$4P# \U[\I(W'H'ZEA]\[4;>_)<MDWYQ$R$BZP)%/
M\=&!5L5R ?$.WPRG#ZKU/J&KRH(7Z'RG(]8MV<-2CB7[[:*F6_2:+*2_!T_$
MYLIRV%PESYN%&S]O /4>!^PS"V27(;K44Q!3,4W(B0+YW=KFH3$$'5$;U]-1
MP/AP&7X%K QD*@#[XJ>[&(UKYECN^?I. 3 *G,J97D(%SPF,^M)U,G<D3:5]
MBTLD:JN-R^,W$",OIXPX)#5E"?;E-Z-6$VKG=]T77QW*=(%P)HMWH$V=V>MQ
MQW[QF9;/@6MEH67S3> LQF[CLAD]1"B9);'2;5@@>>+4WNSFRWIQ#ABK)F.#
M=W%:XP9BR#^?#^L/C2?$K5VW1(J92#L"+U!-;OL4P/3^TF[6SZ%HH$K'-J3^
M6&QG3XF!9&7U./*/S#'#=NG[P54*X)JQ!_I?K]K&_&/\=#>8A/PPV:5Z,#-7
M=N0863K[]Z-U *PQF8DX:F;;5 )O[T&SZ/'*)6O)Y4OT^V6 :MMZCQONC,Y&
M9I-C>MMJ57::P!?ZFPL<\;S/F9FV^7@;F[V/.:6 Z[ML=H^CC%5F#Z]-VDBW
M[D5 -E5?Q7IT3$ .K3+"@HIPHG[-9Y%"RU/X&^),2JS7TWESF^NFSM:7V7>H
ML:BW.K<TY?#4CPDY'HKGM.<F6MF;/[IE*ITX4"\<DJ]4GNS@4^$M+@L>W1^<
M^FD=:36I$34)B4*KD89:+,B_T(]VM,_D*WVY.<UXBK\-NFBVL=R9T%&9(SVP
MC*C_J?4-^D=BR3:I*L'M2./B^U[/L.RG*__J4*;_!U!+ P04    "  U@YU:
MTVN'Q\I7 0"E:0$ $    &<X.3<U,#=D<W Q82YJ<&?$NW=4D\O;-AHKBA1!
M.@@J-720+L(6!4R0(!U"B4@3$)#>B4J3OBDA2MT00@@A("4T*4H5$)#>>Y.>
M(&!HR<E^UWF_\UOK^^<[YSOKG'E69E;6S',_UTSFON_KRJR'.D%= -P$ZX!T
M !=HUPO:!:!2  +/M!\]N6/B:/_*P_.UI[.+H\\=D(>]]!TS.6E9.0!U&A )
MN/B_4"Y=HGW^;2]?HI7+ER]?_+>Z?)E67[KP'\/^:^C_W4)MOU   %RX<N&_
M"N#_+!=HC[ARE>[:=?H;%P"7+OQW^9\Z;P(N7J#!NWSIRI7+EVD]8;0^P&66
M*ZQWY1Y=O65H1W?/BTW^74K^-4&MBF_L1H-$H?LOO=]?I^?@Y.+F$181%0.*
M*R@J*:NHJCU^HJVC^Q0$-C8Q-3.WL(3:.S@Z.;]R<?7Q]?,/" P*CHB,BH[Y
M$!N7FI:.R$!^_)19@"I$%V&*L2655=6$FMJZ^H;6MO:.SJ[OW3U#PR.C8^,3
MDU.+2\LKJVOKOS8V2?N_#PZ/_I"/3UAHD"_^NWAT_T*^<#'@W_FP7+YR5^XJ
MZR-#.CNO6_?DWUUCTTK)K_AV7?"^$9']I?<@/8>0PJ(PZ5_4_P7Z?PWS^_]'
MH/\'YO\!F?H5P'+M M.%Z$L7:.A9+EQBN4"= C!<ND#[<HD%H DX/_OGXEMZ
M@!C@?[=A[H/=)N]U<=BJD!!H3$*CN8N;RU++S>FIJ6ERC/G[N:DY1MM]L1?O
MN<K9[T:KC!H:LHF7O 5<;(Z.HI=.Y/CUK?::THQ@R'ZYX+']A\ 8S?R\]?17
MZY^B>!1\&!R P]'*MZYIW6P?2;"[UEF08,]5B&)+!0FE/EW57+0[^XL*R%_O
MU"0;N\'.LJ#GMC%GQQ@JX*WN6;+ N=.2P8G8?9DSZ0[X_D\J("J&=(D2D\=%
M!2SJX^'[[@+F^52 A@L5L,!"!=RA BSKTBAQ#+U4P(T*V%GU_V1<=_07?" 3
M3KX,_ZXYYB%$!11$R%,!K=OF5( 4,]D"?E/S5Q IF<(V-4X%B P>!@O\7LNC
M7!#89S[,BM7\]<^/%N(7=BJ@]S&%0Z"=^80_U)Z&2(E !717A_U?J"/^/P2M
M:>JV9K!%_']E#US:QRT)G*4S\U$!$\M+GN</;<>'[:B =[J4IC8J *2[3W<+
MW@UJ%SB2[X)OFAHGXY,9_F/[3$"/[Y^^_M_?A_\V9R7D&"I ^%*7YI$*.8L*
M,# G'$S %PRI@/(W5,"0X=F[]OE](R^Z\X2*^1.$R?*6?=M_3.-0IF/^%H4O
M\&+( QA?X%ZK+7/=R+W4D&OJ>N4;F9+(SU^W^(:F1/)]6.J>SJ98%.V@1_@\
MN(]_2#-S)OH)1K29=H!C)(JQQ@C=*QH>NL*7CTWJ'7MFRWLE8(CI4SWVA-87
M]N# '_J20A*JG=DXDRAA9?U'?8_Z.D#?($P@& *B7"O?:,M*+B=V==6.\SB_
MU[A#OM_1D(C&-C5\)J['*B2^W)_K<TRZY*=(B)JIU/40R13[$:45C;CJW::V
M)-_82Z<WO?29*T&17:PM%\_S=XQZ.IKK-QCH ]+2EY@M[L9_2A)0[)7SRQ"X
M\7&Q@GW&41&""/;)$^(S0?=R*_=RBA7M.*R4-SPX67S0']).D2+6OO<M&E>W
M6Y+B;)U2\&E[?5+6@IW<4 NVMF;]_)?'7E'27<F$0G&/WA<+7E!#E#D+-%>
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MKAVJ*#+J00>E%*>+XZZ_:-"7,1^_.[KF_%<Y-P<ZFPWX=V_>/^7MZ@\1_1;
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M4EPK48HZFD>'MD_G'4.:F-?5140W+6:NRFTP\$LP0HMH7HZVS=Z<ZIX]%1M
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M=(LA_AQR-*D0*MO>&"K'OFY^GAM?6LNH3%]O4=R[MBC9LF,2YRO"-LMK<GD
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M0#RD.'9M$+</:>&:%.DRIH1CFZPTQ-PEU^K<M<1,&";CYO;PNIZW#WRQ.Q[
M&6=T^!C\5O;6E58@.WEY6T,PQM]LUV1@^KZB9@9@:S@!X<;AI?#*7O/2W023
M49GL*MCZ G@DTN>3TR.,$J[CRI/NC)7J^;Z'N+;#3;GRN!!%C2RT=_A?CV=5
M9GD^QB"Y/1EP1@A=$QSO=0Y*[!D@]=$D1-<8B>,?*?<Z*1B0R;!O4YJH2,5J
MJ&$*74=>W%")S$5!F715>WI:B[8U"P10T/E7[*QS 1>T"20WT^R(EJXBT_S?
MV7S#VN)LKU.M<SB+)A J1<["8$.#\GEA[5$-T6JP[AJB-BR8?^SY*0<M:/J.
MY,Q^Y.TTAYMAZG"),'MCJ8(>>/ #$T>(R!VQ>\H#DS>]8G[-!96!!\*M44XF
MOF)/\<KMR1(XHX;/B7/SHH*"(\_J28C#%WV/CN:&1(0[KCYI>#9@A*[P=[6@
M[Y3G,%4-1'Y'YZX8XR9'4$'.':!RYH8>HV9Y<V##CR%WZH\(M6YOY[MJ3H]^
MGA(V(@*FT<RS(/_F6Z?M<EG;O>@BNE G?!T[Y+!]!OA UY]O-8&'*3&= =SI
M1-6+^]"JG=!+^3_'8BUH>:<O4RX]N[D<+/.)FV#P*;X;$7R8<X<Y"&U^W:H]
MKD:'!5BO]_VDT&>QY S@BW.3Y4Y.S>4O$%>>));WRSK6./\>VKG2%PD(;Q[I
MS!JS^S]&(IR^-/L6B%'Y4%\T43DVQ7W=6RW)3FQM>NZQCD"US^@B_T*QK*L1
M^!%.2* T#F7KXY*F?BO\Y('@0M))3W+\_6<Q_,]GX]7Y7;)9V379#=@ !?\9
M]K&+5XRY5QQX>N=^1\08Z#@0;7V S^W^X0H\XOM4H*2-6SJRR>&W=U6E9T$#
MEAHG-*LBNQ+M8O)[_38[!9DVN\C'ZW9@*0186UO+86A].X3#O<B],%O'31DF
M+D[A3)@D<TY'22U]>5:0K_J6#6R85)<[=UPQ=OPGA[/)IUE$V$];X.!^,"+B
M__59^@NSD&67W[(?IMXU0)]2W)84SZZ)?O V%->?JK 9 ZTB4@ZM MPT&]S<
MWQ5Q+QU8JU'*HS[E0%^L8Y:YG5"]C];M[*!.O0HS/77/S;P4U"**35P[?;IR
M<U.U'HZ,CS)F*-2VL\9:&QO"@S4Q3F8O+X7@=2S_\)&WR9,;Y">?Q#>R$V"\
MU_O8"KI:5IB9-%']'<Y#P0',Q-& QVMUJM^@B,,CC^B<Y9UWB4K=+TJ)R==8
M$Z496$LBM&P6AXG^!>=#%<[S]>H2JDO91;RA!=ZQ"3T:#QN9F6-^_?AVS;*1
M&19 =ZIN^"UC.19U/#BQ;"K_6 Y4+_;[,;!UJ!T#=OV-_E:K06R8ZY?^X$C5
M (]9"QZF%A*/F>4D'^B5E/V(OGLH9_J;W/;Y$4OJ7R)SUY4,DQ>5?7L-*\9[
M&G\]8'@Z'9/X76=;PCB9[0)-^PQP2790-ZLCD=DVWU/2F.;XO5K ZWL(B!56
M,/S,=*E5/>572.*C@+;P\IE3G7E8#:06&^-C _;#\3?0M$_Z.D+5\V;39US=
MH#.O4U(2:TV+/^VY'H15IZ!6CUC/<?!D2&WJ6!(F,O;K.EFB:)99/&H@3W52
MB+1G'(=F;M4JN/>W<]1%1<,K;=0PD'.KPK$+9LTAM8CQ_+?F.AO3#G@Y(&2O
MC:O6\F"3;P/G9,><6#>FJUT.CYD0:Q@DI*GEGY#_VP1*[T&$_K-5<_)J*^Q3
M>CO?U4&4).L?BY8:^ V8YD1NQH:!/4\>B>BSHW=97ALJT.R((D_*'>M=[X.7
M>=N^;.U+O12'* L6D27&.89_1H%O>3XC"<#:I1N;O8N?[)W([Z?<!J[#%(ZI
M.A9$D[&Q=:-:Q"1UP3JQ->.BS;"*>-&RS8.M_6S?W-7@.Z<56(RK7.+\N/F4
M>5>991_/JP@3DJ.9](^N'R*MP&$J9[!"#;M7U4>19#>-9N^PK,SEHD%3;ZC,
MX/.3:!:;XIOU8AI7:_SSM?5N6N95G $$YSQA!QWAHC3\K*I]>X-$O;MMZ^3]
MVB@=G-V[^T_GGS+'Q\<C<YDJ>-Q"GHL797]ZHGS/*L7'O.3G*Z]1F^LI+-?0
M0G:#9>CB/0\C]-P:05A>T.$[P26_C;^R?=;;/%,Z3_26I-O'X@&B*4J LYG5
MDA]AH$-UK]Q/;)J*I,*8M.F_211-JFF1)W#LS]L.<+G3S>+$B^\CFE($J_T/
M;5R0QD0O?D3H]9#TNN;*DN_K[[^=#IT!0/S$_?B B2=^"<6]NI+('NKRSBNO
MP7HAV74L!\:\;>J+#!G)[6.S3L09A.ATB:1*EHV\A5WX!R@>3I(;V\UBL)YO
M[)>]8S/*)MFE-N5N+YKR2NW@1.?!3\'C/YNV=LVWYHL2L">_L9(G?QG9'@?M
M5O,T\'#=IC,F6T$\8,-&<#5P8*.C1P[<<2S^"!(G#GBPAHJ*]VJMNGBJ-O;R
MTU_MEHK 44+UVXVWF1#)V)ENR$700J39&6#Z.LL9P//:MGS+#'_C_ 2XR\:*
MFCNS"G<V<J_V+Q^B8PD):BY"%_=O-[R@C_U_[-^N0]HG9;?Z6@A,KO3'U*@\
M%"A:1M2OFD289$K/NJ_X,&92(('<*^Q<E;:($AH0L@]T\F+7EL5PFTBQ;]$L
MI'P)GW#<QM\JD^=#Q/VT^>>%Y7(XVPV3#'23#+US-.N#$U,2;B,M]@1.B/G-
M)H*BXM8Y'"ZY\X(N;8HR65>WTF</F@D)5ZQMHS(?I-NJ<7-[#_]=\[ VYS39
MM=']MC*\@CAF2PS*&CV KP2N;S>XUZ8&XM(<%/,,P)%OPKE>8CYE/#<*'TC>
M% &C\XKT?+SG3>P*$7I'-KV3FI99\XKEKD3I$QV"X0>VA7JD14!LJD@@CD&P
MH#SIS;X%M<^A=VC/7?F? 7]57TA-0@>X?TUB3Q6\_>;0M$+NAK:OO_?#WWI_
MIC_]>7OUT.N"3/I\17S%+&=NNH>AJU2<8:U/,BK.$.*>&XO5,Q'D]H(DH\#K
M CL>7<(>8U"! /)SJF1D(W&SR3:.?K=FJ[&%<%N_V"W POAHH@W=<(?Z$('+
M&[,V'^U1J!J623>S*FH[+3ATN^>[X"#,V!I2M<'3*_WK0?OLHY@H;EGA =]]
MHO-QUQ><D%8*NX"XB7 MN3O5-!URN,9R<ZXZ0813Y;;4<*N>=++=FEO+1(2>
M/LIOEMVM2#*PG^_4AFOS_[9'^Y_'E0[;"L\. B^]K^'25N6G$V;[F;&Q(MLV
M>_5&6]91FRF+MC='>MEPGB?L47C[^U9<;]Z.6X]X3$/X63>V>BVC>W82UTZ,
M"]032:N46[FS7#L#19%YR'FN8AN+'7>?R14YUQX0RZ<R,3U=A(YT4S-ZM8,K
MZMN0B> E<!&OU;RHIE>J= 8W6!+5"8;$UG@?VNZ[GE:'/PZUHPU--T:'\P^H
M <DNP;NH3I)S/U$U8,PP0?QQRU$Q'CB*K:'*_GJ94E42R:1RD[GX)^#Y@_7'
M-DQ=7ER:T$2,)=O*M(LF1J$7(Z$E_%K(P*K3(!8J4C2JK8S!;55#>)UHXX,2
M/X>R/\2K6,,&DB*5"D(KDC'=P=N0^=A)"7*M2WC%R'S'2M/_GJ-9T F[O,YV
MJ,'6>W/RM*T+G^C  3K(^5C0H'^CF< U":KXI"@8976A%ZZ[M8VM1@V,(6?F
M4FE(A_7E+L(V2)3*C<0[FKB+VUFP'(:-&B$J4A="!QH(&G=N5QZQT*^F%H25
M34M^)"[X].6<O!BF/"-?274+FCD#,$UJ10&<_7^E8M%?$E] 8CO\3C,#.2K+
M6PRS)I2(YQ3<=UNU%X#O01AC>^!VG_(1Y=5&D8H"(:(K8[6UD(I.@2-16\ZP
MIO1"UQJ;][DK%L.5(>YY2T>Z\<,Y!;:3_Y98F$/WO>H. N6E05>O>6FNM>X;
MF3" <W/T6'W0Y+C7R+&D  /M\RCFKW0PQNG%*Y+P HS&E'EAG6??D6/AVL!N
M^;:)D*;)A[3T6=L;H:#?Z2WAUX?\C\=ZKFC9)Y:1G[?X=0-XWMA7HW7\*K23
MRRV_N',),Z+H[SJW:'4/S=^WS!8<OS$1@>I9U[1?AX3VHMVO@"J[>TAT_Y[5
M&2G%%.F&RZD_6HQQ@@R'_@A;1^U),,AI7]'VFML!'\?(;M8-"TNR]3A4_LM$
MFV<(1[J[U L<Q"I*D]R:6X)$"#+QORF.:2&P1T=),ELR*8(?%7'<IJP++)T!
M9'9=E_/2M;(N?Y\8FA7JDM:N:C!O:S9%#$LB:V7+RLK*$_LW+\%6_Z$N)*,R
M8]5&[<U&# 86'>7))MT1H;%O__KT^G7"ZVJ-J]*XNP\*OV@<.MFE4*3)O4B7
MR>OTWN\V\\^+\66VKI)F#<MY='VI;FP$*ID''YE^.J'CFEEDE)_R)1\1[,Z/
MSO8/"3#Y&93]#U U?*!BTODM\9#TW&:P32GD!R#(S5,BK5!]8U%Q7-#-Q.HB
MO:14B^LH_%:6A+WI'8%H9+WQ<CG-ZF!;&-Y@:&$AL](P_&$"9#E)?%-1*3LQ
MH-\'=US-0%7&OMD"P;'05,6)**!C=4WLA<?_@M[,3<\"O&NS]&.SC^/8S@ I
MN;-G@'<:H-,?J[T<)X*34]?O(XZ71\X DC^/^1K8#E]^8QF)!^_)3"B= 0S\
MH#>;NU;V9M79)\1?!8VR95Y\%/=6GTN6NE<@PE9@XKJ2[/@P93_&HWL#5/5H
M-R-XUT4COV8P4F:RLQ<L7.L'4?N;YG[.UEAI[E2.CO#;6V)JUZ@VD=Z4(ILI
M#>*0K'(&UYK[IF>@ED,JD[O?P&NWG&M,Y7K<_GU<A#K"S[04('-,ZZGKA^&;
MD18;K/OH@7A.<.% W<V:#PY[8>*D$WKB1RX3"YHKT*1UX*C-5<9X 2?T9!C/
M:)",=M7.;^M15'8IGD"\::3BZ8Q,6V4SIK7Y,*,6E&8.]4&KQ8M2\HKM:. ^
M63_ZC><W98'!*1L44V5537R3.3,F_M?SKG\==EB_A)ZD?M@1HYRCQFQ$DTD9
MUK#  V,&.@P"(\J\W,RZ<G$ASTC9/7I@3U*? D'LWU7]*VJA-FHH5S^7L92X
M 5TC@JFND.[D0+S"<,9##'=)Y/-MD/!6] D[1U--Y(E<@QS-NIAFTVZ.>$C:
ME;Q!AN5;YOPP\O:V]\Y=VOYH?T7BKMLG.9Q07.N] S=:R,<X^&B9DK]3:HMI
M,DX44RGC;#&R#!NUA;CK9V93Y+@-*P3%\)KRX-V"=KQ!PSJ8+9Q]=+6HJ&0?
MG@B"]KV'L]#ON)P!;I6#V%H*8(&M/])4A*]'1)P!3*AB'S&8BD$Q:XI4]\6+
M=UJLZXD!I>$;,Y3/'T# :XFRN+0^P82;.D#P (Y+)AN<7BGNBI2-P? /?LCI
M7>FPD,*=#S$69.R#R5!Q>) JE\.=XF&(+]B_D9>J7(QVP.AU#LXG%U2I2R-H
MIF< .F,VIB/_,-BYR>VX2,#J@C]\%A\&,H!U AKWPQHC/>_%#_D$A)6T\#(O
MQV65Y,S,.^OM[3PWPI\0E[IR.3S#383EPQHNN>_]H771']AEFXA)0$R+V-VZ
MBEP&LBP)S@RF"2B9T[P:O'A?::/S&8#<-Q.]SN!![+M>D7T.L+?_6*;7-EZE
MO7//:4SI,3?467^X,!QT=^A-3H#)Y^P$EP/A%(;^_JS%LN+;OWPLW&[)7]-C
M+N<P19X! @6WV@NY]7B'#QPWGRSSA7OZ'?$FQ6R/KQ"&<+@9;Z@\MTD0'/:=
M( CV=M=!NE(.G1V%A:HT.L.>V,J$*6Y?:>\;LY_>;+KC<= <3#CAM^&G1J'O
M<I OO\.PW6;V_<MJ[+36>&B^C,BPO_WL#+!4:EUU4UBX)V04=-TI:$*RT.Z>
M7N8ME)=)08_F=;_<&85V*:."<0>TQW*^-0C^M*47%BWVKS.WP@J23^1EI-EO
MC&YO#M;P)&DA*9(3ZW1H;:(L^=X$_F43/EWPO/)%C6?3[91.RZL"FZVLETCY
M4MU/K[QWT@E8D?OD=.=Z"&1H8&L[%#_F5/!XE=-N_'N]@,AO3^R?^(H1W]E5
M6"+X,:)E7CI#=JLK[YZZOD;= _#W^(Q]G"A>54ZU<@9RPN8V<R6A7/D.2SNW
M'F&KVZ 1]BWBV+BF?%A%HE+ZT;.(6:N*&+*;K,1/IM@B-29_+JAC'.-T^]9M
MY^@/V(@B?6!WB)&!'UY;<NZ]SP<,]F>!KS;YD5'2\\V?M'?(D>1[\=E&D@NE
MONXF.5<JZQ7R>S1 %<OYF"!]Y,.1)=Y4N=^6JG.5-S2<KS'["I 0WRVUWGQ)
MLYE9=&+X7/A/M4^3>EQ2#,V\T;%G7;7/.=S#7=&]?K.\"'= / .$K)VF;JIB
M)04%ZWMZ/&PL;=-1JRDC]4.)[<"QQOVR+4AK(LM8J #-L4"W:'GX:(X[-:9.
MPYTK\2GI,@IQ&@T>*+[3LO(2LU/4FLITXQUJ^.(U1(0Y7&.:SM5A\$MH43'R
M2A0V&F-BET^J*5IWS6\:SE"V0<1SF*+ME8T]"M'9ESBKPX/:K0Q2Z\K8$8Y_
M/E*H"M7]"?<QHGH?'NUBUB>$A@SG,\Q'HOBL2/48A6;VNXM]@IPTR%K0\4N:
M\[X['%CYL4ZVF/8!5ATJ4Y'UIPQ*#4LZOK8:Y4D,JW'968"[MI4Y><^K>7_)
M*J*@TUDSI[?7Y+B+E&XVF;:2DG ]3O@6%H;\[7:+CC\5F^Y#-5GLS=63//?:
M7U,54":N[?6<AG%0H0F%GL[*/B&\^:C%XDK'VLZQ/4QK_Q/5J6A&DH6FTQH.
MK.G?O1KZ1'RX3"U-H*Z"ZGJ;.RA"MK3J2VN[#FV,_U*K>Z^W+=J95R"NTV?Q
MZTB; 0XLNVQW:-?7TV.:$1QCL_NZ^G6^MJIG0%W?@$^"]$]G+J1*&4MDJR%>
MB1V/(QF3V%S <?SU9$1HSW \L3RI]EQ**]''0>5][UC>G1ALV<_0B>2#&']L
MHA95 I>[GO2L7V9)HK\\3+Q<ZJYE#]C_+5G%]+O+K+:SN8,V1[>R%X'97NK/
M>*ULJ\&^HLWM7.]'_C(I#PUB4_B,L]V.A8;\5@O*YN,.[ZW5YSK,<U,R'_Z<
MA_%VB^68F_90941FPM <*EX%^'V%K$+PRB/\VIU@@UQTP0!>J*OP[O?J1K5&
MA[Y$)> :E<IC2LUKS%XA[V5FSS _;?DRNK1MWN9[IVT2_WWEJM=ZB!ATKC#8
M*O\?Y;+[TZ]XP]-:%?VMI@0S+=6],(9F:-7PH"FD9KS*,]XPTL18(6I@.'8;
M)#0SWI6@GV[P2^I&!M@89_(^7I9#E&2@0TDV09:/S(67G;"?UIZP4,LH$I^V
M9C6WM&)VW9]:QAJG,#\UJA[@ZV+%0%.#<[\;$ZN#M&%%=SA<L]+:83WA;HG3
MZ #;U%E?QJJ:FYAWV*M=-\X+KQ%!,\+@O/ B'28F._=*CCR8$DK' ^S>=N/L
MI*3PB07+ZD;&R?=G-8N<YKL-]<:)N<BDH>)4MPV=V-@0T:"-XL6HX>%A8<&J
MZBKDW<K*"#9I'9G!YUU?GGW!/U:^P2;,_U:4,O92M[(KAW3\L=T0\>'^O+ R
M/W(L[*9.0'C0B?X9(.+SR;TM&TQ@#DWRV7"#@(VY<MO#'#M_]VR8D_:L6#Q[
M,<&?N:>''&V[M[7<=_$O;F&'RPTM8M-U8W?TV%>W'4G.3D@/3\^NM</Z.$AM
M#LVU-^/9$(9A(S3!K3U-SM(4YNJ;8F>306H@=(M((8ZOU^7F"$X:F[B(AZWB
M^>R^G0&:C(A<FW^'"](4\<NF7 NK3ZCQF?4!!9;??I!DF/GD1+XNKL=6)<0H
MA<BJJ. Y"?:H9J-UPP^XCA&4K*OL<M=:35D3AB++(;B^C1N,&!TD<"-VB3A#
M6S5/47_0TX9;H4ZT0&I92T<KG,5_J=S-[,Y=4N'#^+6]>.[E%O;R(6)GB3C^
M!T3X[M2U)JYLA 8/?O;QB_1'G07M*7*)]S-.,YXWN)K<+#]\6-.^BF+6]*Y9
MB*EI),\K3EJC!Y OF#V@AI5$C$"G:<:FAXORTMJA(X>0',K00UQ\\^.D7!G-
M<UJ?G;;SLJR:)!8J^-UF-=54SOVF]<03.]:4Y^[D +-ATY?JFW>=<>P+_7FK
MKQ]]=2%+MU$>T6"51,>/18Q22>538E:#R*0 O:Y%K*EW3G0;12#\Q4.>6Y\0
MEE5V^<:M8*E:'91!WBP/L7B(K-5M^Q?( WCA)("Z!F+9S6*D);749 PC\U<"
M BUZVI$"Y=W03[R#YNT5@9*"9.8RW4>'WA7#+S*1>VE9EV=+ZQIO?1UJ[<?K
M7%T;GV6!_LI1;,]2G>?$</9ZZ=L2$S]WP\;$?Y5=>VBMPV(3;V6%Y003R@P6
ML&",,S#@7,#+S#MZ1,M3*^F,+%L=,S;583.V3"XCC3?KGF*Z]LE)RS7(AB\S
MM3S_CCE4:%F'6([4U7PJY;^=8O2L,._QHR_61KQ)'\IX)^-5C-%>"B(I?BO&
MNB0\L[MA!GO7A+QG@(F@?H:L@O"3=GV\*N57Y0.\"F]RR=<CB%$.N$O&J7!(
M:<\Q5[ (P^A=I*0G'6G6[/;Y0'\T:?;7&8 (:EGMNZ,[PSK=#Z7H;+)H88NK
MR-L33$QWI-<WAY>)8<J=IDDO8759(M:-SGU?==Q?*"3=2V1Y_<CO]N-5N$5+
MF%VE_F@(:&KD^[<1(J[GY)R?!%(J)5+]6WB?T1(2E @D>OX/L\CHRO+]NFT_
M*,0]?"-+4LRUR7*R=D0WD8_6<0P_X:-!BJ9@ML^)0_1[L&@=E*6UA@I( %,<
MB9W\.2904C7B,?%A1.@0<LQ>1'GP(*>FA@W?23.2Z<E_RL[0<O5]?C*.5#R7
M85:/!:/MA1542=@U$F56Q,/+5<-9Q2AYSC_S9MWBQW;U%0ROBKV\IL[:<#*6
M03U,0$\ZX[G,T/,G2_2 \O-$Q_WC@?0,O])]*?81LP"A]5E5321 .>U5:M,C
M+>7;[6S=#!=!4IN[A);VG(V%SIXWF=S]NS7%Y,H0Y7VM;DG6F=ZD+EZHK?\G
M/=.EP[ (2.7HPAF@,K&HX3*=G'4U7,EM>/)&?U&HP<PFQT2;OVQ%;-&R6JB\
MM]F8[,1X!;DB7G:^\&7'7XH3P<,:,>XF8O\"?_8H@&2ZMO:\$1G<- M&:9R"
M?LI+0S2T?2O_V\2B C^NNC%(-:GRMZ.5,]()%F.FT%[!PVZCQY9MR-N5\](W
MM#1O 9G-);?P#1$;6)Z^3: )QW]-GY9X[Q_9D]CJSOY.1$<H2X-Z3= -?N4E
MR[2H!&.J(-N,Z>3@I?AHNFXD;H?.-PE9"O0.4R#-B*TLP\NZ+]G(6\K&8M57
MB=7>-R%TB #IY.A\VD)&>1K)OLVETU^P+C82]?R/K+\MR0?\\SF<-@'+<5E$
M[UYN-*3@CM6X>E,F!U+^.R+$] -Q"+T=+MN\FZ$G/+,J+DP1[;4@=RD&R$T=
M/D[(*(8_9:<IGC+\[\Y1N/%_("C3*-\,8M@KBH]E8:6EZTPR,#:2CYS2 FXD
MU*8?LSRXD^-I8/L-%F:4"DS$G) >2)[\]=WV..BP[R.1$-'M9D[?*']N<R0)
MU04/3U2N[8:)'6>#IE."L])G0+$U<ON@5U26R'*0V&DK?7C0W\UZY?%!^C''
ME80OA&G8>_W4.ZE#=->;T?0+!HVG=2J*N% ^1\W- W]<[Y2C;U/[\D%XGZT
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MJ*H%*25<W\(+*AO%SR4EBNA)+E;-1O\P>_-0^>.,:6V'_8[9,=@'";(#%K<
M8_"=[+K&5N5";48+>-$GG3J9NMHP^;60+=%F$)&CM<>^*5.:%*J%60Z&O_<'
MLCX!14GL=HONUQ.'=L75A#"I)@.RG/&X:"-T:2'C,4*:%]!U!K!K#8H/S1+
M?9VQOSJ2(,KR1+,@*5K  I;62;[YH3HIAP_2XX NSABTO=62YGYM2CXGE>)L
MF,&=C->MT9/*6,ZO&NU]'%\^,A&N"RS.8H#;)7YHO%07DG/R;*OR8\/]J54+
M?HMDTXH:>M$,ODA\Q'BPF-C9T\H=^.&-LY-E2#67G%5'M(D8UQ.CPQ3E^,<O
MPB]RI9JVS-AK\3"H^WP0%<8PDO#%6B+;,:&[KS-F!;KF$+IYC2^;O.2,WG9,
M^S(JQ%GA7XF BQ1Z,1Q7!#6+;N?E1,>AYO$/DQTY?GW?=!C<.@/0A/7;5?6;
MZ;>V1IK#+F^["==Y5083/LU7?NX0I7GJ(<77B16.]R+K][\-R'Q[I00MXG$4
M\!>\..^W<XU2(5%GO.2PA5'0P+>;U?2&]^J^F>3.4-05+ <3"T3!:(NI^!UP
MFNE3;H6 F4^]*R8MPH22R&Q&GS8,_V#<:D@P6P ">?5UMJBOZ(GY\2WZ+Y3@
M^@5*(JNKC0SJ4.76=#YQ-LP.^VLX4&D!7U#>7SH8O\V\GV+0Y.@MWJ)N:E_#
M%C^[PT180AMEZ-_OSA_*YNSFB,<9(OG<[2^!'R$M2A/0O6K#R="VXV)#'R2)
M5_ PFG&.N#/>6\0XX-T\#54O#[?F/\W%,,H,EG\O4/*WPM3$"[(E(=#AF[3E
M__8UT60E6QI97>%,,CIG  98XY,!3_\P62/;D?(BD'F8$EDG3:;[. QNT. 2
MW^JMI"6.;[9'?OFJ=%GS9)&I0[']UBUP@U*=MQEGETB]/#B95UA10(DX#[Z1
MJBHTZ?K8)VZ62[W?)V[F*-+FKW^I1,</33.9+#PF"C.K(:X#X'H4AKL$IU2R
M_SA_EKOXAE&<K8K$;+?DKZQ1'DH%;BMK-C6"L.XQ'_N,^I!@-R/)9AX4Z>ZQ
M&^^SP<,JVQI$MFG?<)&T]Y'.&TV^4:K@.;036I/BAISUDKV/G@?[NRB[7=/E
M!/L%A2@A;)IMQ_%J%6[47UAI?+*3F4J8L$][_//VTOKDK4%$/*Q;*\2H_KDX
M1SE6MZ(P?(-.:MSVR.)J7,OZ[_[-YYF-?_^$_SLH< 8HR;0\ ^#^^![Q\)P!
M[O_:I+>95]+QWEH[^C.$6[#W34=UW =1LI;U'.85$?3A,8.25ZDOGQ9 #RQ,
MMIOG+;NA;R0E7D]^DSZL_8PO*#T#/*4\(GI7!?_AU1"P98Z-@Y)R-V9-1;Q0
M'Q##VKTW/)3!P]"\0;I7\VO\M)19J,=M[(\V.T%NHJN%^" ZG$M 0&@B*"_Q
MM^V'J2W=OH\V*EL]B9_J/&=Y)*.FR/O4*3,7A,LM6*JUCG:_8V4JI(+^9V!F
M4!#)"1JE]ZN4X"\HM0G!DN8>>\C^G*]*F]XB\JGY 06TU;]C-?3.I99@IQ'9
MI]Q9J.-+^0;8@)CUQ^'D5D*/%Y'ZIU"?)$SA4)55\C@GI1;MN=E]^E]T9?DQ
M$B'*75+!P&\H8+.USO[KT^3PAS!("_TAG'750BNJX2X,T==ZPZ7G^PO/XMV@
MW'>S@R/&C5*ZKBG42Y^MY5Z _UB]"@_)<KY!>=$MFA$J/^2UD7?EDF%6^?ZG
MW[A$F[&I.:RC$ 3EEJIK/7H$87(PG$%+**7PE7:\=E;15$KR"T.EW,]D9&T9
M\#)YN!C\U=5-6U! PL2];['C'UV^Q59N,9N'-77$K9.C=C3J=#WF:CF3.Y_E
M'XA)#5%+Z^:DEM-@G>N_QQG&[&^FZ9MLB/D8G13Q)ZH/?GT_9$/1['JZ<H=+
MXLD0;6#?#AHKK.>3C'TX+VR+<J\,4NX\'@AN#%HY"-.?N'-Q'WB:&'X/9CIE
MO*7LJI27$02PA+/!/#L"R7&4?[XZ?9%PK"F-V+,\=:P;%K+W,OANR)C8X1VJ
MWP:[]@+W>N['T/W--6QTWK?AE;Y4U$O7X601Y?8>?<NLLFD%VP_>?UR&FHV.
M)A1%0YY3W'RQ90LQJ+B'J, X'%X9>T<L$%@6O>8VTS@ZUCXI1O6/_N119^P?
M)C*FN76PGYE^*2_[VY_ZSIJAG*KJBK3LQLP%G3"9JY2(0=<G][]2[PGRSL9Z
MF[=#="3QT9%7"^C#Q&6P%=)$@1QG?]7&F.2HA$!;@V-T#1%E\?&E"=>;'$;Q
MOUQ>BT"PW#<QFAF.'"*^Z%1B_N(E!MTJ#75@36Q$ADF0,&?CEH&./C&\QX+X
MQW.7Y39,;S7*A*GA<*WTYW:+_"N[H,XKWV07O7+F*.@DK$R)U[G^%GM&/P-,
M$)#'.4.4# 7]CR<_:/JG%HZ+BWTGMUZ3](^?3N@0@26AJE2!GP+R;)+Y+G)I
MIF> %/=8A'SPS<8V6QPU?6X&?:ZY&VYGN2\J9<D>%]6.[H+XIZMPWA*VY\IT
M]B-BD)Z]TJ(W=8>PZ('=C SG"U_[/^VL@#- TPMB8T7HQ=^2PX\<^ND/78R(
MZ1^%W0._P;ZW:S"AY58_K1W?E/-^AS[-^LMX/V@V87*$V13H]]\M?N,G?=&S
M1U:' DKH2C\IF8E-#^-90V;ROGM%2F]GY>_#*?I59]S74 @U4'-\VA86TDS.
M_/DG+D/0<,C]J;1SJD'1#2SO9>\3J^/P>X.GDR:F4W^7W#@#_$3>;MR-]DR;
MH?D:#I6!;?9_9,L0-HK-C6-K&EL/D1D5^B:8,X"9VD/:\7.:Y33+[=!_1O3\
MIAB71I30GZ^8S=55O_P!)3M<GQ(9GW)];&'>:IDHO?RX+=S_??-0.^4'34GT
M +FBR;I6G8'.2C:9E^3O&_#^TV4>SL(:5[BNSWQ5MWB?]KIN7E0CB A_E*E,
MK8QMD(0=0*CPCP[I9E3]6'^SKC&RAMA7A-&=S-0<J.G;SOODL9\5PP'#*]85
M&MSSXRF>4UX**A+Z;[%1N4,J:C>O&Z(S*NH*3-)'Y38%!T0U7')3=R;EN6)Z
M2O:D9,-.-!]"-:66 [L9O:V_%W'F'#&??H$['WN^A3.]\3M5'[XPVW>KJ*%R
M-I;$VBD62&"54P,FS%R8<LX= _\&%%/+?U4.M@>,OP7=IERC!/7:&=:XVT%M
M.&&JBE L57; 'U@O@7]NG?]@?X.[TPXQ3UI6P,027)'SF,/U7(F&'MD-3$'C
M8\A"[>'@_N<!XH0;Q39>IL>B:^KEX,:@>L)"[[)\VWUXLVP.Z\%SESG3"XCG
MHW>X3/J1R:S]R&%\5$XT7CT'8YB>%)=3<S"_#5T;K''31($NSJYI6 GR.@WE
M=Z=X'^4M*Y3O\4I[)UN3O@_'@WH>AGN>&-*86**)W7TW86J6JWC1QXM32TFX
MVJJR,OZ@2E-YUKL(-\NPL4S%+Y,*K/-!X\\6&I]UTA+,"GXTV]LS&*=\Q@,#
MI!%DZ=@!Z51-E)YI3$R-@A?G$>P0C,A9DY+2,_A@B53Z$G. E'VXHFD R1++
MT&G2K6YK$CYILK4( #ZE]\CM:,\6:?I!;HS!7+? %-7^J-27 \-"%NI2/!6C
M=_ZY]_4?6E<4(8V"TU1T5ZBHQMCPXHN_9)!M=+3(JS6*CWFT)-HJ-_)PZN*$
MBI5FL/"8MH*ZCX[F[-7=%T>QE)[L>IKG+,/?3M8USU(=+[K_',R+?KESM>G?
MC^1/W@FAA0[^0"!"?W2ABJ-R4Q&^I5 %7Q]644%N+[ 1&S>HC%,'DI#MJ;G0
MP"W&U;6I6[L*L?<%UHO+7-=F\R;N[V\+V"@$9@X(=>CO92(/5+2OO\DY3YK%
M<9PV?/K?MM.N%T?77B_\G(46\>*LX>-*R:N@>B-H4/GO4P;"K\081L"I,U7_
M));OP1G@QVW"&2#O.(:&#CQ.D:37D<X  URG?:GP?ULNGC-D-OCNG/Y<N=:O
MG'&6X4;<#ZIAZ\M82%S!$]FYN210\N2GPP='?[9VI2Q=N._4"3V(8@:^B!(:
MB7S^O?3= PV^F + $60GW$Y8'YB SI+!?"QZ>%QIJ-N8#LK9AK5S:9HP%)MU
M7(G2#@#'W;3E#Y<ZQR$# /"6&@\O #YSN8YKR4MVM>[:L0/=_^"_8\ZW0-N9
M+&< W>$SP(/9T!?_.;$Q'T)Z0+MQA><:DB80F>N6$^K0<!@Z*@NZ3 9^OLPZ
M1H9%.9XN^!B7MX367WX\6<_"FCM\Y1ZV=/_P0^-VY@5QE4:CEJUA^9['R[8T
M,ZMJC8!]9-D5T8#&TLCC4=L9K26MCGE3VAUJD/E3R1-1.%=HX05>%XXYKS &
M0K<P-*:["%-R&-:X5?'N6(Y+T-# E8H4Z<26Z<4_&[0VTNOQMP#VV#9['HK
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MC7<H.1V7!K%^D1:K)82A8XT#JM@#<>98 0XS-[F3'TP_8>L<IK1?WU1Y8:Q
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MQFNC//HT%@-+1U$V6UBXGW[_%-G/L/Z^?.$T4(:&7EG>*^@QPT!3SB%OQG2
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M9F1&']J>L'%6'Q@<<R.N_HRZ>7S*2#'>3),ZA/-J4&/JY/'$"1O[VISK=NO
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M(9QBS9_"";S33@8N"^A]CGD<37C'O HC]'(YWON$33*9_X1MQ2"?Z[)(7LU
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MRBLC73J*2^I:5O?)3*8XC%<Q [PHEE6>LE7*O  #I5*P.DI0:4@)^6Q1 19
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M.UQ,'_#2B$0>ZP)F [Q83IGN-P1J:_1@536.]N6CYCCZI5XDL!&_.LK[^*$
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M@+2J<#4M<![<M7L;^368$)8C[8UG#YM$+^-=1!X-/3%P7C7D/;NZZVT_I_K
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MDEU9A%!%6KE[=M,A+M D6?IR505"R'\<I%?##"6#*\5S\+CGS[ 1S$":2)P
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M>G+6Z6/Z3XLU$!IBE>2IH6EB(HT.]$TOFR?;PZ(V0#!YN$!B (P$QA+U>_W
MQ4@C/[214[CR3>=KRDSC7=@VO;&S9X8[F0R,&\F)E$V)K*+;" 4...0K^Z62
M("TZ@N5PU:KK"U/,>BKQ-<8)\Z">O3W08\2ZTIH60R\!?.EO+;T\,YC]SY;(
M/ "[6QS&UJ5&W]C2%7#;S%->$/G!@?2YZB64,EXP5K,.=@*_N6MT(9E+M!,'
M9$B(I ;7,D>Z_)'NW?XSF<)R=;A9U^)\ X*H0R975$26_)6T^JQ^;R,"8(IF
MTD@C6&QS90:V +459JO7JQVL%B<"@+I6I9"B 9;4JY<J$>ZLK [OU3TIMEO<
MC2LWWPT!;)(BZ E5VX7N^<\M_NFKHBZV)>V%:!L>6OZ>\\7Z94M72,O8;Q]4
M>M_Z72D BKH:7>CAYLVBTI7@_9 D%"Q\@0(7\E,$Z2!!?P<7W_@TNTY0N*UX
MN\U^$F,NC I3'_)L0#6>!"G84X\1DL-MYDFNUO[RE\V 7^?N3(HX#]9>!_R-
MZ6J$!\ KV2H/B '36T:_L88RXP"( .$CG:J7Y6P;M8MN2$ _XL(SG@S"Y!JZ
MC1H]MFA3+OD4Z7-_ 10Y3Y$1MDNYX#0-G1=KL8PXC;EBH6W+YR$DE(IZ3G?A
MLX?7(SW)=KD$1+W.3RJ_)H74'REKVBC,E]E/C]RDD];8A6^MJ'3_#Q7*H'+5
MH)L28#VTC6B-7GIPI+2^"1XF.OFT&H;RY+(GJG8SK6B%\V2&U-6A6G:^!4NU
MC:'&@VX<<I_^'%D>0\?&TR2EC,1>=+U^WC/U^4%E\H,;5@6JNR@]'5%5X7V4
M/U6SQC-Y+/##IF?U-%;7]C)K(9.Q2+%5CUQ++7=65)I>KP!#3\N:R#:AF:OV
M_WDB]=_;]"KQ"%1<J9.ZF&*C:8_7_:N?$88.,M/U&TU-"H)9C8"AQ-](-IFD
MD=J 2H_?FCE/KJ].<K,3W%AJ:7MGLE06>W004+RH4Y^F1G #J:C9%O9%Q@(F
MK:86K%N?2#68!E95VG7%!58V#BOGX!OV<2^DX.6VYTR5ZAKTHK5++(2<';-N
MH.2!<\ Y$J@I4=I^))Z:B;QM4GQ==,/TG*BRQX*2K6:I\64F;"T5J_#EPS+H
M:T]M>0K1I%A1@1'&_\V+",37S!:OZ;="FT[+,!>]R2<R\__DNHG$7_CJ@A6@
MI7X[' \ATXQ*@_B_#&B<_B7A:/_$4C7$LU"NY2TJ)DP1_N5F%LFOH,W%H)8T
ME3#I:2/D#7A@RLOE@"N_=F.]6Y!D22\,1M(IML^?CE\KXGGQU@: 8@G%-RI!
MZP%-Y.AVTCP>U'+6(2L$&&D%9DF)WS+AW88J0C,RH>5J)@L8$0([H;^4BV7V
M\2@1D?+7WD&)Z9WD>9?(IO8BE]>?OW*WS%;DS5O*I2GO^:#[-=\]!9;[1IX7
MGZ!Y!7@*ZSO8!THE'1%L[I\NQB.HC._EOA1C9")1?+30(*=P;3T,%]. !J,'
M'L-<G[\0741O82A*<\2D04]IL67PU]/2F[6%V<H=J]:D:I)Y7,0CIKAYYVS(
M?Q[1;8-7T>)0ENZ)'**-)NK#W&3F53"T:FY3QB-4EE8D<MW;9H)U"H3/5JW:
MYCV;"A^&3UTBY(F]5.^@W%4QN''4 GA3VUK6V.<5 .QYQVUM7JE870U+ N24
M [+TD L$>"1_BG(1T6QF8V"M86!N8/1G>;(?JQC-HLT<NH\*E^C9DR:V("4!
M-MT*YJ7R6P?^-:SU==>#P)'Z2K1I7Z''DW\6*%])>QNV5]GU_9+JW:#$UOUF
M4%GJGO7!5^&JQ?E?)#+#B__,X92!T=?^_N(*"Q,@F_YB M9(=DM.%BZRK-JD
MHN2*/R]&=%O*,2K$9?V)#X^EP>K]WAJ*/1@4& 94T?<&ZMV]R07D6K"<IL[@
M<L/CIL:KGJ^*GO2R1 Y1TR<.+!$G=A)]AO6-/I2&2JV8/K$FGP!9O8\Q.H&,
M;?'?6U^[N0[%,FYV9%FTM;5JO!RZ\)M]5RLUU"E&WS?"\9?'40_NW&-]CZG>
MIO%F5L!K_>=R<1_IHZ*;BA.51.&U>*0>U2[Q(V'?N0=0I:N>!<JS*O;48*.M
M?M+G"]**%<HV$CJB7XY=!ZP'3*X>:N)!,&_1Z<.GP5B%Z1'6QLXPO4P*77&7
MY?8YF[5M-JO2)13"_,&!.'O%(M+(\BR/Y%U*W&!KS^\OB_J_++EJ,S%M<:Y/
M92<$.R^<SRIP_<:72'PVG?YJ(LLGX^A;$YXKJU1**#H<"Q;\+GB#!,;K3R7.
MKMJ$9B#<-:D]_)2H^W.2%J5#?#GT. (7:W#-:+%'> ZZR0CHFAMQ(.V2@7A2
M)^H^&=KUO1M'"E\D[L33=RVH9]>8?SJ6-:^7?5B^>-?MQ@9-V-V [7@AH]Y%
MKH4<2(JHW?Q[:]@OC)31[8X^FSD,2[WWV.2BJ?1#5<5^@UC,8*N(<K]7H W^
MSDB5%)^\261H >::8>([E"(5RGR-OS/X"&\)Q?G\-NOXFV8 +OQ(S%=<B6&@
M*ID9=K60@!V^OKO)"--AP;Q3,R/.<[66W@A-6O6Q--?"FA=A>OO5WJ[V_^#@
MZU''2+U,H(N<2/=>-N)V\3^2+F?)%<4SX@79@2;"^8O">%G*25ZG4SKW2V>5
M^TX'RV9=16_7HA(K_P UQMU(=F\ZF13 EF 6#%! \ZN5Y299-P\^-+@N;5'6
MN' !R.1$:64#18M%DSE'U4=YWE^XQ'@LD^AW?:Y5R")!^##G!W?-@E2<Z(8]
M$D/;^S_)K7DSE)A&4CSV"**;VT2N?7-,#99G&274L@.=V<A5;HJT^_1><RQX
M:>7$2!*55?% EC!VKRWK$EQ]Y(W>SX?1(SN=L18V8%Y,5Y@0R&Z&)&X.VQ0S
MEN5PY7J#]@]T(IO]EB$385_]Q%1%QF0JNN0=Y$.+$<WE>C\X E7];52H88OV
M#X(FN=@.S'.O?G!P&IQ;E4H!&--"TN*N_PRM;)E.([EXH4#CRZHMXL<N)?K:
MDSM[+?YGLC/"2@H/^L>O.B4^'7ZDE:9)"WE9XE<PMH]69 2^IHVJ?JN.===+
M#8?!O&&.IPS2\9P"Q))LD8?5_K KKU;Z[XO E%(-NI[?S?J#-5'XT;AKUG.\
M C7T\(J%1A7!W)[L6"@ 63]LLMYOSM=BMAW>8Z90WXLBC;1;F!M#O,+OV?")
M;]9,PY3,$P_F-FP:(T!\3QE9>N<O#%]1:+GZ1*V>FN*'C9N=OG1R,K;LM"([
MN!KJU'5MA2MC[+I-J68W4,?30XC+M:8X8!*_*VJBFVYM;O!W:.6R5CXWSJ&/
MP6Q/QQB7VB3_2D&\,9"]Z^M@H"I,>;@&AY)^< 3([UF28O:+PC.!4#SX!=9L
MDKB30+]$,9+V?^%\]OJP5(B=*Y,/R$^D8/R83<<7[_:4N4SKO$59:X[L(=JQ
M+; BLY;FK,^[P3XN^G*/"\U]<O2S^;SRQ.7+]3X$PO[=L''"_/EI_O $5^U(
M&\01A<0AN, 1E+>U PQ(Q>U*P@ES!K+.WE^*(\.5][,/=S3X!NR2E>2@UU@&
M$Q1_JG-Q6;,-!*_Z2&\ZHC#]8TYB=%'(V[*^PS9C/M4*9N]@KGS_9$JG!\TM
MRJ-?ZA(8X8^PP5=\.ER(_L/MKJB.;^O4 ^>U=EV[9S*X6JY:\C5'QF7W&XGJ
M,WG\ZL2BKDT]&C_A@)C9[QU;%+R]=;8@ #'(@QD6/CGL&IYP\@P?2*B_;*8J
M-4'0NQ^2,ITG+1UV5-1'?^$^1R@P._5[ZXD<+3T;7=3O]1Y9O<3^P3'(^W9T
M</%S&3/DU9GX:PR*<*+&=G@></-A(<[]^NMXNJ]UW?OFM,L?T<&,8W"LH0JC
M#=Y^+%OYKV^[G<E-F=U7?E]7"S:<6]7>C&J-D3P_V1,!$4>%A-NW;1<[*=!$
M@I\/5Y9F@*K]0[ H@ZGWZ?YW(XO'_T8$1,6=$TL=8 !'!7#*?MIX2\^SVD_K
M!CEAY-2Z+<5I&W7H:?&JO/WDG!''"1>[Q><'QZ4)$BM_Z#T?_ <'O3?U(*;L
MMTWXBF9#]Q2JGC/@*+:D.RM_]4+;7V[;(O-:BQ.?57.6@"LR]EU//Z<O:KEN
MJX23#%ZJTF(P<1=$,9%$DZED.:% R_F^ 2@.23*I<5T(MBE1U"98VA#=+?+\
MA&8(A58:K^[MCX7WK[%(Z30P(9K?OD79FP:MV=@Y33(*"/^8&=N"LAY]-PL]
MVZC/-MKY?VG0>"C<<_?LW?^]8>7_;X )[+G^@V/X#];D:9:1W ^.F;G=V)M2
M;,'X[27CK[CXW\-T3W#%MW]P>"L_.B/ ]([>,*G_\X73I/I<X]97?U_\Y]J7
M5QP07,6E#LOJ0<76=XV6 >]"_LQ9_OI;IUJ.YG76A82P"[FH$,JFP+O Z2B0
M4#\(7_QW(*0HZG,_XBY)P]K<MA&Q--ZZ]"_F992'N+>76AXX;A)/VH]Q=S$*
M\<6YD!Y\YR^6,J8AASRB7 /QT)!EJ-].U4JZD)"%Y4S9_CC,IDRZN?MY:)MF
M0SWD?W4FYWUNY_G8XUT;N'2USIL-?W;ZZV+X'Q+^9W\_6'L09Q7?CN*P>SFG
MO6NT>K>YJ^O)XH935Z[M]#_XP^'8&"'L"D&VI?,'QS6RIV>4OM12:\1BL0.N
M^$8' 1!>,[WLD$BB.L0O9];,9,1N2'Y84):UW[S4;C;Z/"(G42!V32[GB]KT
M?S](P:P&.;WU*%K;\6\CDJ>?=[6[D](Z8W'4/N^0F_N9 ]NK],'-TZO?;C;&
M/RQV",4QZB]!(XL^U2B85*2P<4 '_$O+1YRJMKZ$S\<P1=/CJ03[7+=9U^=E
M169'?_Q/\_;_X/B_[.]&HRL@[&<,J2Q /FV/$_-'2A] .)M)I/9HY$I>G>JR
M"HLA!\:ILEK3PCK=;)P65X2:7BL_?,ZO>T'O?!9F1)L)U:QQ&F$[II(=A1#9
M+!]K<\%J^GIS^J,'<_AWF]['/Y4A*@+\!@2;X])6;X\>_180'D%V$>!T&_Z$
M\Q\<5GDW>V3>Y3W_;F1H)+KLKQ/[BFTI$;4NA<*^6 ':0F<*E:S=Y+0;27DT
M]'1Y2U(OGL<VO->O>P[P@\,ZZXY0FG V>?02M]#$C. UY+URP-+)BR'/QJ/&
M%.,V9V% ';>(WI3=Z4&'!CK3P,=JI3A\3!9D]<ZSI1,[-V3Q=K!PG3H*Z*;T
MU#OHE1CX<O,"/P^;.21+8L%3X7/K>H4'\5CA%RHM:OS^I;K_[61\:Z1FRXRW
MGO^:MR#2#X\7;%D.W6HK%6 _]B,K(>-D6CI9D@3ZIP-%C.#][.%2ZB([Y+&7
M?_#EV$AYKN#. 06]62*6D/ QVRC+V0RA&LPYK \N-=(#O\F YY2 P<$EK@9^
M24Y?Z,CCBWJKOS-;PC"[)@8-]0K##G,.,,-B@K*;LF'UL<)4F<JJ?='9^9F3
M0$:L0]_%_B\G=V>^NIX$SH>4=_2R4I(^YCGU*" A[ LS[GGZM9_I29A;VKL^
MQ"4KP*C?Y:=1$(1R@R:MSYYH@W+U2:7Y//O5/AQ[)S9BBXW/QCTO+G>O]1,=
MNDK<_7U-;Z+6Q]Z^6$UP53<3&@+0^0)F9:2'YKP:O3C.Z_>\!! W9Y$7>AA!
MM <%V(63.!^!:& C%;4365[6>6VSF1.EGSF;'^W<%5<J4H0(/'5"_X4NP5R-
M&S)(?_]F8)6E'BC4#'\J,FHUZ/HB_HM0VP(L.IVKGIEW<0NJ?TW(XS $>5!6
M1[(Z96@=-69DY$D5#'CD\^#S^.QQ-:#XH:/9P/%A2]JWK;*Y>?$W@V6?-^33
M()"<1A:OH&Y_0U4@D;9_XO2#(PEWGUW9HYBLM=K&['(7=U,:Z&4F]2;\\]2#
M]C3 .,CCXA7]$Q"Y>F0[7-6JTSW)26$P;)2NJ$<GIHSFW71X2+[6MZHYE_$1
M%0+17L7TC3O\X/!R4HNS'* 7;;E/;J.Z&[&KF:U7'!J?,]V//9S6 E39T.Y*
M<GRSA?I:TLV*R!#T7E_T>*6[XE2.;3JB+;'VL]$%=E/\B<Q/]JM#N>-^>W7<
M]DQ@4]L-(@%WLR]]3SL4%LG91-P_#OIH%4-V<9)7[T9:O\:Z:M<0N9Q<9\3
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M/&K65LY(I3.5Q&P-<*RP-?E^Q@F7/^\@^?%.0K.*4G\+4\,VGIS\D#'+"\+
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M%,V>24!8_WZ>NJS4'98#13B)29HEODVG*9G9]FB7[[Y:J,[+63>L63+5A,]
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M[\4$^9V/%[>LCES3=9T25-,L:%"5#>S&]IKR9)\'_UCN8^I<BZ3&2!2WO1Y
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M#ZBZV - WMS$N%P:O9L$]4*B5F4*P +A YG 3C!Z((FTV0;6H [,->I>ZV)
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M&F2YMU3S'9^=R@S%D6(7B8%)VSALT\,#7N^B^\6BF0#Q0MF;VQH(XH]HSU2
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M*UT7E.]:;8&9<;_[[98^Q9_,@?UL3+((?)=@DGD5<"YX#.3^-,&]?US[!B]
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MGQ))E_![9021:K @3BUZ0QS]G;XT1NZ\^.2['/W9A5Y<N>DE67?_S4.;EYQ
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M;B8#JSZLE^%7FD>\QHJ-.K0#-K9,!(.^"2/)+]JWL[RJA^\%'&KFI H842)
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MZG^%#8@EWAP+87O3FY?E&OI)/3)PMO/3>4[0VKTA80D$XFO)9F>4+-A)+^L
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MU=7UINN(Z#Y5MW&1CCT:O(!TH^*"EO$'H9O#LH>#/LYYKF7O*C9,AE;V!OU
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M7$?BYN8^]L-Q<Q]Y+M#_*ONK]/\J#AGT! ! /*"_!/Q#H*,C>'C!?/S'3X
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M(_<DN_,PMXNL\78+/2<_WAR:3 QV5[(>K//1:=TTT/!KM6Y23\-L:"0J<XF
M"TL\C1[G]-$+.J8@]0R)J# [6DADR,V=L>]-ZZB'(XW++$0H[!FZ]-JC=*IF
MT)SESM6=[M:6D:(7LIM(AEV?4!:4V(UC<KW<@Z4W$D=2C42;GG9,RI1:JH1
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MEI7H^[9G]ZP?NM,\K<$E,-"-XCG& :D<#,W$IO?57SQWSO8>Q;Y+SY-:H%>
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MAGR*D?Z7U!.=1S-%,EWB1&CK\TC.S-\!4$L#!!0    ( #6#G5KUP\?"? L
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M]TCYV(_A<?Q0AAP+^?$>7E:V<\KLIZY:<[CZ\9V_])B3_UIJX>OW7% 5.$W
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MA)FD@Y#P W8DS,M@N3 HML%$C@^JK%9^.%!ED,\"80]I)P&5P$YZ\OP$27
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M"(IF ]D $ %1-RY!S3P[[?3*W G<[@=M=LQ#>6P\J31/%&:*(!K($$8T05
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MG_YC [FJN5%=_]+9/U;W5<Z9ZMJ%D[\]S+\U$:](_*5 N#2O;P+A=PW\)4"
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MXU2SK5/;+(TH\L\_;COB39S[QGV^6'"__XV."V[;R7KF'$TZGA0Q,=7YD;N
M!^<?DJ6FTHKYL\?/OF69.G!7:^RMR!@/@[_WX^%G2HI/ @U_/G3_^'6]F DG
MV1<K?&A*@J:^??10LRWXL'W]CM.IJ9O;-;+91@J7!9LN%"+(L:+O/BQ;],D]
MC.8D,B92NG;&H-E-DLX=MNWVKBOS_>_O/+AK--%NPD./IN@N#[\R/3IK89L+
MP;/UCQ]MUN30SQM?O5CTP]L[/75&F&8T7]O_J2DC^"NSY8^%CM1MO'O_70T2
M>/U6(D)4;GQM;O+(AM=>>_C,@FX+/"O/?_[NEG3]@(@L;;CXI5H-.Y?V7_%3
M@P5?=OEY6\\-TY=$M__\,IAH]_KG\\(3OY/+Q[*<?^4^N?V3ICX_/[]DQGY<
MO^^-D8Z%=;N*N_7<U-H]XJC\X?"K<GD1YQ2MQP>_U_K0%VMZ/-#;W@R%;Z\;
M\T5W]"Y_[?775RR,OLPF7X#&/W1L/=JQ9>R9]JMOP4>MVCV[W6WC)@__I/:S
MI_N^/Z$T<O;TXW=L?W"$W6+4F9OBSAYD!)!.=[:Y;4#1[/<6[<CMO+]A@VZ#
M1@UZ7B/JW?#.'YXY\8M6O>.;1?<,K^OM>+33!N/L8<Z-V-'!=%F'XEK%T5!L
M_\ 5T\M']]DV=_5[HQ=I2?G !9-;-EK]ROJOJ8:E+S3O/^"K/?L$QQ]0C1RS
M53DP>M_*$PIF?L70X:)[&^S/C"1J;9P<N#,8OE_B?'+?B>"'5=TW<NRRW?>^
MM'3H(WU]\Z:O'6HK?6JB7K+GMJ)7GQBR?>9K]\\0[5FZH-2Z?<O60[:WLT^X
MO]\^Y^W,W&G+.J]N=JS%@,FGMYK@F1,'MK-\\.@I]9T/'WRX^=WJ+KG&S4?:
MZ;RRYV91*VKM^)/;A_Y09C.7?7>L^X/NP^)=QLM?M)D'=_J/[;RP4&>6+W][
MX;D1P5?VAKM<_M)RV#>M]PSY6KZHL6[Y6=,Z1V[0J>&7OPQ=6K;JSRB^[%G5
M+S0G.FJAS[&LN/ZS@XI>S*Z1?__ ^Z\MP;<&WO2W^W2'7+'NL4(^]4MZM2+;
M^6+1X[TN3 +V,YOK=SGNOG#J[?/R7N\=FG1/@^\&7IC01['@0NV?+W#<ZKFM
M[>//G#$M.6_K_F&]I0[Q[<"S9X=LDYV;.VO$Y+5GS#^U!8:?F/*#-_4Z,NS$
M8_?6+UTSJ9_AY< W91_VZ/S]IO7.!QN_T7YAX*$E;YD[?S=HP#GODB?W']\-
MC6RW9,W1KV-O/N1+O[O:<LRZI=:ZN)F9]<S1H9\MCKW^BESQZ7U6P[W>.Z#>
MG:<]?6)X=%I)Y,U#"[ VCV\YL&!]]N4)M1]KN1V:1=+'[YO>9_[(^9B<:I7K
MO?EPFV>V[>Q0K\?<YX9U2<V;<'AD\/&?)JPYDE\RHO.**;:>_N]ZUS^3';98
M:^FU]OO,.Y4+H!37%_)093#_H)Q\[_Z/_6?['.B]J+3Y,77ZFW7/?MWZS6:M
M!XX<O04^YWV].;NT;RUAHJEL4]L532]TJ/B7@Y<H2Y2U&Y9L=V+J&-'LZ-KO
M&Q_KDNNT8\,Y^2.O-\-[E[PO^M!::_W4]**#"9!.?!5Z$*85D?=.#!BN:?&4
M)-TF?O)QZ9?-9UD?&==SC.C@=_FN'^]]R%'[@F_0B^]]L#]$42'2(RX2USG?
M>>/PY/#A/\"I5<XZ=0[Z2SOM7#Y^[<N1]@)'7=VG^PY^\M2S14<W#)YRKZ?^
M<W7Z/CIZ6^_^8_SMA_GJ-MJXX5SJW,3@ME??7]#?,G3,^EG/49.:3OWB6+]N
MVU>U/K+^W%?TL'2K_I_MW+.H[YF^G[IQ=XM:[[7>[]^5S_6:96!BD;>[[3I"
MWC66?U:1&.6\9]J>9)=5;_9EOOFIQ?N-FCZQY5;YPXTOC!/290\,V?-98\]I
MM7M6UX8M(_>)&ZW?=V;06%G7CT^5BY<.$W*LL.F2@.0@[_&99]5YW@+?Z8HW
M1GWV[>3>"^Y-WM/FAS>'3/,>T2<$69+YZ)D-*UJWW3MGQM#-Q@0Q %*V2NXM
MO656N.6;BSO^,'0I,W3DW*^;=T1OO>?V#P:W^_S>@=OGY?M/Z_GJR6$?GY,K
M-J_Z9M$CO&--##,6;;=9C'LV/7=HVIS2 Z,>V=5MZYBS[5C7ND&=47C1"7%)
MQ9BZW\6&8M,G+>[G63BLP[22]8_.)4Y.F?[\[-'E+[C]H^_PM%K7-I[L>>?^
MVS]?.:OL**"^9]_9%8X>8]_[].O6+=[]8?YXV=+50R=_4_%HSQ_OD0V53>KQ
M^L?^ &_?BF7/RK&FU1CB=3X_['[(W4/6K?/*[QU-6U-G=DR\.[N%5&(CP(K1
MDUP/-M>T'- *7;7NB9?>U#3]=MM;HAE].GXUYO7>+^Y\ZN,?IP];U&SF)^\=
MM'TYW_YV<;\!6^XNK&\N7]+IP+?IXFF/CWO),O[="WV6GU@7?_GHSN3MI'WB
M@X[RJ5-7##C?3-!@=[>M\RV?#!_[W++Y3SXP]^>?-]M(6>R.&>]K6**Y7#&3
M+R'O;^)]O"$QA$HU&=F#^O$>R9B#(T<,3@Z>MTO3?,3P7RVY3#FK6.39NN1#
M0M&E]5N#)R1VDN]_K9JX]BOC@;D[!FP?(AORR?+I+R4>W)U:W=?_W.YTBQ/Y
MS4<3/P]?\@V\_\?7/C[P8]E7;?N7[>,N3B#G>XX!0[<OI^]O.;FHZ]9W=G[X
MKSWC99&C)64]8F/*-67JRM6A?X^V6E;<\739SD^V#^CR98]=H\<-7_!!C^\6
M?-CYZ?/#)KUP]HLWOCL!* I+*RET[<QN[\\6[9I8-G!V8O&@V,[R/0U3'UO6
M&=J-&_#H>.EY)_[*]@T-%GPPW;)[R?AUAGZO-UD\<]]8&!H9'+E]W+'XD;IM
M/YEG.+7-&N" 08Z:8=4],.A OT-KT'X?#/9-6KTNTW[*MGN)_3-;)(YNJOWM
M8P,&K=S1_VBG.4*SX[,Q[:T*7NKY&9^^\7+SEM\?6!??W./_M6;=T7!HW7YR
M<X4D>C#1:XC>Q6B)Z#UZ[Z,S&(P@2(CH(T0GA-%F],YH44/T.GIB]#J('N7E
MOONM>[]OO;O6^^.]M?9?Y^RU]]G[G+-_NR0LF@@EVJ''%0]S1-:B\%^<\$UZ
MW<[=>7;'.3ZUGS<-W+H5_WTU-@ :=F:_Q.=#,2BDW?C%97G90<T7;CM0MIJ!
M+M2;-R[*G?2F&)%7(!.0MQRH$GJ<S59&%/NZ<4CR->U7P"=Q+1LBO]W4(.".
MU6[CYU50;6A?B7]'#L:7SI(Q4M!N:.O0QYF=7> E@O:AU CPKI/@]I)!KMVA
M&W9VA0(G_[!@^*T@GL+8#SPS'&GJ)XH=EUH5&3)0@R<A^FL(2X*';G3T#]8R
M2",G7]%XX V@XLOU\X/37Y7-"4?PCN -X'USX$3P5;00"W+I*$5*$;?1)KB7
M4M'ZN,.06\MQP93MX-II.$HJ@PE4DTT"LW(83/\T2AGE%,L->^12GC3L;QW(
ME*[JMYP.I%*C#9U>:B;UPGLUJOH<0D@;$$=F'> VQ=-6TX&1(HDZJ.Q$?@Z;
MT7.X0R<[XPB!W<U>>KXW^YIQ!H0/1Z""1@W3!U<,.RJ[)FQ-NTO565C>9K*L
M+^(,MNE%?(#.#4CF!(,.3"\4;V_^Z?7\+>Y/!$RDLOB.S &(<=U! S0>;5<#
M(['-LV58K6Z?<-L7JXD/0Q#Y8R0+ORT'L,0B/"$J84Q-YTVW!(!)QE70:VJ9
MXABQ3^)XM5RJ*QY'O."QZNYL4627EX'=CID]^(HA>NO-V]OXL)C$]$ Z_9<-
M5'V$H>TP"PH(UDN+[-ZQY'-/?^/!^[B9D82I5JU+@2U^GY,YWJQC2[?,4%XV
MW)LNR*.\F!L WI+FATGGMVZ.1]:N@Q26C!$>1 5UOML3!#\)NW#\UI-L/S+?
M;!L-.NT15H&F[Y66S7\]?7<>GR3GV"U1N]-#*Z1ALKQ -1OK](!<Z^U^K08V
M*[;VXYL=DMCAB7VS7;,?O0?O\XH_1+L1M2Y%YY?...AKGLUJ/:C:U]+NS3O>
M;*Y'$^\L+@2TJ*H=OD,>0!G59#J"7DS*\,EM.DSK@0]D[N9%V2?_$<_&FTFA
MS,%W<97:FY=I.$C;Y!F_^U>:PN[>0)Z?]WYT8HSXDR5H/W)>#NKQ)A+^Z!>L
M\0Y-W3(RMI"B/UCQ%J(3]$D4HLXN56"%]S3CXDIVZ<X/43,O/5\LEGKS+JT-
M&4!F+]*9R<C?]/YW=@M06 X<"TMQ+(6C(LS8(L>%B-P)*DCO]I>?'E+N6&SF
M8)W>RELP9,.92_D\;WVR5\'J/>I\^R"G' E/Z*:;&(@?C#+42TZI>?"A:G(F
M=2ZAPAL3(9D]>M5^T&: JH#E2<+6+H_C=.7B--68"HS$1ZOX=$VB?AP6ZB5R
M^P/K5XETL2LRR8%O+W-0K\S"QX8KBA(-6Z+BM%8L=S$7;7B[YW)Z9XTD^=G6
M3Q\[9P.9CZIWN!Z1[>CY!S/_O^QO$R?;]M2;NJ4ON\ 7Z!7DC&8+AL""#6OX
M(<\&R)]]&RH).E4_'_SF>:7&4KD7NQM 9W*2V4[;;FH)L,R(] @KVR 0TB E
M?]/-^@H8]Y@+[L:5^/%5O"T5Y6K?P535U8Y'TX+P^I/ +\<< 06OUG -U_G2
M"G*1++AW-A=/,3< 9>"_EO-PWL.9"Z>,$X5%<+;03L% QNT;0-[]EG$9+]_Y
M8!U?M,,0Y&?<ENZ$$KGL4FIKW/$-8 QO<3,;U+3W%"GY+QV<OR"":7_ 4NGB
M!K!)56L=U60G^2FO&539.+L"(Y9Z?54&UDFT<!=ZB<50YOF,K_WB>A-/YDSX
MV91#[MN=U.!KRVML957ZC'=.-,\4.L 'O=*+Y)Q#TA))07K=%TW3]*$;2:/:
MD5[W640TOIK'1D2S^:[TW  DJT=M3G3;V)^<+V1% ZM2SGQ:,+@1.ZP/++A-
MUS2WC_Y<L&UHY\BH)1'7%WOMZY#;O8/H+-UK"WKS/UF22GC'))SO.8%!+0>B
M0U)Y81:73J,%IVFVC%S4-'OGC-[R^OWLZDMX^]F>%T7!R930$@BIY=U31E3X
MN;4AMTK</N)0T9)C66VMH_6,.^!2;53K&IM#>=IN^@UK$15\2N'7]IME*[B!
MD>&I97LP%_?;+-*=FA$;_\>7XE4A%2+ND+6G16<<>5#N2;\]/;U3[D -2K"-
MJG/$ D6,E!LK2X*V"\K9,2"0:VN>.C3>U[..OJAC.AT]KINVPS_T)/Y">6BJ
MJ20(%-9AHMRGXAS3G(N==:CK]T)5FSM!1,@?;B'SR 7GER-^T'=!>1&A@I1\
MG)V)OLY"M^W=PQG\4A?%0(6?KJD91"/T\S])N<SOL9[RH<U-[;K;TQIVHLP'
M?67G_>/("S.4R&G[4?Q68(_")KZ8B8V(>!I <8N4#8G'/IZ9]E,#U/< '2GX
M/-Q_??!WGS ;GI:.)Z0!R)@9U[#S\3G6"2:(4)-+&Y'VA'Z)1$-R67^:KM@B
M/>]YJX)F1/0S^PYNW=!%JL(V;#JJ*8E'7X1"8,TVZ<V.=]STB.PTS(7A/=6[
M/7["ETV.1^)7JDGGE04!Z<X67]J31KYIR9'GSIEW+\4!W1C"&9&2T9T,?+/2
MQ$]UHKL0FQS[C1?QD=IN9=C]+]%U?R0[N2;ZGZG\,^][^^0.RZF9:PY-QQX=
M[=K""S!/!(1!]=*9C7PY-=:<CW(&3L#+0%Y_:A6R![>L'X\F,^VYT)KL\<%*
MQ3]4:O5-+WQOZLL*5',,(1APNW^;-SRG1':!ZE:]!NLQ"IDQ6[T[5S+PFB,?
M75C*/:L/->!__\UN;JK^!WO_H5*=&.A07#26NG$(! "I7NEE$[SRF:50(IQ[
M]!65WS@E7>C"*IDVMB<#242G?ZQ^(2=9JM<^I&!;( 79L8ZDFS7,ACKVP=.:
MM:Z0)%I  ;IM)(*>#[/T3@'2+*;Z4^X5E=OESNW+/!SCJK0\5^6#TSC3<*(R
M14_P= F,8V#>R(5\5I"7%%F%4= 9:&:O63GQ A4Z;IO[A!9QHTHGU9&?D.GI
M.5DGRA9&2U.4L;;C$-ZZRLJ)?C5/JYFK IZ/*6-.U,=K*<;5>8U3QS3Z-=BI
M9%XB@^93KBT7M]^/:\>%:!P?6K+!07=>5W<U,Y7?X<FM?B&F->NUN+0R$'1L
MN<P3&"$(4V^:"K;#-ZX9J==A\H,N;S]2LABN;%OMHY^I045=T\WT=0.?PBKI
MQ]91)EQ;X%21 WSQ]U)I?"8LWLG1\BQN]<7WC?9?U4N$*M8D*"\8Z@\^4E1Z
M_U'[3( R=;\47DSV;:-4CY?=.>VV3]5TSZ4#@Y4PM]OLAG6=J9.C$VVQUJ]R
M-08JBF#^F;"+L-%^0>.*SOA0W9^S^4=KQJZ,]*7&E+K1=JF(WPOSNQ\$Q(3<
MX1)7I\8K^B9S#>-$H]AF:7WG<FHQV4SHK;3(Y<4&[R!6P9[*5HX*C'7QI$+5
M)AD\]T%S *8^<E#*JC 5=*\7(E,TO+Z,7F]%"R>VR3*%$,M#F(-8FE_P:U!O
M5HRV4]8_A*G86!'!6Q#&GZ'*3[+SQ Y#6RRIHFM;#U1G,_3=I,WPESOVOX/@
MIG&"1AK^CUV<B]@?O)@8UA"8/P/S^"9R :V>NQL=VM*(Q6R;5IL@7N;V"#@!
M@9\_]]C0OKE]LH*1T4V_=O8.BT;1F+*S-+P.MK$97NHSV)\Y56BC*!\;#/=I
M,MVE6 O(=Q.E8UW68+*2IL;IK4F.E_)*076L'\:JKSM U,=8W25-8 U'*Q(&
MKXI1126I_892U5]]6PU3Q(^3#@RX9O9#I]QU2N=4O4QD'95+Q*N6W'L24^&H
M7)/T'G6V-!P,$E]HFS$UIB0T*^(C,*4CJZ]^P/9 L$KQH'&05>!5]!U>V?9^
M\I_%;_-J)IY*%-O6FJ;-6L.FSHDK-OJ\:CBGN%QZ<?8+>0ONPX>FCZ/[8>7O
M,"[%Y2A8"<6HA$.6?8C6GLH8)H'^2:&8 S%Y:FC]@;YH%G"=",VS K@!1%T5
M]BY8<NI=G"R6"9OO'=?3(#*/=24<?@#)H1L6CPH*6NDH)*E-=[#3Z_,LO+(Y
M4D3.]K?SBIMGBU!;VYG.HB@FU[ 229I;K+!GC#6-K<?ROFF+,E+ER5M"%[R-
M_U Q<04]8E3Q[5C?$J3YQWW67X&)Y'YV49=CF0Q9@V;R(+3.;%?/8VQTHL<J
M09R5T"J^2;;7=2#T!J!:2+E58M"N<7\/.?D$?X7R9WLHJ2O:^CR[SQ# D5/.
MV/$*%:)#S_CMX[O*L++--#*YQP]N?:%M!E[_7@;EQDYA?6/=[TVRNK)<VJ:?
MB.XP#WH,D#6$753;9_[G #^/OMLF#@BY#N= 2D9U,_ M7!%KZ4QXLL[W[:_/
MQ!_I$&,KE:+K@^4^3'S\BY%.^928[J>03)3LO,'C QAN ^K_H:%$&[O[;63E
MF#628:DSVUYI5/EO>;Z445+F31=T67F_!(M[[?1>+)S$[:'XD0[[83%_L\U2
MU34FSRHV4S565) JRM.%&-> T^%Q#1B[[NY^_;D;@)8JRR,YK_]H=>UE5@P>
MKN:97&3XI"_K:VY@B9)I'%H*V0&P-PEO_M*;G_LE4U][?25F2 $*ZU=8Z[WX
M&ZK_S6[TF>@,7W*X#8F/VV2B>:(L<HX4+>U:^RO9K7]Y6/2# ZB>$(Q.^-ZA
M>E;7='V_D8S\P7.]5RP"X4T/?>K1XC_*ZD)GA&@M\1G384<N/%WUS3'@2C2(
MAN%+"$:T4T!V\5Z?^ U L3Y#AK.TH,;$9=MMR!=<F$! ST0(6TNX<]!4+",R
MY[#"BS'+U@QQ0\2<-L2;^R<=<N)[&B&ZY]IR^K8T_[J,M%^.-/[E9B=>_&6+
MK8K/!:4?3+;=?^.LE@0[='^X(A%?-Y#H>_A;-'")3DO%N["S/D5Q'"GU/$%K
M2#[PAZ\/W(.J)D1;A.SKR#ZF1AR_IO8S60_QB%^40II.F?\7A,A#0]6O1]EZ
M+W&GRJYUJMM)VI>#/'Q)G2G,37E[VT;^JZ:B/4M_S ']HR+->>"K7I$<IZ72
M'7=/_4MXM9RJ3(M=Z(W%:M;2@<JTM&(K4%IA6'FZP<L];HJ73;Y'(&G5O>$8
M:WSV\RKX:&*AZ.^-+/_^DE+JOB NE3R:M77TC/F\1P:%C=G&=%I*8_-V/=G
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M.=E&J*35)9($W*H\XJ]B>>9H^"PB0IH@XO7_2D]O9OX+4$L! A0#%     @
M-8.=6G=$:.]:Y   .V$' !(              ( !     &0X.3<U,#=D9&5F
M,31A+FAT;5!+ 0(4 Q0    ( #6#G5H;>GQ)9@,  (X.   1
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M  !G.#DW-3 W9'-P,2YJ<&=02P$"% ,4    "  U@YU:TVN'Q\I7 0"E:0$
M$               @ $T)@$ 9S@Y-S4P-V1S<#%A+FIP9U!+ 0(4 Q0    (
M #6#G5K3@+NNG#4  -Q(   0              "  2Q^ @!G.#DW-3 W9'-P
M,6(N:G!G4$L! A0#%     @ -8.=6I@RV%4P#0  #@X  !
M ( !]K," &<X.3<U,#=D<W Q8RYJ<&=02P$"% ,4    "  U@YU:]</'PGP+
M   X#   $               @ %4P0( 9S@Y-S4P-V1S<#%D+FIP9U!+ 0(4
M Q0    ( #6#G5JN!DK<.0T  /$-   0              "  ?[, @!G.#DW
M-3 W9'-P,64N:G!G4$L! A0#%     @ -8.=6AW,<YT+!   U00   \
M         ( !9=H" &<X.3<U,#=D<W R+FIP9U!+ 0(4 Q0    ( #6#G5K)
MHB)]*P4  / %   0              "  9W> @!G.#DW-3 W9'-P,F$N:G!G
M4$L! A0#%     @ -8.=6FZ#,]UQ6   (.T  !$              ( !]N,"
H &<X.3<U,#=G,#)G,#(N:G!G4$L%!@     .  X =0,  )8\ P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>d897507ddef14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:eras="http://erasca.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eras-20241231.xsd" xlink:type="simple"/>
    <context id="P01_01_2024To12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761918</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761918</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">eras:JonathanELimMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761918</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">eras:DavidMChackoMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001761918</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">eras:ShannonRMorrisMDPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="P01_01_2024To12_31_2024" id="hidden140094653">DEF 14A</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2024To12_31_2024" id="ixv-4809">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2024To12_31_2024" id="ixv-4810">0001761918</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="P01_01_2024To12_31_2024" id="ixv-4853">Erasca, Inc.</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="P01_01_2024To12_31_2024" id="ixv-4857">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-2315">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity Award Grant Practices &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;We have had no program, plan or practice pertaining to the timing of stock option grants to NEOs coinciding with the release of material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-public&lt;/div&gt; information. Annual grants of stock options to employees are typically approved by the Compensation Committee or our Chief Executive Officer pursuant to a delegation of authority from the Compensation Committee in the first quarter of each year as part of our annual compensation cycle. Our Board or Compensation Committee may also approve grants at other times as they deem appropriate. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The timing of any equity grants to newly-hired employees, or in connection with promotions or other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-routine&lt;/div&gt; grants, is generally tied to the event giving rise to the award, although &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-executive&lt;/div&gt; new hire stock option awards are generally approved at the beginning of the calendar month following the individual&#x2019;s commencement of employment. For all stock option awards, the exercise price is no less than the closing price of our common stock on the date of the grant. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth information for certain stock options granted to our NEOs during 2024. In the event an issuer grants stock options or option-like instruments within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K,&lt;/div&gt; Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-Q&lt;/div&gt; or Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;8-K&lt;/div&gt; containing material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-public&lt;/div&gt; information as required under Item 402(x) of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-K,&lt;/div&gt; Item 402(x) of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;S-K&lt;/div&gt; requires tabular disclosure of certain information related to such awards. The table below is being provided because certain of the stock options granted to our NEOs during 2024 were granted within the period commencing four business days prior to and ending one business day following the filing by the Company of a Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K,&lt;/div&gt; Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-Q&lt;/div&gt; or Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;8-K&lt;/div&gt; containing material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-public&lt;/div&gt; information. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:40%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Name&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Securities&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;the Award&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;the&#160;Award&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;at Time of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant &lt;div style="font-size:75%; vertical-align:top;display:inline;font-size:6.6px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;the Award&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage&#160;Change&#160;in&#160;the&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Closing&#160;Market&#160;Price&#160;of&#160;the&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Securities Underlying the&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Award&#160;Between&#160;the&#160;Trading&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Day Ending Immediately&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Prior to the Disclosure of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;MNPI and the Trading Day&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Beginning Immediately&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Following the Disclosure of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;MNPI&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Jonathan E. Lim, M.D.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6/20/2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;632,759&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;934,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;David M. Chacko, M.D.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6/20/2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;278,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;411,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shannon R. Morris, M.D., Ph.D.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6/20/2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;137,142&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;202,531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(1.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMethodTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-2320">We have had no program, plan or practice pertaining to the timing of stock option grants to NEOs coinciding with the release of material &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-public&lt;/div&gt; information. Annual grants of stock options to employees are typically approved by the Compensation Committee or our Chief Executive Officer pursuant to a delegation of authority from the Compensation Committee in the first quarter of each year as part of our annual compensation cycle.</ecd:AwardTmgMethodTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="P01_01_2024To12_31_2024" id="ixv-2321">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="P01_01_2024To12_31_2024" id="ixv-4858">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:AwardsCloseToMnpiDiscIndName
      contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis"
      id="ixv-4860">Jonathan E. Lim, M.D.</ecd:AwardsCloseToMnpiDiscIndName>
    <ecd:AwardUndrlygSecuritiesAmt
      contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis"
      decimals="0"
      id="ixv-4861"
      unitRef="Unit_shares">632759</ecd:AwardUndrlygSecuritiesAmt>
    <ecd:AwardExrcPrice
      contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis"
      decimals="2"
      id="ixv-4862"
      unitRef="Unit_USD_per_Share">2.03</ecd:AwardExrcPrice>
    <ecd:AwardGrantDateFairValue
      contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis"
      decimals="0"
      id="ixv-4863"
      unitRef="Unit_USD">934458</ecd:AwardGrantDateFairValue>
    <ecd:UndrlygSecurityMktPriceChngPct
      contextRef="PAsOn06_20_2024_JonathanELimMDMemberecdIndividualAxis"
      decimals="INF"
      id="ixv-4864"
      unitRef="Unit_pure">-1.43</ecd:UndrlygSecurityMktPriceChngPct>
    <ecd:AwardsCloseToMnpiDiscIndName
      contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis"
      id="ixv-4865">David M. Chacko, M.D.</ecd:AwardsCloseToMnpiDiscIndName>
    <ecd:AwardUndrlygSecuritiesAmt
      contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis"
      decimals="0"
      id="ixv-4866"
      unitRef="Unit_shares">278812</ecd:AwardUndrlygSecuritiesAmt>
    <ecd:AwardExrcPrice
      contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis"
      decimals="2"
      id="ixv-4867"
      unitRef="Unit_USD_per_Share">2.03</ecd:AwardExrcPrice>
    <ecd:AwardGrantDateFairValue
      contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis"
      decimals="0"
      id="ixv-4868"
      unitRef="Unit_USD">411750</ecd:AwardGrantDateFairValue>
    <ecd:UndrlygSecurityMktPriceChngPct
      contextRef="PAsOn06_20_2024_DavidMChackoMDMemberecdIndividualAxis"
      decimals="INF"
      id="ixv-4869"
      unitRef="Unit_pure">-1.43</ecd:UndrlygSecurityMktPriceChngPct>
    <ecd:AwardsCloseToMnpiDiscIndName
      contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis"
      id="ixv-4870">Shannon R. Morris, M.D., Ph.D.</ecd:AwardsCloseToMnpiDiscIndName>
    <ecd:AwardUndrlygSecuritiesAmt
      contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis"
      decimals="0"
      id="ixv-4871"
      unitRef="Unit_shares">137142</ecd:AwardUndrlygSecuritiesAmt>
    <ecd:AwardExrcPrice
      contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis"
      decimals="2"
      id="ixv-4872"
      unitRef="Unit_USD_per_Share">2.03</ecd:AwardExrcPrice>
    <ecd:AwardGrantDateFairValue
      contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis"
      decimals="0"
      id="ixv-4873"
      unitRef="Unit_USD">202531</ecd:AwardGrantDateFairValue>
    <ecd:UndrlygSecurityMktPriceChngPct
      contextRef="PAsOn06_20_2024_ShannonRMorrisMDPhDMemberecdIndividualAxis"
      decimals="INF"
      id="ixv-4874"
      unitRef="Unit_pure">-1.43</ecd:UndrlygSecurityMktPriceChngPct>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
